CN1938303A - Azaindoles useful as inhibitors of jak and other protein kinases - Google Patents
Azaindoles useful as inhibitors of jak and other protein kinases Download PDFInfo
- Publication number
- CN1938303A CN1938303A CN 200580010348 CN200580010348A CN1938303A CN 1938303 A CN1938303 A CN 1938303A CN 200580010348 CN200580010348 CN 200580010348 CN 200580010348 A CN200580010348 A CN 200580010348A CN 1938303 A CN1938303 A CN 1938303A
- Authority
- CN
- China
- Prior art keywords
- optional
- independently
- alkyl
- nitrogen
- sulphur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 27
- 102000001253 Protein Kinase Human genes 0.000 title abstract description 11
- 108060006633 protein kinase Proteins 0.000 title abstract description 11
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 274
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 246
- 229910052757 nitrogen Inorganic materials 0.000 claims description 209
- 229910052739 hydrogen Inorganic materials 0.000 claims description 196
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 192
- 239000005864 Sulphur Substances 0.000 claims description 192
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 191
- 229910052760 oxygen Inorganic materials 0.000 claims description 191
- 239000001301 oxygen Substances 0.000 claims description 191
- 239000001257 hydrogen Substances 0.000 claims description 189
- 229920006395 saturated elastomer Polymers 0.000 claims description 184
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 163
- 150000002431 hydrogen Chemical class 0.000 claims description 127
- 229910052736 halogen Inorganic materials 0.000 claims description 102
- 150000002367 halogens Chemical class 0.000 claims description 100
- -1 p-toluenesulfonyl Chemical group 0.000 claims description 71
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 57
- 125000002619 bicyclic group Chemical group 0.000 claims description 56
- 201000010099 disease Diseases 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 48
- 125000004429 atom Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 239000011435 rock Substances 0.000 claims description 43
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 41
- 229910052731 fluorine Inorganic materials 0.000 claims description 30
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 30
- 229910052794 bromium Inorganic materials 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 229910052801 chlorine Inorganic materials 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 25
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 24
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 206010003497 Asphyxia Diseases 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 208000006673 asthma Diseases 0.000 claims description 15
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 15
- 201000006417 multiple sclerosis Diseases 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 208000019622 heart disease Diseases 0.000 claims description 11
- 208000020084 Bone disease Diseases 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 239000003981 vehicle Substances 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 9
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 150000003851 azoles Chemical class 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 5
- 208000030961 allergic reaction Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 229910052796 boron Inorganic materials 0.000 claims description 5
- 230000001066 destructive effect Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 3
- 108090000433 Aurora kinases Proteins 0.000 claims description 3
- 102000003989 Aurora kinases Human genes 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000003890 Coronary Vasospasm Diseases 0.000 claims description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 201000011634 coronary artery vasospasm Diseases 0.000 claims description 3
- 230000008694 endothelial dysfunction Effects 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 2
- 206010036600 Premature labour Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 229910052770 Uranium Inorganic materials 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 230000003836 peripheral circulation Effects 0.000 claims description 2
- 208000026440 premature labor Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 339
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 336
- 238000005160 1H NMR spectroscopy Methods 0.000 description 251
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 121
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 83
- VJDGIJDCXIEXPF-UHFFFAOYSA-N 3-bromo-1h-pyrrolo[2,3-b]pyridine Chemical class C1=CC=C2C(Br)=CNC2=N1 VJDGIJDCXIEXPF-UHFFFAOYSA-N 0.000 description 79
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 52
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 33
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000005441 aurora Substances 0.000 description 27
- 239000002585 base Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- 238000005406 washing Methods 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 20
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 108091000080 Phosphotransferase Proteins 0.000 description 18
- 102000020233 phosphotransferase Human genes 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000000376 reactant Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 15
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 108010024121 Janus Kinases Proteins 0.000 description 13
- 102000015617 Janus Kinases Human genes 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 12
- 125000001931 aliphatic group Chemical group 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- MFZQJIKENSPRSJ-UHFFFAOYSA-N 5-chloro-1h-pyrrolo[2,3-b]pyridine Chemical class ClC1=CN=C2NC=CC2=C1 MFZQJIKENSPRSJ-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 8
- MWDJROWZDUZXBP-UHFFFAOYSA-N 3-bromo-5-chloro-1h-pyrrolo[2,3-b]pyridine Chemical class ClC1=CN=C2NC=C(Br)C2=C1 MWDJROWZDUZXBP-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000001994 activation Methods 0.000 description 8
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000003810 ethyl acetate extraction Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 229960001866 silicon dioxide Drugs 0.000 description 7
- 238000006884 silylation reaction Methods 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- DYLMDYMZICAJTK-UHFFFAOYSA-N 6-bromo-n-[(4-chlorophenyl)methyl]pyridin-2-amine Chemical compound C1=CC(Cl)=CC=C1CNC1=CC=CC(Br)=N1 DYLMDYMZICAJTK-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000042838 JAK family Human genes 0.000 description 5
- 108091082332 JAK family Proteins 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- JAGFTISVIIETEZ-UHFFFAOYSA-N n-benzyl-2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-amine Chemical compound C=1C=NC(C=2C3=CC=CN=C3NC=2)=NC=1NCC1=CC=CC=C1 JAGFTISVIIETEZ-UHFFFAOYSA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100032306 Aurora kinase B Human genes 0.000 description 3
- BGAZUGBRFXXIMG-UHFFFAOYSA-N CC(C1=CNC2=C1C=C(C=N2)Br)C(=O)C(C)C3=CNC4=C3C=C(C=N4)Br Chemical compound CC(C1=CNC2=C1C=C(C=N2)Br)C(=O)C(C)C3=CNC4=C3C=C(C=N4)Br BGAZUGBRFXXIMG-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 3
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000004567 concrete Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- XARFPUIPIOPYGA-UHFFFAOYSA-N n-benzyl-6-chloropyrimidin-4-amine Chemical compound C1=NC(Cl)=CC(NCC=2C=CC=CC=2)=N1 XARFPUIPIOPYGA-UHFFFAOYSA-N 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000007738 vacuum evaporation Methods 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 229910052728 basic metal Inorganic materials 0.000 description 2
- 150000003818 basic metals Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229950007655 esilate Drugs 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- QWRADTLPANSRDT-UHFFFAOYSA-N n-benzyl-2-chloropyrimidin-4-amine Chemical compound ClC1=NC=CC(NCC=2C=CC=CC=2)=N1 QWRADTLPANSRDT-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 108010041788 rho-Associated Kinases Proteins 0.000 description 2
- 102000000568 rho-Associated Kinases Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000007070 tosylation reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- SQDFWBUESZGRBR-UHFFFAOYSA-N 1h-azepine;1h-indole Chemical class N1C=CC=CC=C1.C1=CC=C2NC=CC2=C1 SQDFWBUESZGRBR-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ALSLDAQZLACBCR-UHFFFAOYSA-N 3-(3-phenylmethoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical class C=1C=CC(C=2C3=CC=CN=C3NC=2)=CC=1OCC1=CC=CC=C1 ALSLDAQZLACBCR-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- HGWTWNZFRKQGKG-UHFFFAOYSA-N 5-chloro-2h-pyridin-1-amine Chemical compound NN1CC=CC(Cl)=C1 HGWTWNZFRKQGKG-UHFFFAOYSA-N 0.000 description 1
- WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 description 1
- NRSGWEVTVGZDFC-UHFFFAOYSA-N 6-chloro-4-n-[3,5-difluoro-4-[(3-methyl-1h-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine Chemical compound C=12C(C)=CNC2=NC=CC=1OC(C(=C1)F)=C(F)C=C1NC1=CC(Cl)=NC(N)=N1 NRSGWEVTVGZDFC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091006515 Anion channels Proteins 0.000 description 1
- 102000037829 Anion channels Human genes 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102000042871 Aurora family Human genes 0.000 description 1
- 108091082291 Aurora family Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- YPZMPEPLWKRVLD-PJEQPVAWSA-N D-Glycero-D-gulo-Heptose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O YPZMPEPLWKRVLD-PJEQPVAWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010026851 Marrow hyperplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- HBOPVJJZFWIXOS-UHFFFAOYSA-M [Na][Zn]Cl Chemical compound [Na][Zn]Cl HBOPVJJZFWIXOS-UHFFFAOYSA-M 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002521 alkyl halide group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N dodecanoic acid ethyl ester Natural products CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- YPJKMVATUPSWOH-UHFFFAOYSA-N nitrooxidanyl Chemical compound [O][N+]([O-])=O YPJKMVATUPSWOH-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- XWINCPYLXQTPQV-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1.C1CNCCN1 XWINCPYLXQTPQV-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- FWSPXZXVNVQHIF-UHFFFAOYSA-N triethyl(ethynyl)silane Chemical group CC[Si](CC)(CC)C#C FWSPXZXVNVQHIF-UHFFFAOYSA-N 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Description
Technical field
The present invention relates to kinases inhibitor.The present invention also provides the pharmaceutical composition that comprises The compounds of this invention and uses said composition to treat the method for various illnesss.
Background of invention
In recent years, by understanding the enzyme relevant and the structure of other biomolecules better, helped the research of novel treatment greatly with disease.The important enzyme of a wherein class that has become the broad research target is a protein kinase.
Protein kinase is made up of involved enzyme on the extended familys structure, and they are responsible for the control of various signal transduction processes in the cell.(see Hardie, G. and Hanks, S.
The Protein Kinase Facts Book, I and II, Academic Press, San Diego, CA:1995).Because the conservative property of protein kinase structure and catalysis, they are considered to from common my late grandfather gene evolution.Nearly all kinases all comprises a similar 250-300 amino acid catalytic structural domain.Make the substrate difference of its phosphorylation they can be divided into several families (for example, albumen-tyrosine, albumen-serine/threonine, lipid etc.) by kinases.Identified usually and each the corresponding sequence motifs in these kinases families (see, for example, Hanks, S.K., Hunter, T.,
FASEB J.1995,9,576-596; People such as Knighton,
Science1991,253,407-414; People such as Hiles,
Gell1992,70,419-429; People such as Kunz,
Gell1993,
73, 585-596; People such as Garcia-Bustos,
EMBO J.1994,
13, 2352-2361).
Usually, protein kinase mediates intracellular signal from ribonucleoside triphosphote to the phosphoryl transfer of the protein receptor that participates in signal transduction path by influence.These phosphorylation events can play modulation or regulate the molecular switch of target protein biological function.These phosphorylation events finally are initiated outside replying various born of the same parents and during other stimulator.The example of this stimulator comprises that environment and chemistry stress signal (for example, osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin and H
2O
2), cytokine (for example, il-1 (IL-1) and tumor necrosis factor alpha (TNF-α)) and somatomedin (for example, granulocyte huge have a liking for cell-G CFS (GM-CSF) and fibroblast growth factor (FGF)).Born of the same parents' external stimulue can influence and cell growth, migration, differentiation, hormone secretion, transcription factor activation, Muscle contraction, glucose metabolism, the synthetic control of albumen, and one or more relevant cell responses of Cycle Regulation.
A lot of diseases are all relevant with the abnormal cells that incident the caused reaction by above-mentioned protein kinase-mediation.These diseases include, but not limited to autoimmune disease, inflammatory disease, osteopathy, metabolic disease, nerve and neurodegenerative disease, cancer, cardiovascular diseases, transformation reactions and asthma, Alzheimer and the disease relevant with hormone.Therefore, the great efforts of medicinal chemical aspect found can be effectively as the kinases inhibitor of therapeutical agent.
Janus kinases (JAK) belongs to family tyrosine kinase, is made up of JAK1, JAK2, JAK3 and TYK2.JAK plays an important role in the cytokine signaling conduction.The downstream substrate of kinases JAK family comprises the signal transduction agent and the activator (STAT) of transcription factor.The conduction of JAK/STAT signal relates to a lot of abnormal immune reactions, as transformation reactions, asthma, autoimmune disease such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis and entity and hematologic malignancies such as leukemia and lymphadenomatous mediation.The drug intervention of JAK/STAT approach was commented on [Frank
Mol.Med.5, people such as 432-456 (1999) and Seidel,
Oncogene, 19,2645-2656 (2000)].
JAK1, JK2 and TYK2 are that omnipresence is expressed, and JAK3 then mainly expresses in hematopoietic cell.JAK3 only with common cytokine receptor γ chain (γ
c) in conjunction with and activated by IL-2, IL-4, IL-7, IL-9 and IL-15.In fact, demonstrated by the propagation of IL-4 and IL-9 inductive mouse mastocyte and survival and depended on JAK3-and γ
c-signal conduction [people such as Suzuki,
Blood, 96,2172-2180 (2000)].
The crosslinked pro-inflammatory mediator that causes of high-affinity immunoglobulin (Ig) (Ig) the E acceptor of sensitization mastocyte comprises the release of many vasoactive cytokines, thereby causes acute transformation reactions, or mediation (I type) anaphylaxis [people such as Gordon,
Nature, 346,274-276 (1990) and Galli, N.
Engl.J.Med., 328,257-265 (1993)].The vital role of JAK3 in the reaction of the mastocyte of IgE acceptor-mediation set up in vitro and in vivo [people such as Malaviya,
Biochem.Biophys.Res.Commun., 257,807-813 (1999)].In addition, also reported by suppressing JAK3 and prevented the type i allergic reaction that mediates by mastocyte-activations, comprise allergy [people such as Malaviya,
J.Biol.Chem.274,27028-27038 (1999)].Can regulate the external threshing of mastocyte at mastocyte and prevent the anaphylaxis of IgE acceptor/antigen-mediation in the body with the JAK3 inhibitor.
The successful target-seeking of the JAK3 that is used for immunosuppression and allotransplantation acceptance has been described in recent research.Studies confirm that give the JAK3 inhibitor after, the dosage of buffalo heart allotransplantation in Wistar Furth acceptor-dependency survival, show in graft versus host disease, regulate harmful immunoreactive possibility [Kirken,
Transpl.Proc., 33,3268-3270 (2001)].
The STAT-phosphorylation of IL-4-mediation is related to the early stage and late stage of rheumatoid arthritis (RA) by hint.The rise of the pro-inflammatory cytokine in RA synovial membrane and the synovial membrane liquid is the feature of disease.The activation of the IL-4/STAT approach of verified IL-4 mediation is by Janus kinases (JAK1﹠amp; 3) mediation, and IL-4 relevant jak kinase in the RA synovial membrane, express [people such as Muller-Ladner,
J.Immunol., 164,3894-3901 (2000)].
Familial amyotrophic lateral sclerosis (FALS) is a kind of mortality neurodegenerative disease that influences about 10%ALS patient.The survival rate of FALS mouse is being handled the back increase with the JAK3 specific inhibitor.This show JAK3 in FALS, work [people such as Trieu,
Biochem. Biophys.Res.Commun., 267,22-25 (2000)].
The signal transduction agent of transcription factor and activator (STAT) are especially by JAK family kinase activated.Recent result of study hinted by with specific inhibitor at the JAK family kinase intervene the JAK/STAT signal transduction path treat leukemic possibility [people such as Sudbeck,
Clin.Cancer Res., 5,1569-1582 (1999)].The JAK3 specific compounds has demonstrated, and can to suppress the JAK3-express cell be DAUDI, RAMOS, LC
1-19, clone's generation property growth of NALM-6, MOLT-3 and HL-60.
In animal model, the TEL/JAK2 fusion rotein has been induced the marrow hyperplasia, and in hematopoietic cell system, and the introducing of TEL/JAK2 has caused the activation of STAT1, STAT3, STAT5, and cytokine-dependency growth [people such as Schwaller,
EMBO J.17,5321-5333 (1998)].
The tyrosine phosphorylation of STAT3 has been eliminated in the inhibition of JAK3 and TYK2, and has suppressed cutaneous T cell lymphoma, a kind of cell growth of skin T-cell lymphoma form.These results hinted the JAK family kinase in the JAK/STAT approach of constitutive activation be present in the cutaneous T cell lymphoma [people such as Nielsen,
Proc.Nat.Acad.Sci. U.S.A., 94,6764-6769 (1997)].Equally, STAT3, STAT5, JAK1 and JAK2 have been proved in being characterized as the mouse T-cell lymphoma of LCK overexpression at first by constitutive activation, thus further hinted the JAK/STAT approach in the abnormal cell growth [people such as Yu,
J.Immunol.159,5206-5210 (1997)].In addition, the STAT3 of IL-6 mediation activates and can be blocked by the JAK inhibitor, cause the myeloma cell to the apoptosis sensitivity [people such as Catlett-Falcone,
Immunity10,105-115 (1999)].
Making the interested kinases family of people is the relevant volution-spiralization albumen serine/threonine kinase (ROCK) of Rho-, and it is considered to the effector of the little GTP enzyme Rho relevant with Ras.ROCK family comprise p160ROCK (ROCK-1) (people such as Ishizaki,
EMBO J.1996,
15, 1885-1893) and ROK α/Rho-kinases/ROCK-II (people such as Leung, J.
Biol.Chem.1995,
270, 29051-29054; People such as Matsui,
EMBO J.1996,
15, 2208-2216; People such as Nakagawa,
FEBS Lett.1996,
392, 189-193), protein kinase PKN (people such as Amano,
Science1996,
271, 648-650; People such as Watanabe,
Science1996,
271, 645-648) and lemon and lemon kinases (people such as Madaule,
Nature, 1998,
394, 491-494; People such as Madaule,
FEBS Lett.1995,
377, 243-248).The ROCK family kinase has been proved to be and has related to many functions, comprise exciting albumen stress fiber of Rho-inductive and adhesion plaque formation (people such as Leung,
Mol.Cell Biol.1996,
16, 5313-5327; People such as Amano,
Science, 1997,
275, 1308-1311; People such as Ishizaki,
FEBS Lett.1997,
404, 118-124) and the downward modulation of myosin Phosphoric acid esterase (people such as Kimura,
Science, 1996,
273, 245-248), platelet activation (people such as Klages,
J.Cell.Biol., 1999,
144, 745-754), the aortal smooth muscle that causes by various stimulator shrink (people such as Fu,
FEBS Lett., 1998,
440, 183-187), the replying of zymoplasm-inductive aortic smooth muscle cell (people such as Seasholtz,
Cir.Rez., 1999,
84, 1186-1193), myocardial cell's hypertrophy (people such as Kuwahara,
FEBS Lett., 1999,
452, 314-318), bronchial smooth muscle shrink (people such as Yoshii,
Am.J.Respir.Cell Mol.Biol., 1999,
20, 1190-1200), non-myocyte's smooth muscle contraction and cytoskeleton reconstruct (people such as Fukata,
Trends in Pharm.Sci2001,
22, 32-39), activation (people such as Nilius, the J. of the anion channel of capacity regulating
Physiol., 1999,
516, 67-74), the aixs cylinder indentation (people such as Hirose,
J.Cell.Biol., 1998,
141, 1625-1636), the neutrophil chemotaxis (Niggli,
FEBS Lett., 1999,
445, 69-72), wound healing (Nobes and Hall,
J.Cell. Biol., 1999,
144, 1235-1244), tumor invasion (people such as Itoh,
Nat.Med., 1999,5,221-225) and cell transformation (people such as Sahai,
Curr.Biol., 1999,9,136-145).
More specifically, ROCK and relate to various diseases and illness, comprise hypertension (people such as Satoh,
J.Clin.Invest.1994,
94, 1397-1403; People such as Mukai,
FASEB J.2001,
15, 1062-1064; People such as Uehata,
Nature1997,
389, 990-994; People such as Masumoto,
Hypertension, 2001,
38, 1307-1310), cerebral vasospasm (people such as Sato,
Circ.Res.2000,
87, 195-200; People such as Miyagi, J.
Neurosurg.2000,
93, 471-476; People such as Tachibana,
Acta Neurochir (Wien)1999,
141, 13-19), coronary vasospasm (people such as Shimokawa,
Jpn.Cir. J.2000,
64, 1-12; People such as Kandabashi,
Circulation2000,
101, 1319-1323; People such as Katsumata,
Cirulation1997,
96, 4357-4363; People such as Shimokawa,
Cardiovasc.Res.2001,
51, 169-177; People such as Utsunomiya,
J.Pharmacol.2001,
134, 1724-1730; People such as Masumoto,
Circulation2002,
105, 1545-1547), bronchial asthma (people such as Chiba, Comp.
Biochem.Physiol.C Pharmacol.Toxicol.Endocrinol.1995,
11, 351-357; People such as Chiba,
Br.J.Pharmacol.1999,
127, 597-600; People such as Chiba,
Br.J.Pharmacol.2001,
133, 886-890; People such as Iizuka,
Eur.J. Pharmacol.2000,
406, 273-279), childbirth in advance (people such as Niro,
Biochem. Biophys.Res.Commun.1997,
230, 356-359; People such as Tahara,
Endocrinology 2002,
143, 920-929; People such as Kupittayanant,
Pflugers Arch.2001,
443, 112-114), erectile dysfunction (people such as Chitaley,
Nat.Med.2001,
7, 119-122; People such as Mills,
J.Appl.Physiol.2001,
91, 1269-1273), glaucoma (people such as Honjo,
Arch.Ophthalmol.2001,1171-1178; People such as Rao,
Invest.Ophthalmol.Vis.Sci.2001,
42, 1029-1037), vascular smooth muscle cell proliferation (people such as Shimokawa,
Cardiovasc.Res.2001,
51, 169-177; People such as Morishige,
Arterioscler.Thromb.Vasc.Viol.2001,
21, 548-554; People such as Eto,
Am.J.Physiol.Heart Circ.Physiol.2000,
278, H1744-H1750; People such as Sawada,
Circulation2000,
101, 2030-2023; People such as Shibata,
Circulation2001,
103, 284-289), myocardial hypertrophy (people such as H0shijima,
J.Biol.Chem.1998,
273, 7725-77230; People such as Sah,
J.Biol.Chem.1996,
271, 31185-31190; People such as Kuwahara, FEBS Lett.1999,
452, 314-318; People such as Yanazume,
J.Biol.Chem.2002,
277, 8618-8625), malignoma (people such as Itoh,
Nat.Med.1999,
5,221-225; People such as Genda,
Hepatology1999,
30, 1027-1036; People such as Somlyo,
Biochem.Biophys.Res.Commun.2000,
269, 652-659), local asphyxia/pour into again the inductive damage (people such as Ikeda,
J.of Surgical Res.2003,
109, 155-160; People such as Miznuma,
Transplantation2003,
75, 579-586), endothelial dysfunction (people such as Hernandez-Perera,
Circ.Res.2000,
87, 616-622; People such as Laufs,
J.Biol.Chem.1998,
273, 24266-24271; People such as Eto,
Circ.Res.2001,89,583-590), Crohn disease and colitis (people such as Segain,
Gastroenterology2003,
124 (5), 1180-1187), axon process (people such as Fournier,
J.Neurosci.2003,23,1416-1423), Raynaud disease (people such as Shimokawa,
J.Cardiovasc.Pharmacol.2002,
39, 319-327), angina (people such as Utsunomiya, Br.J.Pharmacol.2001,134,1724-1730; People such as Masumoto, Circulation 2002,105,1545-1547; People such as Shimokawa, J.Cardiovasc.Pharmacol., 2002,40,751-761; People such as Satoh, Jpn.J.Pharmacol., 2001,87,34-40), Alzheimer's (people such as Zhou, Science2003,302,1215-1218), benign prostatic hyperplasia (people such as Rees, J.Urology, 2003,170,2517-2522) and atherosclerosis (people such as Retzer
FEBS Lett.2000,
466, 70-74; People such as Ishibashi,
Biochim.Biophys. Acta2002,
1590, 123-130).Therefore, the exploitation of ROCK kinase inhibitor can be used as the treatment of conditions agent that treatment relates to the ROCK kinase pathways.
Aurora albumen be a family three kinds of very relevant serine/threonine kinases (be called Aurora-A ,-B and-C), the m period of their cell cycle is very important.Particularly, Aurora-A the maturation of centrosome with separate, play a significant role in the formation of mitotic spindle body and chromosomal certain separation.Aurora-B is a kind of karyomit(e) courier albumen, and it plays a significant role aspect correctly the finishing of arrangement, spindle body fit-up inspection point and the cell movement of karyomit(e) on metaphase plate regulating.
At many human cancers, comprise observe in colorectum, ovary, stomach and the invasive duct adenocarcinoma Aurora-A ,-B or-overexpression of C.Except the amplification of AURKA, the locus of coding Aurora-A is relevant with the patient with breast cancer's of tubercle-feminine gender poor prognosis.In addition, but the overexpression of Aurora-A has demonstrated the transformed mammalian inoblast, produces the aneuploid cell that contains multipolar spindle.
Now, many researchs verified in the human cancer cell line due to the siRNA Aurora-A or-disappearance or the inhibition of B, dominance feminine gender or neutralizing antibody destroy along with the mitotic development of cell cumulative with 4NDNA, and in some cases, endoreduplication and necrocytosis appear then.
Protein kinase is attractive and the target of attested novel treatment, is used for the treatment of human diseases, comprises Gleevec and Tarceva.The Aurora kinases is attractive especially be since they relevant with many human cancers and they aspect these cancer cell multiplications of promotion role (people such as Harrington,
Nature Med., 2004,10:262-267).
Therefore, be starved of to develop to be used for the treatment of and activate the relevant various diseases or JAK, ROCK and the Aurora of illness with JAK, ROCK and Aurora, the inhibitor of preferred JAK-3, ROCK and AuroraA protein kinase, particularly for most these diseases, adopted not too suitable treatment at present.
Summary of the invention
Having been found that compound of the present invention now, and the pharmacy acceptable composition, is effective as the inhibitor of JAK, ROCK and Aurora protein kinase.In specific embodiments, these compounds are effective as the inhibitor of JAK-3, ROCK and Aurora protein kinase.These compounds or its pharmacologically acceptable salts have general formula I:
R wherein
1, R
2, R
3, R
4, X
1, X
2, X
3, R
5With x be as following and trifle is defined herein.
These compounds and pharmaceutical composition thereof are used for the treatment of or prevent various illnesss, comprise, but be not limited to, heart trouble, diabetes, Alzheimer's, immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive bone disorders such as osteoporosis, proliferative disorders, catch, the disease and the virus disease of immunity-mediation.Said composition also be used for preventing necrocytosis and outgrowth method and therefore can be used for treating or preventing apoplectic in perfusion/local asphyxia again, heart attack and organ hypoxia.Said composition also is used to prevent the method for zymoplasm-inductive platelet aggregation.Said composition is used in particular for following illness, (comprise as chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer, but be not limited to, ovarian cancer, mammary cancer and carcinoma of endometrium), hepatopathy comprises liver local asphyxia, heart trouble, as myocardial infarction and congestive heart failure, relate to the pathologic immune disorders and the neurodegenerative disorders of T cell activation.
Detailed Description Of The Invention
1.
The generality of The compounds of this invention is described:
The present invention relates to the compound of formula I:
Or its pharmacologically acceptable salts, wherein:
R
1Be T-R ' or-Si (R ')
3
R
2, R
3, and R
4Independently be halogen, CN, NO separately
2, or V-R ';
X
1, X
2And X
3Independently be N or CH separately, wherein the hydrogen atom of CH is optional by R
5Replace;
X is 1,2,3 or 4;
R
5Each appearance independently be halogen, CN, NO
2, or U-R ';
T, V and U independently are valence link or the optional C that replaces separately
1-C
6Alkylidene chain, wherein this chain at the most optional the and independent quilt-NR ' of two methylene units ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR '-,-NR ' CO-,-NR ' CO
2-,-SO
2NR '-,-NR ' SO
2-,-CONR ' NR '-,-NR ' CONR '-,-OCONR '-,-NR ' NR '-,-NR ' SO
2NR '-,-SO-,-SO
2-,-PO-,-PO
2-or-POR '-replacement; And
The each appearance of R ' independently is hydrogen or the optional group that replaces, and is selected from: C
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In specific embodiments, occurring for twice of the R ' of formation ring is (for example, R on single substituting group
1, R
2, R
3, R
4Or at single R
5On the substituting group) and form monocycle or dicyclo.In other embodiments, occurring for twice of R ' is (for example, at two R on two substituting groups
5On the substituting group) and can with and R
5The ring that substituting group links to each other forms bicyclic condensed ring.
In specific embodiments, for the compound of top direct description:
If a) R
1Be the substituted ring amyl group, x is 1, X
1And X
3Be CH, X so
2Not C-R
5, R wherein
5Be fluorine or OMe;
B) if R
2And R
3Be H and R simultaneously
1And R
4Independently be selected from H or Me, x is 1, X
1And X
3Be CH, X so
2Not C-R
5, R wherein
5Be OMe, NO
2, or fluorine;
C) if R
1, R
2, R
3And R
4Be H simultaneously, x is 1, R
5Be-SMe NH
2Or the optional NH-piperidines that replaces, and X
1And X
2Be N, X so
3Not CH;
D) if R
2, R
3And R
4Be H simultaneously, X
1, X
2And X
3Be CH, and two R
5Form the optional dicyclo that replaces of condensed, R so with the ring that links to each other with them
1Not CH
2CH
2N (Me)
2
E) if R
2And R
3Be H simultaneously, R
4Be NH
2, and X
1, X
2And X
3Be CH, R so
1It or not substituted-phenyl;
F) if R
2, R
3And R
4Be H, R so simultaneously
1Not Si (R ')
3
G) if R
1, R
2And R
4Be H and (i) X simultaneously
2And X
3Be CH or CR
5Or (ii) X
1, X
2Or X
3In any one is N, R so
3It or not phenyl or by O-phenyl or N (Me)
2The phenyl that replaces.
2.
Compound and definition:
General those that describe above compound of the present invention comprises, and their disclosed from here classes, subclass and kind further illustrate.Except as otherwise noted, otherwise use following definition used herein.With regard to purpose of the present invention, chemical element is according to the periodic table of elements, CAS version, Handbook of Chemistry and Physics, the 75th edition evaluation.In addition, vitochemical rule is at " Organic Chemistry ", Thomas Sorrell, University Science Books, Sausalito:1999, " March ' s AdvancedOrganic Chemistry ", the 5th edition, Smith, M.B. and March, J. compile JohnWiley﹠amp; Sons describes among the New York:2001, and their full content is all introduced herein as a reference.
Just as described herein, compound of the present invention can be chosen wantonly by one or more substituting groups and replace, and these substituting groups are that top generality is illustrational, or by the concrete class of the present invention, subclass with plant illustrational.Should understand phrase " optional replacement " and can exchange use with phrase " replacement or unsubstituted ".Usually, term " replacement ", no matter whether the front has added " choosing wantonly ", all is meant with the hydrogen base in the specified substituting group replacement known structure.Except as otherwise noted, but the optional group that replaces can have substituting group at each the position of substitution of group, and when available more than one when being selected from the substituting group of specifying group and replacing a more than position in any known structure, each locational substituting group can be identical or different.The substituting group combination of the present invention's expection preferably can form those of stable or chemical available compound.Term used herein " stable " is meant when experience be used for their generation, detection, and be preferred for they recovery, purifying condition and when being used for one or more purposes disclosed herein, the compound that can not change basically.In certain embodiments, stable compound or chemical available compound are under the condition that does not have moisture or other chemical reactivity condition to exist, when under 40 ℃ or lower temperature, keeping at least one week, and the compound that can not change basically.
Term used herein " aliphatic series " or " aliphatic group " are meant that straight chain (promptly, unbranched) or side chain, replacement or unsubstituted hydrocarbon chain, it is saturated fully or comprises one or more unsaturated units, or refer to monocyclic hydrocarbon or dicyclic hydrocarbon, it is saturated fully or comprises one or more unsaturated units, but its be not fragrant (being also referred to as " carbocyclic ring " " cyclic aliphatic " or " cycloalkyl " herein), it has the single point that links to each other with the molecule remainder.Except as otherwise noted, aliphatic group comprises 1-20 aliphatic carbon atom.In certain embodiments, aliphatic group comprises 1-10 aliphatic carbon atom.In other embodiments, aliphatic group comprises 1-8 aliphatic carbon atom.In other embodiments, aliphatic group comprises 1-6 aliphatic carbon atom, and in other embodiments, aliphatic group comprises 1-4 aliphatic carbon atom.In certain embodiments, " cyclic aliphatic " (or " carbocyclic ring " or " cycloalkyl ") is meant monocyclic C
3-C
8The C of hydrocarbon or dicyclo
8-C
12Hydrocarbon, it is saturated fully or comprises one or more unsaturated units, but it is not fragrant, has the single point that links to each other with the molecule remainder, the arbitrary independently ring in the wherein said bicyclic system has 3-7 unit.Suitable aliphatic group include, but not limited to line style or side chain, replacement or unsubstituted alkyl, alkenyl, alkynyl and hybrid thereof, as (cycloalkyl) alkyl, (cycloalkenyl group) alkyl or (cycloalkyl) thiazolinyl.
Term used herein " heterolipid family " is meant that one of them or two carbon atoms are independently by the aliphatic groups of one or more oxygen, sulphur, nitrogen, phosphorus or silicon replacement.Heterolipid family group can be to replace or unsubstituted, side chain or unbranched, ring-type or acyclic, and comprises " heterocycle ", " heterocyclic radical ", " heterocycle aliphatic series " or " heterocyclic " group.
Term used herein " heterocycle ", " heterocyclic radical ", " heterocycle aliphatic series " or " heterocyclic " are meant monocycle, dicyclo or the three-loop system of non-fragrance, and wherein one or more links are independent heteroatomss of selecting.In certain embodiments, " heterocycle ", " heterocyclic radical ", " heterocycle aliphatic series " or " heterocyclic " group have 3-14 link, wherein one or more links are the heteroatomss that independently are selected from oxygen, sulphur, nitrogen or phosphorus, and each ring in the system comprises 3-7 link.
Term " heteroatoms " is meant that one or more oxygen, sulphur, nitrogen, phosphorus or silicon (comprise arbitrary oxidised form of nitrogen, sulphur, phosphorus or silicon; The quaternized form of arbitrary basic nitrogen or; Heterocyclic can replace nitrogen, for example N (3,4-dihydro-2 H-pyrryl), NH (pyrrolidyl) or NR
+(as the pyrrolidyl of N-replacement)).
Term used herein " undersaturated " is meant that this part has one or more unsaturated units.
Term used herein " alkoxyl group " or " sulfane base " are meant the alkyl with the previous definition that links to each other with main carbochain by oxygen (" alkoxyl group ") or sulphur (" sulfane base ") atom.
Term " alkylhalide group ", " haloalkenyl " and " halogen alkoxyl group " are meant alkyl, thiazolinyl or the alkoxyl group that replaces with one or more halogen atoms as the case may be.Term " halogen " is meant F, Cl, Br or I.
Use or be used as major part herein separately, term " aryl " as a part in " aralkyl ", " aralkoxy " or " aryloxy alkyl " is meant to have monocycle, dicyclo and the three-loop system of 5-14 link altogether, wherein at least one ring in the system be fragrance and system in each encircle and all comprise 3-7 link.Term " aryl " can exchange with term " aromatic ring " and use.Term " aryl " also refers to the heteroaromatic ring system that defines below herein.
Use or be used as major part separately, term " heteroaryl " as a part in " heteroaralkyl " or " heteroaryl alkoxyl group " is meant to have monocycle, dicyclo and the three-loop system of 5-14 link altogether, wherein at least one ring in the system is fragrant, at least one ring in the system comprises one or more heteroatomss, and wherein the ring of each in the system all comprises 3-7 link.Term " heteroaryl " can exchange with term " hetero-aromatic ring " or term " assorted fragrance " and use.
Aryl (comprising aralkyl, aralkoxy, aryloxy alkyl etc.) or heteroaryl (comprising heteroaralkyl and heteroaryl alkoxyl group etc.) can comprise one or more substituting groups, and therefore can be " the optional replacements ".Unless top and have in addition herein definition, the suitable substituting group on the unsaturated carbon atom of aryl or heteroaryl be selected from halogen ,-R
o,-OR
o,-SR
o, use R
oThe optional phenyl (Ph) that replaces, use R
oOptional replace-O (Ph), use R
oOptional replacement-(CH
2)
1-2(Ph), use R
oOptional replace-CH=CH (Ph), use R
oOptional 5-6 unit's heteroaryl or the heterocycle that replaces;-NO
2-CN;-N (R
o)
2-NR
oC (O) R
o-NR
oC (S) R
o-NR
oC (O) N (R
o)
2-NR
oC (S) N (R
o)
2-NR
oCO
2R
o-NR
oNR
oC (O) R
o-NR
oNR
oC (O) N (R
o)
2-NR
oNR
oCO
2R
o-C (O) C (O) R
o-C (O) CH
2C (O) R
o-CO
2R
o-C (O) R
o-C (S) R
o-C (O) N (R
o)
2-C (S) N (R
o)
2-OC (O) N (R
o)
2-OC (O) R
o-C (O) N (OR
o) R
o-C (NOR
o) R
o-S (O
2) R
o-S (O
3) R
o-SO
2N (R
o)
2-S (O) R
o-NR
oSO
2N (R
o)
2-NR
oSO
2R
o-N (OR
o) R
o-C (=NH)-N (R
o)
2-P (O)
2R
o-PO (R
o)
2-OPO (R
o)
2Or-(CH
2)
0-2NHC (O) R
o, each self-existent R wherein
oBe selected from hydrogen, the optional C that replaces
1-6Aliphatic series, unsubstituted 5-6 unit's heteroaryl or heterocycle, phenyl ,-(O) Ph or-CH
2(Ph) or, though in the above the definition, two self-existent R on same substituting group or the different substituents
oWith with each R
oGroup bonded atom is common to form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo.
R
oAliphatic group on optional substituting group be selected from NH
2, NH (C
1-4Aliphatic group), N (C
1-4Aliphatic group)
2, halogen, C
1-4Aliphatic group, OH, O (C
1-4Aliphatic group), NO
2, CN, CO
2H, CO
2(C
1-4Aliphatic group), O (halo C
1-4Aliphatic group) or halo C
1-4Aliphatic group, wherein R
oEach aforesaid C
1-4Aliphatic group all is unsubstituted.
Aliphatic series or heterolipid family group, or therefore the heterocycle of non-fragrance can comprise one or more substituting groups and can be " the optional replacement ".Unless top and have definition, the suitable substituting group on the saturated carbon of aliphatic series or heterolipid family group or nonaromatic heterocycles to be selected from listed those of the unsaturated carbon of top aryl or heteroaryl herein in addition, and comprise following in addition :=O ,=S ,=NNHR
*,=NN (R
*)
2,=NHC (O) R
*,=NNHCO
2(alkyl) ,=NNHSO
2(alkyl) or=NR
*, each R wherein
*Independently be selected from hydrogen or the optional C that replaces
1-6Aliphatic group.
Unless top and definition is arranged in addition, the optional substituting group on the nitrogen of nonaromatic heterocycles is selected from-R herein
+,-N (R
+)
2,-C (O) R
+,-CO
2R
+,-C (O) C (O) R
+,-C (O) CH
2C (O) R
+,-SO
2R
+,-SO
2N (R
+)
2,-C (=S) N (R
+ 1)
2,-C (=NH)-N (R
+)
2, or-NR
+SO
2R
+R wherein
+Be hydrogen, the optional C that replaces
1-6Aliphatic group, the optional phenyl that replaces, optional replace-O (Ph), optional replace-CH
2(Ph), optional replace-(CH
2)
1-2(Ph), optional replace-CH=CH (Ph) or have 1-4 first heteroaryl of heteroatomic unsubstituted 5-6 or heterocycle that independently is selected from oxygen, nitrogen or sulphur, or, although as top defined, two self-existent R on same substituting group or the different substituents
+With with each R
+Group bonded atom is common to form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo.
R
+Aliphatic group on optional substituting group be selected from-NH
2,-NH (C
1-4Aliphatic group) ,-N (C
1-4Aliphatic group)
2, halogen, C
1-4Aliphatic group ,-OH ,-O (C
1-4Aliphatic group) ,-NO
2,-CN ,-CO
2H ,-CO
2(C
1-4Aliphatic group) ,-O (halogen C
1-4Aliphatic group) or halogen C
1-4Aliphatic group, wherein R
+Each aforesaid C
1-4Aliphatic group all is unsubstituted.
Term " alkylidene chain " is meant can be fully saturated or have one or more unsaturated units and have the straight or branched carbochain of two points that link to each other with the molecule remainder.
Term used herein " blocking group " is meant the reagent that is used for the one or more required reaction site of temporary interruption polyfunctional compound.In specific embodiments, blocking group have following one or more, or preferred all character:, produce the stable protection substrate of reaction that takes place at one or more other reaction site places a) with selectivity of productive rate reaction preferably; And b) utilize the reagent that can not attack regeneration functional group, productive rate is removed by selectivity preferably.The blocking group of illustrative is at Greene, T.W., Wuts, P.G " blocking group in the organic synthesis ", the third edition, John Wiley﹠amp; Sons describes in detail among the New York:1999, and its full content is introduced herein as a reference.Term used herein " nitrogen-protecting group group " is meant the reagent that is used for the one or more required nitrogen reaction site of temporary interruption polyfunctional compound.Preferred nitrogen-protecting group is rolled into a ball also has top illustrational character, and the nitrogen-protecting group of specific illustrative is rolled into a ball also at Chapter 7 in Greene T.W., Wuts, P.G " blocking group in the organic synthesis ", the third edition, John Wiley﹠amp; Sons describes in detail among the New York:1999, and its full content is introduced herein as a reference.
As mentioned above, in certain embodiments, two self-existent R
o(or R
+, R, R ' or similar definition herein any other variable) can with form with their bonded atoms are common that 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo.
Two self-existent R
o(or R
+, R, R ' or similar definition herein any other variable) with and the example of the common ring that forms of each variable bonded atom include, but are not limited to following: a) two self-existent R
o(or R
+, R, R ' or similar definition herein any other variable) combine with same atom, and form ring jointly with this atom, for example, N (R
o)
2, wherein existing two R
oForm piperidines-1-base, piperazine-1-base or morpholine-4-base jointly with nitrogen-atoms; And b) two self-existent R
o(or R
+, R, R ' or similar definition herein any other variable) with different atom combinations, and form ring jointly with those atoms, for example, wherein phenyl is by existing two OR
o
Replace existing these two R
oWith form a condensed 6-unit ether ring with their bonded Sauerstoffatoms are common:
。Will be appreciated that, as two self-existent R
o(or R
+, R, R ' or similar definition herein any other variable) when being connected jointly, can form various other rings, and the example of describing in detail is not above thought restriction with each variable bonded atom.
Except as otherwise noted, structure described herein also can comprise all isomerss (for example, enantiomer, diastereomer and geometrical isomer (or conformer)) form of this structure; For example, the R of each asymmetric center and S configuration, double bond isomer (Z) and (E), and (Z) and conformer (E).Therefore, the single stereoisomers of The compounds of this invention and enantiomer, diastereomer and geometrical isomer (or conformer) mixture also falls within the scope of the present invention.Except as otherwise noted, all tautomeric forms of The compounds of this invention all fall within the scope of the present invention.In addition, except as otherwise noted, structure described herein comprises that also difference only is to exist the compound of one or more isotopic enrichment atoms.For example, have just with deuterium or tritium and replace the structure of the present invention of hydrogen, or have just and use
13C-or
14The compound that the carbon of C-enrichment replaces the structure of the present invention of carbon also falls within the scope of the present invention.This compound can be used as analysis tool or the probe in the biological assay.
3. the description of illustrative compound:
As top general describe, R
1Be T-R ', or-Si (R ')
3In specific embodiments, when R1 is T-R ', T is the optional C that replaces
1-C
6Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO
2-or-CO-replaces, and R ' is hydrogen, C
1-C
4Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl.At R
1Other embodiment in, R ' can also be C
1-C
4Aliphatic group.In other embodiments, work as R
1Be-Si (R ')
3, R ' is hydrogen, C
1-C
4Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle.In other embodiments, R
1Be hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3In other embodiments, R
1Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).R for example
1Group is yet described in herein the table 1 and 2.
As top general describe, R
2, R
3, and R
4Independently be halogen, CN, NO separately
2Or V-R '.In specific embodiments, R
2, R
3, and R
4Independently be hydrogen, R ', halogen, CN, NO separately
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR ' (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2, or-O (CH
2)
4N (R ')
2In other embodiments, R
2, R
3, and R
4Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2) 2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2-or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R
2, R
3, and R
4Each is hydrogen naturally.In other embodiments, R
2, R
3, or R
4In one be hydrogen.In other embodiments, R
2, R
3, or R
4In two be hydrogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be halogen, CN, NO
2, or V-R '.In other embodiments, R
2And R
4All be hydrogen, and R
3It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R
2And R
4All be hydrogen, and R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring.In other embodiments, R
2And R
4All be hydrogen, and R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.In other embodiments, work as R
1, R
2And R
4When being H, R so
3It or not the optional phenyl that replaces.In other embodiments, work as R
1, R
2And R
4When being H, R so
3Not aryl, heteroaryl, carbocylic radical or heterocyclic radical.The R of illustrative
2, R
3, and R
4Group also comprises those that following table 1 and 2 provides.
As mentioned above, R
2, R
3, and R
4Be optionally substituted separately, and in specific embodiments, R
2, R
3, and R
4Optional and independent by R
6Occur to replace for z time, wherein z is 0-5 and R
6Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or Z-R ", wherein Z is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In other embodiments, z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR ", NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".In another embodiment, R
6Can also be-NR " CH (CH
3) R ".In other embodiments, z is 1,2 or 3 and R
6Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C1-C
6Alkyl) ,-CO (C1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and wherein aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.The R of other illustrative
6Group is described in table 1.
As top generality X is described to formula I compound
1, X
2And X
3Independently be N or CH separately, wherein the hydrogen atom of CH is optional by R
5Replace.In specific embodiments, X
1, X
2, or X
3In two be N, and X
1, X
2, or X
3In remaining one be CH, wherein the hydrogen atom of CH is optional by R
5Replace.In other particular, X
1, X
2, or X
3In one be N, and X
1, X
2, or X
3In remaining two be CH, wherein the hydrogen atom of CH is optional by R
5Replace.In other embodiments, X
1, X
2And X
3Each is CH naturally, and wherein the hydrogen atom of CH is optional by R
5Replace.In other specific illustrative embodiment, compound has among formula I-A, I-B, I-C or the I-D.
In other embodiments, compound has formula I-E:
Describe as top generality to formula I compound, x is 1,2,3 or 4; And R
5Each appearance independently be halogen, CN, NO
2, or U-R ', wherein each appearance of U independently is the C of valence link or optional replacement
1-C
6Alkylidene chain, wherein this chain at the most optional the and independent quilt-NR ' of two methylene units-,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR '-,-NR ' CO-,-NR ' CO
2-,-SO
2NR '-,-NR ' SO
2-,-CONR ' NR '-,-NR ' CONR '-,-OCONR '-,-NR ' NR '-,-NR ' SO
2NR '-,-SO-,-SO
2-,-PO-,-PO
2-or-POR '-replacement; And
The each appearance of R ' independently is hydrogen or the optional C that replaces
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In specific embodiments, R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR '.In specific embodiments, R
5Can also be-NR ' CH (CH
3) R ', NR ' CH (CF
3) R ' ,-NR ' CH (CH
3) C (O) OR ' ,-NR ' CH (CF
3) C (O) OR ' ,-NR ' CH (CH
2CH
3) R ' ,-NR ' CH
2C (O) N (R ')
2,-NR ' CH (CH
3) C (O) N (R ')
2, NR ' CH (CF
3) C (O) N (R ')
2,-NR ' CH (CH
2CH
3) C (O) N (R ')
2,-NR ' CH (CH (CH
3)
2) C (O) N (R ')
2, NR ' CH (C (CH
3)
3) C (O) N (R ')
2,-NR ' CH (CH
2CH (CH
3)
2) C (O) N (R ')
2,-NR ' CH (CH
2OR
9) C (O) N (R ')
2Or-NR ' CH (CH
2CH
2N (Me)
2) C (O) N (R ')
2In specific illustrative embodiment, x is 1,2 or 3, and R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2, or-NR ' (CH
2)
2N (R ')
2In other embodiments, x is 1,2 or 3, and R
5at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R
5At least once to occur be halogen.In other embodiments, x is 1,2 or 3, and R
5at least once occur be-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2OMe) R ' ,-NR ' CH (CH
2OEt) R ' ,-NR ' CH (CH
2OCF
3) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' CH (CH
2CH
2OMe) R ' ,-NR ' CH (CH
2CH
2OEt) R ' ,-NR ' CH (CH
2CH
2OCF
3) R ' ,-NR ' CH (CH
3) C (O) OR ' ,-NR ' CH (CF
3) C (O) OR ' ,-NR ' CH (CH
3) C (O) N (R ')
2,-NR ' CH (CF
3) C (O) N (R ')
2,-NR ' CH (CH
2CH
3) C (O) N (R ')
2,-NR ' CH (CH
2OH) C (O) N (R ')
2,-NR ' CH (CH
2OMe) C (O) N (R ')
2,-NR ' CH (CH
2OEt) C (O) N (R ')
2Or-NR ' CH (CH
2OCF
3) C (O) N (R ')
2, wherein R ' is the optional C that replaces
1-C
4Aliphatic group; NHCH
2C (O) NHR ' ,-NHCH (CH
3) C (O) NHR ' ,-NHCH (CH
2CH
3) C (O) NHR ' ,-NHCH (CH (CH
3)
2) C (O) NHR ' ,-NHCH (C (CH
3)
3) C (O) NHR ' ,-NHCH (CH
2CH (CH
3)
2) C (O) NHR ' ,-NHCH (CH
2OH) C (O) NHR ' ,-NHCH (CH
2OMe) C (O) NHR ' or-NHCH (CH
2CH
2N (Me)
2) C (O) NHR ', wherein R ' is the optional C that replaces
1-C
4Aliphatic group;-NHR ' ,-NH (CH
2) R ' ,-NH (CH
2)
2R ' ,-NHCH (CH
3) R ' ,-NHCH
2C (O) NHR ' ,-NHCH (CH
3) C (O) NHR ' ,-NHCH (CH
2CH
3) C (O) NHR ' ,-NHCH (CH (CH
3)
2) C (O) NHR ' ,-NHCH (C (CH
3)
3) C (O) NHR ' ,-NHCH (CH
2CH (CH
3)
2) C (O) NHR ' ,-NHCH (CH
2OH) C (O) NHR ' ,-NHCH (CH
2OMe) C (O) NHR ' or-NHCH (CH
2CH
2N (Me)
2) C (O) NHR ', wherein R ' is the optional C that replaces
1-C
4Aliphatic group;-NHCH (CH
3) R ', wherein R ' is the optional phenyl that replaces; H, halogen, CH
3, CF
3, COOH, COOMe or OR ', wherein R ' is C
1-C
4Aliphatic group.
In other embodiments, x is 1,2 or 3, and R
5At least once to occur be the optional C that replaces
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
In other embodiments, x is 1 or 2, and R
5Each appearance independently be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR '.In other embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In other embodiments, R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement.
As top generality R is described with respect to formula I compound
5Optional by R
7Occur to replace for y time, wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ", wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In other embodiments, y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".In specific embodiments, R
7Can also be-NR ' CH (CH
3) R '.In other embodiments, y is 1,2 or 3 and R
7Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2-,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2,-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.The R of other illustrative
7Group is described in table 1.
In other embodiments, x is 1,2 or 3; R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or ring are selected from:
Wherein y and R
7Describe in general in the above description and the subgroup.
In another embodiment, R ' can be
Wherein y and R
7Describe in general in the above description and the subgroup.
In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from:
Wherein y and R
7Describe in general in the above description and the subgroup.
The specific subgroup of other of compound of Formula I comprises:
1. the compound of formula I-A:
R wherein
1, R
2, R
3, R
4, R
5With x superincumbent separately general describe and subgroup top and described herein in describe.
In certain embodiments, with regard to the compound of formula I-A:
A.R
1Be:
I.T-R ', wherein T is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR ' ,-OCO-,-COO-,-SO
2-or-CO-replaces, and R ' is hydrogen, C
1-C
4Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl, or
Ii.-Si (R ')
3, wherein R ' is hydrogen, C
1-C
4Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle;
B.R
2, R
3, and R
4Independently be hydrogen, R ', halogen, CN, NO separately
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR ' (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2, or-O (CH
2)
4N (R ')
2R wherein
2, R
3, and R
4Optional separately by R
6Occur to replace for z time, wherein z is 0-5 and R
6Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or Z-R ", wherein Z is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
C.R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ", wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
In other embodiments, with regard to the compound of formula I-A:
A.R
1Be hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3
B.R
2, R
3, and R
4Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2)
2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2-or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R wherein
2, R
3, and R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CON (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CH
2N (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR ", NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ";
C.R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R
1Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).
In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R
2, R
3, and R
4Each is hydrogen naturally.In other embodiments, R
2, R
3, or R
4In one be hydrogen.In other embodiments, R
2, R
3, or R
4In two be hydrogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be halogen, CN, NO
2, or V-R '.In other embodiments, R
2And R
4All be hydrogen, and R
3It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R
2And R
4All be hydrogen, and R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring.In other embodiments, R
2And R
4All be hydrogen, and R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.In other embodiments, R
3Be selected from H, Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (R ')
2,-NO
2,-OR ' ,-CON (R ')
2,-COOR ' ,-OH ,-SR ' ,-C (R ')
2OR ' ,-N (R ') COR ' ,-N (R ') C (O) OR ' ,-SO
2NH
2,-SO
2N (R ')
2Or the optional group that replaces, be selected from C
1-C
4Aliphatic group, C
1-C
4Alkoxyl group or-C=C-C
1-C
4Aliphatic group.In further embodiment, R
2And R
4All be hydrogen and R
3Directly be selected from the tabulation of front.
In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R
2, R
3, and R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 1,2 or 3 and R
6Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C1-C
6Alkyl) ,-CO (C1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and wherein aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
In specific illustrative embodiment, with regard to the compound of the subgroup of formula I-A and top direct description, x is 1,2 or 3, and R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2, or-NR ' (CH
2)
2N (R ')
2In other embodiments, x is 1,2 or 3, and R
5at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R
5at least once occur be-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '.In other embodiments, x is 1,2 or 3, and R
5At least once to occur be the optional C that replaces
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R
5Optional by R
7Occur to replace for y time, wherein y is 1,2 or 3 and R
7Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2-,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2,-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, x is 1,2 or 3; R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, x be 1 and compound have general formula I-A-i:
R wherein
1, R
2, R
3, and R
4Reach herein in general in the above description and the top subgroup and describe, and R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2) 2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be N (R ')
2In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, x is 1 and has the compound of general formula I-A-ii:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein, and R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be N (R ')
2In specific embodiments, with regard to top described each subgroup, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, R
1, R
2, R
3And R
4Each is hydrogen naturally, and formula I-A-iii is provided compound:
Wherein x is 1,2 or 3; And R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, R
1, R
2, R
3, and R
4Each hydrogen naturally, and x is 1, and the compound of formula I-A-iv is provided:
R wherein
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, R
1, R
2, R
3, and R
4Each is hydrogen naturally, and x is 1, and the compound of formula I-A-v is provided:
R wherein
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, R
1, R
2, and R
4Each is hydrogen naturally, and the compound of formula I-A-vi is provided:
Wherein:
R
3Be to have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; X is 1,2 or 3; And R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, with regard to the compound of top direct description, R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated ring.In other embodiments, R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.As top general description, R
3Optional by R
6Occur to replace for z time.In specific embodiments, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR ", NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
In other embodiments, R
1, R
2, R
3And R
4Each is hydrogen naturally, and x is 1, and the compound of formula I-A-vii is provided:
Wherein:
R
3It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, with regard to the compound of top direct description, R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated ring.In other embodiments, R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.As top general description, R
3Optional by R
6Occur to replace for z time.In specific embodiments, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
4)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
In other embodiments, R
1, R
2, R
3And R
4Each is hydrogen naturally, and x is 1, and the compound of formula I-A-viii is provided:
Wherein:
R
3It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.
In other embodiments, with regard to the compound of top direct description, R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated ring.In other embodiments, R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.As top general description, R
3Optional by R
6Occur to replace for z time.In specific embodiments, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
The specific subgroup of other of compound of Formula I comprises:
II. the compound of formula I-C
R wherein
1, R
2, R
3, R
4, R
5With x general in the above separately describe and subgroup in and description herein.
In certain embodiments, with regard to the compound of formula I-C:
A.R
1Be:
I.T-R ', wherein T is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO
2-or-CO-replaces, and R ' is hydrogen, C
1-C
4Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl, or
Ii.-Si (R ')
3, wherein R ' is hydrogen, C
1-C
4Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle;
B.R
2, R
3, and R
4Independently be hydrogen, R ', halogen, CN, NO separately
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR ' (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2, or-O (CH
2)
4N (R ')
2R wherein
2, R
3, and R
4Optional separately by R
6Occur to replace for z time, wherein z is 0-5 and R
6Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or Z-R ", wherein Z is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
C.R
5Each appearance independently be hydrogen, halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ', wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
In other embodiment, with regard to the compound of formula I-C:
A.R
1Be hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3
B.R
2, R
3, and R
4Independently be separately Cl, Br, F ,-CN ,-COOH,
-COOMe,-NH
2,-N(CH
3)
2,-N(Et)
2,-N(iPr)
2,-O(CH
2)
2OCH
3,-
CONH
2,-COOCH
3,-OH,-CH
2OH,-NHCOCH
3,-SO
2NH
2,-
-SO
2N (Me)
2, or the optional following groups that replaces, be selected from: C
1-C
4Alkyl, C
1-C
4Alkane is fluorine-based, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5;
R wherein
2, R
3, and R
4Optional separately by R
6Occur to replace for z time, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen.CN,NO
2,-N(R”)
2,-
CH
2N(R”)
2,-OR”,-CH
2OR”,-SR”,-CH
2SR”,-COOR”,-NR”COR”,-
NR”COOR”,-CON(R”)
2,-SO
2N(R”)
2,-CONR”(CH
2)
2N(R”)
2,-
CONR(CH
2)
3N(R”)
2,-CONR”(CH
2)
4N(R”)
2,-O(CH
2)
2OR”,
O(CH
2)
3OR”,O(CH
2)
4OR”,-O(CH
2)
2N(R”)
2,-O(CH
2)
3N(R”)
2,-
O(CH
2)
4N(R”)
2,-NR”CH(CH
2OH)R”,-NR”CH(CH
2CH
2OH)R”,-
NR”(CH
2)R”,-NR”(CH
2)
2R”,-NR”(CH
2)
3R”,-NR”(CH
2)
4R”,-
NR”(CH
2)N(R”)
2,-NR”(CH
2)
2N(R”)
2,-NR”(CH
2)
3N(R”)
2,-
NR”(CH
2)
4N(R”)
2,-NR”(CH
2)OR”,-NR”(CH
2)
2OR”,-
NR”(CH
2)
3OR”,or-NR’(CH
2)
4OR”;
The heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5;
R wherein
5Optional by R
7Occur to replace for y time, wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen,
CN,NO
2,-N(R”)
2,-CH
2N(R”)
2,-OR”,-CH
2OR”,-
SR”,-CH
2SR”,-COOR”,-NR”COR”,-NR”COOR”,-CON(R”)
2,-
SO
2N(R”)
2,-CONR”(CH
2)
2N(R”)
2,-CONR(CH
2)
3N(R”)
2,-
CONR”(CH
2)
4N(R”)
2,-O(CH
2)
2OR”,O(CH
2)
3OR”,O(CH
2)
4OR”,-
O(CH
2)
2N(R”)
2,-O(CH
2)
3N(R”)
2,-O(CH
2)
4N(R”)
2,-
NR”CH(CH
2OH)R”,-NR”CH(CH
2CH
2OH)R”,-NR”(CH
2)R”,-
NR”(CH
2)
2R”,-NR”(CH
2)
3R”,-NR”(CH
2)
4R”,-NR”(CH
2)N(R”)
2,-
NR”(CH
2)
2N(R”)
2,-NR”(CH
2)
3N(R”)
2,-NR”(CH
2)
4N(R”)
2,-
NR”(CH
2)OR”,-NR”(CH
2)
2OR”,-NR”(CH
2)
3OR”,or-
NR”(CH
2)
4OR”。
In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R
1Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TRS), triisopropyl silyl (TIPS) or triethylsilyl (TES).
In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R
2, R
3, and R
4Each is hydrogen naturally.In other embodiments, R
2, R
3, or R
4In one be hydrogen.In other embodiments, R
2, R
3, or R
4In two be hydrogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be halogen, CN, NO
2, or V-R '.In other embodiments, R
2And R
4All be hydrogen, and R
3It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R
2And R
4All be hydrogen, and R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring.In other embodiments, R
2And R
4All be hydrogen, and R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.
In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R
2, R
3, and R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 1,2 or 3 and R
6Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and wherein aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
In some instances, with regard to formula I-C compound and the top subgroup compound of directly describing, X is 1,2 or 3, and the R that at least once occurs
5It is halogen
CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl),
Perhaps have 0-3 the unsaturated ring of heteroatoms 5-or 6-unit that is selected from oxygen, sulphur or nitrogen, in other embodiments, X is 1,2 or 3, and the R that at least once occurs
5Be-OR
1
In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R
5Optional by R
7Occur to replace for y time, wherein y is 1,2 or 3 and R
7Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2-,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
In other embodiments, x be 1 and compound have general formula I-C-i:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein, and R
5Be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).
In other embodiments, x be 1 and compound have general formula I-C-ii:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein, and R
5Be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is optional by y the appearance replacement of R7.In certain embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).
In other embodiments, R
5Each appearance independently be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In other embodiments, R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement, wherein R
5Optional by R
7Occur to replace for 0-3 time.
In other embodiments, x be 2 and compound have general formula I-C-iii:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein, and R
5Each appearance independently be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).
In other embodiments, R
5Each appearance independently be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In other embodiments, R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement, wherein R
5Optional by R
7Occur to replace for 0-3 time.
In other embodiments, R
1, R
2, R
3, and R
4Each is hydrogen naturally, and x is 2, and the compound of formula I-C-iv is provided:
R wherein
5Be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).
In other embodiments, R
5Each appearance independently be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In other embodiments, R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement, wherein R
5Optional by R
7Occur to replace for 0-3 time.
In other embodiments, R
1, R
2, R
3, and R
4Each is hydrogen naturally, and x is 1, and the compound of formula I-C-v is provided:
R wherein
5Be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).
In other embodiments, R
5Each appearance independently be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In other embodiments, R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement, wherein R
5Optional by R
7Occur to replace for 0-3 time.
In other embodiments, R
1, R
2, R
3, and R
4Each is hydrogen naturally, and x is 2, and the compound of formula I-C-vi is provided:
R wherein
5Each appearance independently be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).
In other embodiments, R
5Each appearance independently be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.In other embodiments, R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement, wherein R
5Optional by R
7Occur to replace for 0-3 time.
The representative ion of formula I compound proposes in the following Table 1:
The example of table 1. formula I compound
The compound of Formula I of other specific subgroup comprises:
The compound of formula I-B
R wherein
1, R
2, R
3, R
4, R
5With x general in the above separately describe and subgroup in and description herein.
In certain embodiments, with regard to the compound of formula I-B:
A.R
1Be:
I.T-R ', wherein T is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO
2-or-CO-replaces, and R ' is hydrogen, C
1-C
4Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl, or
Ii.-Si (R ')
3, wherein R ' is hydrogen, C
1-C
4Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle;
B.R
2, R
3, and R
4Independently be hydrogen, R ', halogen, CN, NO separately
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' C (O) OR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR ' (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2, or-O (CH
2)
4N (R ')
2R wherein
2, R
3, and R
4Optional separately by R
6Occur to replace for z time, wherein z is 0-5 and R
6Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or Z-R ", wherein Z is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or has 0-5 the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or the undersaturated loop systems of getting fully; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
C.R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ', wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
In other embodiments, with regard to the compound of formula I-B:
A.R
1Be hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3
B.R
2, and R
4Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2)
2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2, or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R wherein
2, and R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ";
C.R
3Independently be Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2)
2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2, or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group; R wherein
3Independent of and optional R
6Occur to replace for z time, wherein z is 0 or 1, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ";
D.R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R
1Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).
In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R
2, R
3, and R
4Each is hydrogen naturally.In other embodiments, R
2, R
3, or R
4In one be hydrogen.In other embodiments, R
2, R
3, or R
4In two be hydrogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be halogen, CN, NO
2, or V-R '.In other embodiments, R
2And R
4All be hydrogen, and R
3It is halogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be Cl.
In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R
2, R
3, and R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 1,2 or 3 and R
6Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and wherein aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally, condition is R
3It or not phenyl.
In specific illustrative embodiment, with regard to the compound of the subgroup of formula I-B and top direct description, x is 1,2 or 3, and R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2, or-NR ' (CH
2)
2N (R ')
2In other embodiments, x is 1,2 or 3, and R
5at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R
5at least once occur be-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '.In other embodiments, x is 1,2 or 3, and R
5At least once to occur be the optional C that replaces
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R
5Optional by R
7Occur to replace for y time, wherein y is 1,2 or 3 and R
7Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2-,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2,-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, x is 1,2 or 3; R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
Wherein y and R
7Generality describe and above subgroup in describe.
In other embodiments, x be 1 and compound have general formula I-B-i:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein; R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be N (R ')
2In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, x is that 0-3 and compound have general formula I-B-ii:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein; R
5Independently be selected from halogen, the optional C that replaces separately
1-C
6Alkyl ,-SR ' ,-CN ,-COOH ,-CO
2R ' ,-CON (R ')
2,-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be N (R ')
2In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, x is that 1-4 and compound have general formula I-B-iii:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Alkyl, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
X is 1,2 or 3; And R
5Halogen, the optional C that replaces at least once appear being selected from
1-C
6Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO
2R ' ,-CON (R ')
2,-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is selected from hydrogen, optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, R
1, R
2And R
4Each hydrogen naturally, and x is 0-3, and the compound of formula I-B-iv is provided:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Aliphatic group, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
R
5Be selected from halogen, the optional C that replaces
1-C
6Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO
2R ' ,-CON (R ')
2,-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is selected from hydrogen, optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, R
1, R
2And R
4Each hydrogen naturally, and x is 2, and the compound of formula I-B-v is provided:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Aliphatic group, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
R
5Be selected from halogen, the optional C that replaces
1-C
6Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO
2R ' ,-CON (R ')
2,-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH (CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is selected from hydrogen, optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, R
1, R
2And R
4Each hydrogen naturally, and x is 2, and the compound of formula I-B-vi is provided:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Aliphatic group, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
R
5Be selected from halogen, the optional C that replaces
1-C
6Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO
2R ' ,-CON (R ')
2,-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH (CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is selected from hydrogen, optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
The compound of the general formula I of other specific subgroup comprises:
The compound of formula I-E:
R wherein
1, R
2, R
3, R
4, R
5With x general in the above separately describe and subgroup in and description herein.
In certain embodiments, with regard to the compound of formula I-E:
A.R
1Be:
I.T-R ', wherein T is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO
2-or-CO-replaces, and R ' is hydrogen, C
1-C
4Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl, or
Ii.-Si (R ')
3, wherein R ' is hydrogen, C
1-C
4Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle;
B.R
2, R
3, and R
4Independently be hydrogen, R ', halogen, CN, NO separately
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' C (O) OR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR ' (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2, or-O (CH
2)
4N (R ')
2R wherein
2, R
3, and R
4Optional separately by R
6Occur to replace for z time, wherein z is 0-5 and R
6Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or Z-R ", wherein Z is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
C.R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ', wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
In other embodiments, with regard to the compound of formula I-E:
A.R
1Be hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3
B.R
2, and R
4Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2)
2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2, or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R wherein
2, R
3And R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ";
C.R
3Independently be Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2)
2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2, or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group; R wherein
3Independent of and optional R
6Occur to replace for z time, wherein z is 0 or 1, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ";
D.R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR ', wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR " ,-O (CH
2)
3OR " ,-O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R
1Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).
In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R
2, R
3, and R
4Each is hydrogen naturally.In other embodiments, R
2, R
3, or R
4In one be hydrogen.In other embodiments, R
2, R
3, or R
4In two be hydrogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be halogen, CN, NO
2, or V-R '.In other embodiments, R
2And R
4All be hydrogen, and R
3It is halogen.In other embodiments, R
2And R
4All be hydrogen, and R
3Be Cl.
In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R
2, R
3, and R
4Independent separately and optional by R
6Occur to replace for z time, wherein z is 1,2 or 3 and R
6Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and wherein aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
In specific illustrative embodiment, with regard to the compound of the subgroup of formula I-E and top direct description, x is 1,2 or 3, and R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH (CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2, or-NR ' (CH
2)
2N (R ')
2In other embodiments, x is 1,2 or 3, and R
5at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R
5at least once occur be-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '.In other embodiments, x is 1,2 or 3, and R
5At least once to occur be the optional C that replaces
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R
5Optional by R
7Occur to replace for y time, wherein y is 1,2 or 3 and R
7Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2-,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, x is 1,2 or 3; R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH (CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
Wherein y and R
7Generality describe and above subgroup in describe.
In other embodiments, x be 1 and compound have general formula I-E-i:
R wherein
1, R
2, R
3, and R
4Generality describe and above in the subgroup and description herein; R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.In certain embodiments, R
5Be N (R ')
2In specific embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, R
1, R
2, and R
4Each is hydrogen naturally, and formula I-E-ii is provided compound:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Alkyl, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
X is 1,2 or 3; And R
5at least once go out and be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NRCH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, R
1, R
2, and R
4Each is hydrogen naturally, and x is 0-3, and the compound of formula I-E-iii is provided:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Alkyl, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
In other embodiments, R
1, R
2, and R
4Each hydrogen naturally, and x is 1, and the compound of formula I-E-iv is provided:
Wherein:
R
3Be the optional group that replaces, be selected from halogen, the optional C that replaces
1-6Alkyl, CN, N (R ')
2, CO
2R ', NR ' COR ', CON (R ')
2, CH
2N (R ')
2, OR ', SR ', CH
2OR ';
R
5Be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' CH
2(CH
3) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '; And R ' is optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or be selected from top described (i)-(X
1Vi) or (X
1Ring vii).In other embodiments, R
5Be-N (R ')
2, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).
Propose in the representative example table 2 below of formula I compound.The compound of table 2 also can be represented by II-x, and wherein x is the compound number of expression in the table 2.
The example of table 2. formula I compound:
4. purposes, preparation and administration
The pharmacy acceptable composition
As discussed above, the invention provides the kinases inhibitor compound, and therefore compound of the present invention can be used for treating disease, illness and situation, include but not limited to illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, psychosis, autoimmune disorder, the situation relevant, inflammatory conditions, immunity-mediation with organ transplantation.In specific embodiments, this compound is used for the treatment of immune response, as allergy or type i allergic reaction or asthma; Autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis; Neurodegenerative disorders such as familial amyotrophic lateral sclerosis (PALS); With entity and hematologic malignancies, as leukemia and lymphoma.
These compounds and pharmaceutical composition thereof also can be used for treatment or prevent various illnesss, comprise, but be not limited to, heart trouble, diabetes, Alzheimer's, immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive osteopathy such as osteoporosis, proliferative disorders, catch, the disease and the virus disease of immunity-mediation.Said composition also can be used for preventing in necrocytosis and the outgrowth method and therefore can be used for treating or preventing apoplectic in perfusion/local asphyxia again, heart attack and organ hypoxia.Said composition also can be used for preventing zymoplasm-inductive platelet aggregation.Said composition is used in particular for illness such as chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer (comprises, but be not limited to ovarian cancer, mammary cancer and carcinoma of endometrium), hepatopathy comprises liver local asphyxia, heart trouble such as myocardial infarction and congestive heart failure, relate to the pathologic immune state and the neurodegenerative disorders of T cell activation.
Therefore, in the present invention on the other hand, provide the pharmacy acceptable composition, wherein these compositions comprise arbitrary compound described herein, and optional pharmaceutically acceptable carrier, auxiliary agent or the vehicle of comprising.In certain embodiments, these compounds are chosen wantonly and are also comprised one or more additional treatment agent.
It is also recognized that some compound of the present invention can the free form existence be used for handling, or suitable, exist with its pharmacy acceptable derivates form.According to the present invention, the pharmacy acceptable derivates comprises, but be not limited to, the salt of the acceptable prodrug of pharmacy, salt, ester, this ester or any other adducts or derivative, they are behind the patient who needs, compound described herein can directly or indirectly be provided, or its metabolite or resistates.
Term used herein " pharmacologically acceptable salts " is meant and drops in the rational medical evaluation scope, is applicable to and contacts with human and zootic tissue and do not have toxicity, pungency, an atopic reaction etc., and with rational income/risk than those salt that match." pharmacologically acceptable salts " is meant any nontoxic salt of The compounds of this invention or the salt of ester, give acceptor after, they can directly or indirectly provide compound of the present invention or its to suppress active metabolite or its residue.Term used herein " it suppresses active metabolite or its residue " is meant that its metabolite or its residue also are the inhibitor of JAK-3, ROCK and Aurora.
Pharmacologically acceptable salts is well known in the art.For example, people such as S.M.Berge are at J.Pharmaceutical Sciences, and 1977,66, describe pharmacologically acceptable salts among the 1-19 in detail, it is introduced herein as a reference.The pharmacologically acceptable salts of The compounds of this invention comprise from suitable inorganic and organic bronsted lowry acids and bases bronsted lowry deutero-those.The example of the acid salt that pharmacy is acceptable, nontoxic is and mineral acid, example hydrochloric acid, Hydrogen bromide, phosphoric acid, sulfuric acid and perchloric acid or the amide that forms with organic acid such as acetic acid, oxalic acid, toxilic acid, tartrate, citric acid, succsinic acid or propanedioic acid, or by using other used method of this area, as the amide of ion-exchange formation.Other pharmacologically acceptable salts comprises adipate, alginate, ascorbate salt, aspartate, benzene sulfonate, benzoate, bisul-phate, borate, butyrates, camphorate, camsilate, Citrate trianion, cyclopentane propionate, digluconate, dodecyl sulfate, esilate, formate, fumarate, the glucoheptose hydrochlorate, glycerophosphate, gluconate, Hemisulphate, enanthate, hexanoate, hydriodide, 2-hydroxyl-esilate, Lactobionate, lactic acid salt, lauroleate, dodecyl sulfate, malate, maleate, malonate, mesylate, the 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinic acid salt, persulphate, the 3-phenpropionate, phosphoric acid salt, picrate, Pivalate, propionic salt, stearate, succinate, vitriol, tartrate, thiocyanate-, right-tosylate, the undecane hydrochlorate, valerate etc.The salt that derives from suitable alkali comprises basic metal, alkaline-earth metal, ammonium and N
+(C
1-4Alkyl)
4Salt.The present invention has also expected arbitrary alkaline nitrogen-containing group quaternized of compound disclosed herein.Water-soluble or oil soluble or dispersible product can be by this quaternized acquisitions.Representational basic metal or alkaline earth salt comprise sodium, lithium, potassium, calcium, magnesium etc.Other pharmacologically acceptable salts comprises, suits the nontoxic ammonium, quaternary ammonium and the amine positively charged ion that use counter ion such as halogenide, oxyhydroxide, carboxylate radical, sulfate radical, phosphate radical, nitrate radical, low alkyl group sulfonic group and aryl sulfonic acid groups to form.
As mentioned above, pharmacy acceptable composition of the present invention also can comprise pharmaceutically acceptable carrier, auxiliary agent or vehicle, as used herein, they comprise any and all solvents, thinner or other liquid excipient, dispersion or suspendible auxiliary agent, tensio-active agent, isotonic agent, thickening material or emulsifying agent, sanitas, solid binder, lubricant etc., are suitable for required given dose form.Remington ' s Pharmaceutical Sciences, the 16 edition, E.W.Martin (Mack Publishing Co., Easton, Pa., 1980) various carriers used when preparation pharmacy acceptable composition and the known technology that is used to prepare them are disclosed.Except with the inconsistent any conventional mounting medium of The compounds of this invention, as produce any bad biological action or can accept any other component interaction of composition with deleterious mode and pharmacy, expect that its use falls within the scope of the present invention.Some examples that can be used as the material of pharmaceutical acceptable carrier comprise, but be not limited to, ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein such as human serum albumin, buffer substance such as phosphoric acid salt, glycine, Sorbic Acid, or potassium sorbate, the partial glyceride mixture of saturated vegetable fatty acid, water, salt or ionogen, as protamine sulfate, Sodium phosphate dibasic, dipotassium hydrogen phosphate, sodium-chlor, zinc salt, colloid silica, Magnesium Trisilicate, polyvinylpyrrolidone, polyacrylic ester, wax, polyethylene-polyoxytrimethylene block polymer, lanolin, sugar is as lactose, dextrose plus saccharose; Starch such as W-Gum and yam starch; Mierocrystalline cellulose and derivative thereof such as Xylo-Mucine, ethyl cellulose and cellulose acetate; Powdered tragacanth; Fructus Hordei Germinatus; Gelatin; Talcum powder; Vehicle such as Oleum Cocois and suppository wax; Oil is as peanut oil, Oleum Gossypii semen; Safflower oil; Sesame oil; Sweet oil; Semen Maydis oil and soya-bean oil; Glycols; As propylene glycol or polyoxyethylene glycol; Ester class such as ethyl oleate and Laurate ethyl; Agar; Buffer reagent such as magnesium hydroxide and aluminium hydroxide; Lalgine; Apirogen water; Deng oozing physiological saline; Ringer's solution; Ethanol and phosphate buffer soln and other nontoxic compatible lubricant such as sodium lauryl sulphate and Magnesium Stearate, and tinting material, releasing agent, Drug coating, sweeting agent, seasonings and flavouring agent, sanitas and antioxidant also can be present in the composition, and this will be according to makers-up's judgement.
The use of compound and pharmacy acceptable composition
On the other hand, a kind of method of severity that is used for the treatment of or alleviates illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, psychosis, autoimmune disorder, the situation relevant with organ transplantation, inflammatory conditions, immunity-mediation is provided, comprise that the curee to needs gives the compound of its significant quantity, or the pharmacy acceptable composition of inclusion compound.In certain embodiments of the invention, " significant quantity " that compound or pharmacy can be accepted composition is meant effective treatment or alleviates the consumption of severity of illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, psychosis, autoimmune disorder, the situation relevant with organ transplantation, inflammatory conditions, immunity-mediation.
In others, the present invention includes and be used for the treatment of or alleviate various illnesss, include, but are not limited to heart trouble, diabetes, Alzheimer's, immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive osteopathy such as osteoporosis, proliferative disorders, catch, the method for the severity of the disease of immunity-mediation and virus disease.In others, the present invention includes and be used for preventing necrocytosis and outgrowth method and therefore can be used for treating or perfusion/local asphyxia again, heart attack and the organ hypoxia of preventing apoplectic.In other embodiments, the present invention includes the method that is used to prevent zymoplasm-inductive platelet aggregation.The present invention also comprises and being used for the treatment of, alleviates illness such as chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer (comprises, but be not limited to ovarian cancer, mammary cancer and carcinoma of endometrium), hepatopathy comprises liver local asphyxia, heart trouble such as myocardial infarction and congestive heart failure, relate to the severity of the pathologic immune state of T cell activation and neurodegenerative disorders or prevent the method for these illnesss.
According to method of the present invention, described compound can use effective treatment with composition or alleviate any consumption and any route of administration administration of illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, autoimmune disorder, the situation relevant with organ transplantation, inflammatory conditions, immunity-mediation.Required accurate consumption will be according to being changed by curer's difference, and this depends on by curer's ethnic group, age and general situation, the severity of infection, specific medicament, its administering mode etc.Preferably compound of the present invention is mixed with and is convenient to administration and the uniform dosage unit form of dosage.Phraseology used herein " dosage unit form " is meant the substantial sepn unit of the medicament that is suitable for the patient that treats.Yet, should be appreciated that total service condition every day of The compounds of this invention and composition will be determined by the doctor in charge in rational medical evaluation scope.Any specific patient or biological concrete effective dose level depend on various factors, comprise the illness of being treated and the severity of illness; The activity of used particular compound; Used concrete composition; Patient's age, body weight, general health situation, sex and diet; Administration time; Route of administration; Discharge rate with used particular compound; The time length of treatment; With associating of used particular compound or the medicine that uses simultaneously; And the factor known of medical field.Term used herein " patient " is meant animal, preferred mammal, and optimum is chosen.
Can pharmacy acceptable composition of the present invention is oral, in the rectum, non-enteron aisle, brain pond, intravaginal, intraperitoneal, part (as pulvis, ointment or drops), oral cavity, give the patient by oral cavity or nose spraying etc., this depends on the severity that infects for the treatment of.In certain embodiments, compound of the present invention can every day about 0.01mg/kg by curer's body weight-Yue 50mg/kg by curer's body weight, preferred about 1mg/kg by curer's body weight-Yue 25mg/kg by the dosage level of curer's body weight oral or parenterai administration, once a day or repeatedly, thus obtain required result of treatment.
The liquid dosages form that is used for oral administration includes, but not limited to the acceptable emulsion of pharmacy, micro emulsion, solution, suspension, syrup and elixir.Remove the active ingredient beyond the region of objective existence, described liquid dosages form also can comprise the normally used inert diluent in this area as, for example, water or other solvent, solubilizing agent and emulsifying agent such as ethanol, Virahol, ethyl-carbonate, vinyl acetic monomer, phenylcarbinol, peruscabin, propylene glycol, 1,3 butylene glycol, dimethyl formamide, oil (particularly cottonseed, peanut, corn, embryo, olive, castor-oil plant and sesame oil), glycerine, tetrahydrofurfuryl alcohol, polyoxyethylene glycol and sorbitan fatty acid esters, and composition thereof.Except that inert diluent, described oral compositions also can comprise auxiliary agent, as wetting agent, emulsifying agent and suspension agent, sweeting agent, condiment and perfuming agent.
Injectable preparation, for example, aseptic aqueous injectable or oily suspension can use the preparation of suitable dispersion agent or wetting agent and suspension agent according to known in the art.The preparation of described sterile injectable can also be to be dissolved in nontoxic non-enteron aisle acceptable diluent or solvent, for example, and the sterile injectable solution in the 1,3 butylene glycol, suspension or emulsion.Used acceptable vehicle and solvent are water, Ringer's solution, U.S.P. and isoosmotic sodium chloride solution.In addition, aseptic expressed oil can be used as solvent or suspension matrix usually.With regard to this purpose, the expressed oil of any gentleness all can use, and comprises synthetic direactive glyceride or two glyceryl ester.In addition, lipid acid such as oleic acid can be used for preparing injectable preparation.
Injectable preparation can pass through, for example, be detained the filter of bacterium, or sterilize by the disinfectant that mixes the aseptic solid composite form, the disinfectant of described aseptic fixing composition form can be dissolved in it or be scattered in sterilized water or other the aseptic injectable matrix before use.
In order to prolong the effect of The compounds of this invention, often need slow down compound and absorb from subcutaneous or intramuscularly.This can realize by the liquid suspension that use has relatively poor water miscible crystallization or an amorphism material.The uptake rate of compound just depends on its dissolution rate then, successively, can be depending on crystalline size and crystallized form.Optionally, the delay of the compound form of parenterai administration absorbs by with compound dissolution or be suspended in the oily vehicle and realize.Injectable storage form is by at biological degradation polyalcohol, makes as the micro-capsule matrix that forms compound in polylactide-polyglycolide.According to the ratio of compound and polymkeric substance and the character of used particular polymers, the rate of release of may command compound.The example of other biological degradation polyalcohol comprises poly-(ortho ester) and poly-(acid anhydrides).The injectable formulation that stores also can prepare by compound being imbedded in liposome compatible with when injected organism tissue or the micro emulsion.
The preferred suppository of composition that is used for rectum or vagina administration, they can pass through compound of the present invention and suitable nonirritant excipient or carrier, mix and prepare as Oleum Cocois, polyoxyethylene glycol or suppository wax, they at room temperature are solid, but be liquid under body temperature, therefore can in rectum or vaginal canal, dissolve and release of active compounds.
The solid dosage form that is used for oral administration comprises capsule, tablet, pill, pulvis and granule.In this solid dosage form, with active compound and at least a inertia, acceptable vehicle of pharmacy or carrier such as Trisodium Citrate or Lin Suanergai and/or a) weighting agent or filler such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, b) binding agent as, for example, carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic, c) wetting agent such as glycerine, d) disintegrating agent such as agar, lime carbonate, potato or tapioca (flour), Lalgine, some silicate, and yellow soda ash, e) dissolving delayed-action activator such as paraffin, f) absorption enhancer such as quaternary ammonium compound, g) wetting agent as, for example, hexadecanol and glyceryl monostearate, h) absorption agent such as kaolin and wilkinite, and i) lubricant such as talcum powder, calcium stearate, Magnesium Stearate, solid polyethylene glycol, sodium lauryl sulphate, and composition thereof mix.For capsule, tablet and pill, described dosage form also can comprise buffer reagent.
The solids composition of similar type also can be used as soft hard-fill the weighting agent in the gelatine capsule, wherein use vehicle such as lactose or lactose and high-molecular weight polyoxyethylene glycol etc.The solid dosage form of tablet, drageeing, capsule, pill and granule can be with dressing and housing, other dressing preparation of knowing as enteric coating and medicine formulation art.They can be chosen wantonly and comprise opacifying agent and only can also be, or preferred, at a certain specific part of enteron aisle, randomly, with the composition of delayed mode release of active ingredients.The example of available embedding component comprises polymeric material and wax.The solids composition of similar type also can be used as soft hard-fill the weighting agent in the gelatine capsule, wherein use vehicle such as lactose or lactose and high-molecular weight polyoxyethylene glycol etc.
Described active compound can also be the micro-capsule form with above-mentioned one or more vehicle.Other dressing preparation that the solid dosage form of tablet, drageeing, capsule, pill and granule can be known with dressing and housing such as enteric coating, controlled release coat and medicine formulation art.In this solid dosage form, described active compound can mix with at least a inert diluent such as sucrose, lactose or starch.This dosage form also can comprise, according to standard practices, and other material except that inert diluent, for example tablet lubricants and other compressing tablet used additives are as Magnesium Stearate and Microcrystalline Cellulose.With regard to capsule, tablet and pill, described dosage form also can comprise buffer reagent.They also can be chosen wantonly and comprise opacifying agent and only can also be, or preferably at the specific part of enteron aisle, randomly, with the composition of delayed mode release of active ingredients.The example of available embedding component comprises polymeric material and wax.
The dosage form that is used for part or transdermal administration The compounds of this invention comprises ointment, paste, creme, lotion, gel, pulvis, solution, sprays, inhalation or patch.Described activeconstituents mixes with pharmaceutically acceptable carrier under aseptic condition, and may need any required sanitas or buffer reagent.Ophthalmic preparation, ear drop and eye drops are also comprised within the scope of the present invention by expection.In addition, the present invention has expected the use of transdermal patch, and it has the attendant advantages of compound sustained release to human body.This dosage form can be by with compound dissolution or be scattered in the suitable medium and prepare.Absorption enhancer also can be used for increasing the flux that compound passes skin.Speed can be by providing the rate-controlling film or controlling by compound is dispersed in polymeric matrix or the gel.
As above general described, compound of the present invention can be used as kinases inhibitor.Therein in embodiment, compound of the present invention and composition are one or more inhibitor in JAK-3, ROCK and the Aurora isotype, and therefore, do not wish to be subject to any particular theory limit, described compound and composition be used in particular for treating or palliate a disease, the severity of illness or situation, wherein one or more activation relates to described disease, illness or situation among JAK-3, ROCK or the Aurora.When the activation of JAK-3 related to specific disease, illness or situation, described disease, illness or situation also can be known as " disease of JAK-3-mediation ", " disease of ROCK-mediation ", " disease of Aurora-mediation " or disease symptoms.Therefore, on the other hand, the invention provides a kind of be used for the treatment of or palliate a disease, the method for illness or situation severity, wherein one or more activation relates to described disease condition among JAK-3, ROCK or the Aurora.
In the present invention as the activity of the compound of JAK-3, ROCK or Aurora inhibitor can be external, in the body or in clone, measure.The external test method comprises the phosphorylation activity of mensuration activated JAK-3, ROCK or Aurora or the assay method that atpase activity suppresses.Optionally the external test method can quantize inhibitor and JAK-3, ROCK or Aurora bonded ability.Inhibitor be in conjunction with can separating inhibitor/JAK-3, inhibitor/ROCK or inhibitor/Aurora complex body by in conjunction with the described inhibitor of preceding radio-labeling, and measures radio-labeling bonded amount and measure.Optionally, inhibitor is in conjunction with measuring by the experiment that is at war with, wherein with new inhibitor and and known radioligand bonded JAK-3, ROCK or Aurora cultivation.
Term used herein " can suppress " to be meant with measuring and comprise described composition and JAK-3, ROCK or the kinase whose sample of Aurora and do not having to comprise under the condition of described composition JAK-3, ROCK or the active measurable change of Aurora between JAK-3, ROCK or the kinase whose sample of equal value of Aurora.
Term used herein " disease of JAK-mediation " is meant any disease or other harmful illness that known JAK family kinase works.This illness comprises, but be not limited to, immune response such as allergy or type i allergic reaction, asthma, autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, neurodegenerative disorders are as familial amyotrophic lateral sclerosis (FALS) and entity and hematologic malignancies such as leukemia and lymphoma.
Term used herein " illness of ROCK-mediation " or " disease " are meant any disease or other the harmful illness that known ROCK family kinase works.Term " illness of ROCK-mediation " or " disease " also refer to those diseases or the situation by alleviating with the ROCK inhibitor for treating.This class situation comprises, but be not limited to, hypertension, stenocardia, cerebrovascular atrophy, asthma, peripheral circulation illness, premature labor, cancer, erectile dysfunction, arteriosclerosis, spasm (cerebral vasospasm and coronary artery spasm), retinopathy (for example, glaucoma), inflammatory conditions, autoimmune disorder, AIDS, osteoporosis, myocardial hypertrophy, local asphyxia/again damage of perfusion-inductive or endothelial dysfunction.
Term used herein " illness of Aurora-mediation " or " disease " are meant any disease or other the harmful illness that known Aurora family kinase works.Term " illness of Aurora-mediation " or " disease " also refer to those diseases or the situation by alleviating with the Aurora inhibitor for treating.This class situation comprises, but be not limited to, immune response, as allergy or type i allergic reaction, asthma, autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, neurodegenerative disorders such as familial amyotrophic lateral sclerosis (PALS) and entity and hematologic malignancies, as leukemia and lymphoma.
It is also understood that compound of the present invention and pharmacy acceptable composition can be used in the conjoint therapy, that is, described compound and pharmacy acceptable composition can with one or more other required treatment or medical procedure simultaneously, before it or afterwards, give.The particular combinations that is used for the therapy (treatment or process) of scheme for combining will be considered the consistency of the result of treatment of required treatment and/or process and desired acquisition.It is also recognized that used therapy can (for example obtain desirable effect with respect to same illness, compound of the present invention can with other medicament that is used for the treatment of same illness administration simultaneously), or they can obtain different effect (for example, the control of any side effect).Other therapeutical agent used herein, that be administered for treatment or prevention specified disease or illness usually is known as " be suitable for treated disease or illness ".
Can include, but are not limited to the example of the medicament of inhibitor Combined Preparation of the present invention: the treatment of Alzheimer such as Aricept
_And Excelon
_Parkinsonian treatment such as L-DOPA/ carbidopa, Entacapone, Ropinrole, send rummy Soviet Union, bromocriptine, PERGLIDE, Trihexyphenidyl (trihexephendyl) and amantadine; The medicament such as beta-interferon (for example, the Avonex of treatment multiple sclerosis (MS)
_And Rebif
_), Copaxone
_, and mitoxantrone; Treatment of asthma such as salbutamol and Singulair
_Be used for the treatment of schizoid medicament such as olanzapine, Wei Sitong, quetiapine and (halogen) haloperidol; Anti-inflammatory agent such as reflunomide, TNF blocker, IL-1RA, azathioprine, endoxan and sulfasalazine; Immunomodulatory and immunosuppressor such as S-Neoral, tacrolimus, rapamycin, mycophenlate mofetil, Interferon, rabbit, reflunomide, endoxan, azathioprine and sulfasalazine; Neurotrophic factor such as acetylcholinesterase depressant, MAO inhibitor, Interferon, rabbit, anticonvulsive agent, ion channel blocking agent, Riluzole and antiparkinsonian medicament; The medicament such as beta blocker, ACE inhibitor, diuretic(s), nitrate, calcium channel blocker and the Statins that are used for the treatment of cardiovascular diseases; The medicament such as reflunomide, Colestyramine, Interferon, rabbit and the antiviral agent that are used for the treatment of hepatopathy; Be used for the treatment of the medicament of hematologic disease such as reflunomide, anti--leukemic medicament and somatomedin; And the medicament such as the gamma globulin that are used for the treatment of the immunodeficiency disease.
The consumption that is present in other therapeutical agent in the present composition can not surpass the consumption that gives usually in only comprising the composition of this therapeutical agent as promoting agent.Preferably, the consumption of other therapeutical agent in the present disclosed composition only comprises the about 50%-100% of this medicament as consumption in the composition of therapeutic activity agent for being present in usually.
Compound of the present invention or its pharmacy acceptable composition also can be incorporated into and be used to apply implantable medical treatment device, in the composition as prosthese, artificial valve, blood vessel graft, stent and conduit.Therefore, but the present invention comprises the composition that is used to apply injection device on the other hand, The compounds of this invention of describing in general description and class herein and the group above it comprises and the carrier that is suitable for applying described implantable device.On the other hand, but the present invention includes the injection device that applies with composition, the The compounds of this invention of describing in general description and class herein and the group above said composition comprises, and the carrier that is suitable for applying described implantable device.
Vascular transplantation sheet fixed mould for example, has been used to overcome restenosis (restenosis of damage back vessel wall).Yet the patient of use stent or other implantable device has the danger of grumeleuse formation or platelet activation.These deleterious effects can prevent or relax by apply described device in advance with the pharmacy acceptable composition that comprises kinase inhibitor.The generality preparation of the suitable dressing and the implantable device of coating is at United States Patent (USP) 6,099, describes in 562,5,886,026 and 5,304,121.Dressing normally the polymeric material of biocompatible such as aquogel polymer, poly-methyl sily oxide, polycaprolactone, polyoxyethylene glycol, poly(lactic acid), ethylene vinyl acetate, and composition thereof.Described dressing also can be chosen wantonly by the suitable dressing of fluorosilicone, polysaccharide, polyoxyethylene glycol, phosphatide or its combination and further cover, thereby gives the composition controlled release characteristics.
The present invention relates to JAK-3, ROCK or the Aurora activity that suppresses among biological sample or the patient on the other hand, and this method comprises and give the patient, or makes the compound of described biological sample and general formula I or comprise described compound compositions and contact.Term used herein " biological sample " includes, but not limited to cell culture or its extract; Biopsy material from Mammals or the acquisition of its extract; And blood, saliva, urine, ight soil, tear or other body fluid or its extract.
The inhibition of JAK-3, ROCK or Aurora kinase activity can be used for various purpose well known by persons skilled in the art in the biological sample.The example of this purpose includes, but not limited to blood transfusion, organ transplantation, biological sample storage and biological assay.
Embodiment
Though describe the embodiment of specific illustrative below in detail, will be appreciated that other compound of general formula I can be according to the general method of describing herein, by those of ordinary skills' used method usually, use suitable initial substance and prepare.
Flow process 1
3-bromo-1H-pyrrolo-[2,3-b] pyridines (2)
(4g, 0.025mol) solution that is dissolved in the 100mL chloroform is cooled to 0 ℃ with azaindole 1.Dripping bromine is dissolved in the solution of 20mL chloroform, and 0 ℃ was stirred the gained mixture 1 hour.With 0.5N HCl dilution gained suspension, make the water layer alkalization with 0.5N NaOH, and cross filter solid, obtain 4g (82%) crude product 2, it is directly used in next step.
3-bromo-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (3)
2 solution that are dissolved in the anhydrous THF of 20mL of 3g (0.015mol) are cooled to-78 ℃, just dripping-BuLi 2.5M is dissolved in hexane (6.7mL, solution 0.167mol).Stir after 15 minutes, drip the solution that toluene sulfonyl chloride is dissolved in 5mL THF.Removed cooling bath and stirring at room reaction mixture 1 hour.With the ether extraction and with salt water washing organic phase, with dried over mgso and vacuum concentration, obtain white solid, make it through silicon-dioxide pad (70% EtOAc then; 30% hexane), obtain 3 of 4.65g (84%).
1H NMR CDCl
3 8.4(s,1H),8.1(d,2H),7.8(s,2H),7.2(m,3H),2.3(s,3H)。
3-(4,4,5,5-tetramethyl--[1,3,2] two oxa-boron pentamethylene (dioxaborolan)-2-yls)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (4)
With 3 (850mg 0.0024mol) is dissolved among the 20mL DME, add the pinnacol borine (921mg, 0.0036mol), Pd
2Cl
2(dppf)
2(197mg, 0.24mmol) and KOAc (713mg, 0.00726mol), 90 ℃ were stirred and reflux this mixture 18 hours.With ethyl acetate dilution and water and salt water washing organic phase, dry then (Na
2SO
4) and vacuum concentration.Make resistates obtain the required product 4 of 900mg (99%) through flash chromatography (20% EtOAc/80% hexane).
3-(2-methyl sulfane base-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3b] pyridines (5)
Under the nitrogen, make boric acid ester (boronic ester) 4 (900mg, 0.0023mol), 4-chloro-2-thiomethyl pyrimidine (341mg, 0.0029mol), Pd (Ph
3P)
4(260mg, 0.23mmol) and 2M yellow soda ash (3.4mL, 0.0068mol) mixture that is dissolved in 20mL DME refluxed 18 hours.With ethyl acetate dilution and water and salt water washing organic phase, dry then (Na
2SO
4) and vacuum concentration.Make resistates through flash chromatography (40% EtOAc/60% hexane), obtain the required product 5 of 460mg (51%).
1H NMR CDCl
3 8.8(d,1H),8.7(m,2H),8.4(s,1H),8.1(d,2H),7.2(m,4H),2.6(s,3H),2.3(s,3H)。
3-(2-methylsulfonyl-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (6)
With pyrimidine 5 (460mg 0.0012mol) is dissolved in the 20mL methanol-water (1: 1), add then oxone (2.14g, 0.0035mol), back flow reaction 18 hours.Vacuum is removed methyl alcohol and is used the ethyl acetate extraction water.Water and salt water washing organic phase, dry then (Na
2SO
4) and vacuum concentration.Make resistates through flash chromatography (40% EtOAc/60% hexane), obtain the required product 6 of 160mg (32%).LCMS ES
+=428.9。
Benzyl-[4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-2-base]-amine (7)
Under 80 ℃, heat 6 in the test tube in sealing (20mg, 0.047mmol) and benzylamine (0.007mL 0.061mmol) is dissolved in 1mL alcoholic acid solution 18 hours.Evaporating solvent obtains the 20mg product also by preparation type TLC (50% EtOAc/50% hexane) purifying crude product, uses 2ml 3N NaOH methanol solution to make the product deprotection 4 hours then.Add 2mL 3N HCl and be evaporated to dried.(20-70% MeCN-water and 0.1% TFA (20mL/ branch) obtain 7 of 10mg (75%) to reversed-phase HPLC.
1H NMR DMSOD
6 8.7(s,1H),8.4(s,1H),8.25(d,1H),8.1(d,1H),7.4(m,2H),7.25(m,3H),7.2(s,1H),7.15(dd,1H),7.1(s,1H),4.8(s,2H)。LCMS ES
+=302.0。
3-(6-chloro-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (8)
160 ℃ of microwave heating boric acid esters (boronate) 4 (0.11g, 0.276mmol), 4, the 6-dichloro pyrimidine (0.049g, 0.331mmol), catalysis Pd (PPh
3)
4Be dissolved in the solution 5 minutes of DMF with excessive salt of wormwood, by TLC (20% EtOAc: hexane) change into product.At EtOAc/H
2Distribute in reactant, extraction, the vacuum stripping between the O and by silicagel column purifying (eluent: 5%EtOAc: hexane), obtain white solid 8 (0.035g), productive rate 33%.
1-{4-[6-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-4-yl]-[1,4] Diazesuberane-1-yl }-ethyl ketone (9)
80 ℃ of heating 8 (0.035g, 0.091mmol), (0.025g, 0.181mmol), excessive salt of wormwood is dissolved in the solution of DMF, color changes N-ethanoyl-Gao piperazine piperazine (homopiperizine) after 5 minutes.LC/MS and TLC show the product that is converted into the tosyl group protection after 15 minutes.In reactant, add 1ml 6N NaOH and 1ml methyl alcohol, remove the tosyl group group immediately by LC/MS (M+1=337).At EtOAc/H
2Distribute reactant and extraction between the O.By preparation HPLC purifying crude product, obtain clarifying buttery 9 (0.022g), productive rate 73%.
NMR:MeOD 2.0bs(2H),2.1s(3H),3.6m(2H),3.8-4.3bm(6H),7.1d(1H),7.3m(1H),8.2d(1H),8.35m(2H),8.65d(1H)。LC/MS(M+1)=337
Benzyl-(2-chloro-pyrimidine-4-yl)-amine (10)
To 2,4-dichloro pyrimidine (0.15g, 1.0mmol), benzylamine (0.109ml, 1.0mmol) be dissolved in the solution of THF and add DIPEA (0.526ml, 3.0mmol) and heating reflux reaction 2 hours, by TLC (5% methyl alcohol: methylene dichloride) form 4: 1 mixtures of regional isomer (required with unwanted).The stripping reactant is also by silicagel column purifying (eluent: 2% methyl alcohol: methylene dichloride), obtain the required product 10 of 0.12g (0.548mmol), productive rate 54% in the vacuum.LC/MS(M+1)=220
Benzyl-(6-chloro-pyrimidine-4-yl)-amine (12)
With benzylamine (0.697ml 6.76mmol) joins 4, the 6-dichloro pyrimidine (1.0g, 6.76mmol) in, cause vigorous reaction and colour-change.With the slow diluting reaction thing of methylene dichloride, produce white precipitate.Add the 1ml triethylamine, and TLC shows and changes into product (5% MeOH: methylene dichloride).Directly install on the silicon-dioxide reactant and purifying (eluent: 2% MeOH: methylene dichloride), obtain 12 of yellow waxy 1.17g (5.32mmol), productive rate 79%.
Benzyl-[2-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-4-yl]-amine (11)
160 ℃ of microwave heating 4 (0.36g, 0.09mmol), 10 (0.028g, 0.108mmol), 2.0M Na
2CO
3(0.108ml is 0.271mmol) with catalysis PdCl
2(PPh
3)
2Be dissolved in the solution 5 minutes of 1ml DMSO, be converted into the product of tosyl group protection, LC/MS (M+1)=456.(0.026g, 0.271mmol), 160 ℃ of microwave heating 5 minutes is converted into product 11 fully to add NaOtBu in reactant.The filtering reaction thing also passes through the preparation HPLC purifying, obtains the 0.0032g 11 of white solid, productive rate 11%.
NMR:MeOD 4.95 bs(2H),6.6d(1H),7.2m(1H),7.3-7.5mm(5H),8.0d(1H),8.3d(1H),8.4s(1H),8.55d(1H)。LC/MS(M+1)=302
End product 13 obtains 0.012g (0.039mmol) white solid 13 according to 11 described formation.NMR:MeOD 4.8s(2H),7.05s(1H),7.2-7.6m(6H),8.2s(1H),8.4m(2H),8.55s(1H).LC/MS(M+1)=302
Flow process 2Synthesizing of 5-H-azaindole pyrimidine and pyridine analogs
3-(2-chloro-pyridin-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (14)
Under nitrogen, 160 ℃ of microwave heating azaindoles 3 (80mg, 0.23mmol), 2-chloropyridine-4-boric acid (41mg, 0.27mmol), Pd (Ph
3P)
4(20mg, 0.11mmol) and 2M yellow soda ash (.34mL 0.68mmol) is dissolved in the mixture 15 minutes of 2mL DME.With ethyl acetate dilution and water and salt water washing organic phase, dry then (Na
2SO
4) and vacuum concentration.Make resistates obtain the required product 14 of 60mg (68%) through flash chromatography (40% EtOAc/60% hexane).
1H NMR CDCl
3 8.6(d,2H),8.1(m,4H),7.25(m,5H),2.5(s,3H)。For example, available benzylamine replaces 2-chloropyridine microwave reaction 30 minutes under 250 ℃ of conditions, and then deprotection obtains compound 15.
1-(5-bromo-1H-pyrrolo-[2,3-b] pyridin-3-yl)-ethyl ketone (16)
(2.16g 0.011mmol) is dissolved among the anhydrous DCM of 75mL with 7-azaindole 13.In solution, add aluminum chloride (4.36g, 0.0327mol) and stirring at room reaction mixture 1 hour.Dripping acetyl chloride in mixture (1.16mL, 0.0164mol) and stirring at room 18 hours.Adding 20mL methyl alcohol also reacted 1 hour.Vacuum concentration also is suspended among water-EtOAc.With EtOAc extraction and dry organic phase, behind the vacuum concentration, obtain 2.37g (91%) compound 14.
1H NMRCDCl
3 9.5(bs,1H),8.8(s,1H),8.5(s,1H),7.9(s,1H),2.4(s,3H)。
1-[5-bromo-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-3-dimethylamino-acrylketone (propenone) (17)
0 ℃, (263mg is dissolved in slowly adds 16 in the suspension of anhydrous THF 0.0104mol) that (2.37g 0.01mol) is dissolved in the solution of THF to NaH.0 ℃ was stirred 15 minutes, and (2.27g 0.012mol) is dissolved in the solution of THF, stirring at room reaction mixture 18 hours to add Tosyl chloride then.With water quenching and use ethyl acetate extraction.Dry organic layer and vacuum concentration obtain the 3.37g solid residue, and it is directly used in next step.(5.7mL 0.0428mol) mixes, 100 ℃ of heating 22 hours with above-mentioned intermediate and DMF-DMA.Vacuum concentration, and, obtain the required product 15 of 3.37g (76% comes from 17) through flash chromatography (60% EtOAc/40% hexane).
1H NMR CDCl
3 8.8(s,1H),8.3(s,1H),8.1(s,1H),8.05(d,2H),7.8(d,1H),7.2(s,2H),5.7(d,1H),3.0(bs,6H),2.2(s,3H)。
6-(5-bromo-1H-pyrrolo-[2,3-b] pyridin-3-yl)-1H-pyrimidine-2-thioketones (thione) (18)
To the sodium of prepared fresh (175mg, 0.0076mol) be dissolved in add continuously in the solution of ethanol (18mL) compound 17 (1.0g, 0.0022mol) and thiocarbamide (187mg, 0.0025mol).This mixture of reflux 4 hours.Except that desolvating and resistates being dissolved in the 8mL water.With 1N HCl neutralization solution and use ethyl acetate extraction.Dry organic phase and vacuum concentration provide 570mg (75%) technical purified 18.
1H NMR CDCl
3 12.2(s,1H),8.6(s,1H),8.3(s,1H),8.2(s,1H),7.6(d,1H),5.8(d,1H)。
5-bromo-3-(2-methyl sulfane base-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (19)
Reflux 18 (565mg, 0.0018mol), sodium acetate (526mg, 0.0039mol), (0.126mL 0.0020mol) is dissolved in the suspension 2 hours of 15mL ethanol-THF (9: 1) to methyl iodide.Be cooled to room temperature and filtration.Chromatogram (70% EtOAc-30% hexane) provides 48mg (9%) thiomethyl intermediate.Tosylation provides 49mg (70%) required compound 19.
1H NMR CDCl
38.8(d,1H),8.5(m,2H),8.35(s,1H),8.1(d,2H),7.25(m,3H),2.7(s,3H),2.3(s,3H)。
Benzyl-[4-(5-bromo-1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-2-base]-amine (20)
This compound can be replaced through oxone oxidation and benzylamine since 19, according to flow process 1 preparation.
Flow process 3Synthesizing of azaindole pyrimidine that 5-replaces and pyridine analogs
5-bromo-1-(tert-butyl-dimethyl-silylation)-1H-pyrrolo-[2,3-b] pyridines (19)
Under 0 ℃, (200mg 0.0078mol) is dissolved in and adds azaindole 13 in the suspension of 15mL dry DMF (1.36g 0.007mol) is dissolved in the solution of 5mL DMF to NaH.0 ℃ was stirred 10 minutes, added the solution that TBDMSC1 is dissolved in 3mL DMF, stirred gained mixture O.N..Put into EtOAc and water, salt water washing.Dry organic layer and vacuum concentration become oil, and it is used for next step under situation about not being further purified.
1H NMR CDCl
3 8.3(d,1H),7.9(d,1H),7.2(d,1H),6.4(d,1H),0.85(s,H),0.5(s,6H)。
1-(tert-butyl-dimethyl-silylation)-5-pyridin-3-yl-1H-pyrrolo-[2,3-b] pyridines (20)
Under the nitrogen, and to 19 (1.77g, 0.0057mol), (1.0g 0.0068mol) is dissolved in the solution of 80mL DME and adds PdCl 3-parvoline base borine
2(Ph
3P)
2(320mg, 0.455mmol) and the 2M aqueous sodium carbonate (8.5mL, 0.017mol).Made reaction mixture refluxed 3 hours.Be cooled to room temperature and, use the salt water washing with the ethyl acetate dilution.Dry organic layer also is condensed into oil, and it obtains 1g (57%) desired substance 20 through flash chromatography (30% EtOAc-70% hexane).
1H NMR CDCl
38.9(s,1H),8.5(d,1H),8.4(d,1H),8.0(d,1H),7.9(d,1H),7.5(d,1H),7.2(d,1H),6.5(d,1H),0.85(s,9H),0.55(s,6H)。
3-bromo-1-(tert-butyl-dimethyl-silylation)-5-pyridin-3-yl-1H-pyrrolo-[2,3-b] pyridines (21)
Under 0 ℃, (0.166mL 0.0032mol) is dissolved in 1mL CCl with bromine
4Drips of solution be added to 20 (1.0g, 0.0032mol) and pyridine (0.314mL 0.0039mol) is dissolved in anhydrous CHCl
3In the stirred solution (30ml).0 ℃ of stirred reaction mixture 1 hour is used mixture (1: the 1) neutralization of 10mL sodium bicarbonate-Sulfothiorine then.Separate organic layer, and (3 * 10mL) extract further, dry organic layer and the vacuum-drying that merges with methylene dichloride.Resistates obtains 0.97g (78%) desired substance 21 through flash chromatography (30% EtOAc-70% hexane).
1H NMRCDCl
3 8.9(s,1H),8.55(d,1H),8.4(d,1H),8.0(d,1H),7.9(d,1H),7.4(dd,1H),7.2(s,1H),0.9(s,9H),0.5(s,6H)。
5-pyridin-3-yl-3-(4,4,5,5-tetramethyl--[1,3,2] two oxa-boron pentamethylene-2-yls)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (22)
Compound 21 can use, and for example, 10% HCl desilylationization is also used, for example, and NaH and p-toluenesulfonyl chloride tosylation.Compound 22 can use the scheme preparation identical with compound 4 in the flow process 1.
3-(2-methylsulfonyl-pyrimidine-4-yl)-5-pyridin-3-yl-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (24)
Compound 24 can use the scheme preparation identical with compound 6 in the flow process 1.
3-(6-chloro-pyrimidine-4-yl)-5-pyridin-3-yl-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (25)
Compound 25 can use the scheme preparation identical with compound 8 in the flow process 1.
3-(2-chloro-pyridin-4-yl)-5-pyridin-3-yl-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (26)
Compound 26 can use the scheme preparation identical with compound 14 in the flow process 2.
Flow process 4
2-methoxyl group-4-[1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-benzonitrile (29)
With the azaindole 3 (65.5mg, 194 μ mol) of boric acid 28 (35.4mg, 200 μ mol) and tosyl group protection, yellow soda ash (61.8mg, 583 μ mol) and tetrakis triphenylphosphine palladium (O) (8.3mg, 7.2 μ mol) are put in the test tube.Add entry (323mg) and glycol dimethyl ether (848mg) and make the mixture deoxidation.With the test tube sealing, under the magnetic stirring condition, 160 ℃ were heated 10 minutes, and wherein utilized microwave radiation.With ethyl acetate and water extraction crude product.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain crude product (83mg).Be dissolved in the solution gradient wash-out of methyl alcohol via the purification by flash chromatography crude product and with 1: 1 ethyl acetate/hexane-100% ethyl acetate-4/4/1 ethyl acetate/hexane/7N ammoniacal liquor, obtain 29 (42mg, 54%) and 30 (7.7mg, 15%).
2-methoxyl group-4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzonitrile (30)
By (200 μ l refluxed 4.5 hours in two _ alkane 2eq.) (5ml) and remove tosyl group blocking group in 29 containing 1N sodium hydroxide.The concentration response thing, and with the extraction of ethyl acetate and saturated sodium bicarbonate aqueous solution.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain 30 (30mg, 100%).
1H NMR CD
3CN 10.00(s,1H),8.32(m,2H),7.83(s,1H),7.65(d,1H),7.40(m,2H),7.20(dd,1H),4.02(s,3H).LC/MS(M+1)=250
2-methoxyl group-4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzamide (31)
(10mg, 40 μ mol) are dissolved in the dimethyl sulfoxide (DMSO) (0.5ml) with nitrile 30.To the solution that wherein adds salt of wormwood (20mg) and 30% hydrogen peroxide water-soluble (100 μ l).Reactant is warmed to about 60 ℃ reaches 15 minutes.Reactant is concentrated into the dry doubling water to be ground.Filtration gained precipitation, and vacuum-drying spends the night, and obtains 31 (10mg, 93%).1H NMR DMSO-d6 11.99(s,1H),8.32(d,1H),8.24(m,1H),8.01(m,1H),7.88(d,1H),7.59(s,1H),7.40(s,1H),7.37(m,2H),7.15(dd,1H),4.00(s,3H)。LC/MS(M+1)=268。
Flow process 5
Boric acid 32B-32F (500 μ mol) is placed in the test tube that contains azepine indoles 3 (87mg, 250 μ mol).In each bottle, put into yellow soda ash (53mg, 500 μ mol) and tetrakis triphenylphosphine palladium (O) (15mg, 13 μ mol).Add entry (1ml) and glycol dimethyl ether (2ml) and with the test tube deoxidation and the sealing.With test tube via microwave heating to 140 ℃ 10 minutes.Reactant is cooled to 0 ℃ also to quench with 2N aqueous hydrochloric acid (1ml).Use the ethyl acetate extraction reactant.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate.Go up purified product at silicon-dioxide (50% ethyl acetate/hexane-100% ethyl acetate gradient), obtain 33B-33F.
Under the room temperature, compound 33B-33F is dissolved in the methyl alcohol (20ml) and spends the night with 2N aqueous sodium hydroxide solution (1ml) processing.With 2N hydrochloric acid (1ml) neutralization reactant and be concentrated into dried.Via silica gel chromatography (50% ethyl acetate/hexane-100% ethyl acetate gradient) or on C18, carry out the directed reverse-phase chromatography of quality and (contain 15% acetonitrile/water of 0.09% trifluoroacetic acid-contain, 35% acetonitrile/water of 0.09% trifluoroacetic acid, 15 minutes) purifying, obtain product 34B-34F.
3-(3-benzyloxy-phenyl)-1H-pyrrolo-[2,3-b] pyridines (34B).
1H NMR DMSO-d6 11.95(s,1H),8.29(m,1H),8.20(d,1H),7.89(s,1H),7.49(d,2H),7.41(t,2H),7.34(m,2H),7.29(m,2H),7.13(dd,1H),6.90(m,1H),5.20(s,2H).LC/MS(M+1)=301.
3-(4-I benzyloxy-I phenyl)-1H-pyrrolo-[2,3-b] pyridines (34C).
1H NMR DMSO-d6 11.84(s,1H),8.28(m,2H),7.76(s,1H),7.61(d,2H),7.48(d,2H),7.39(t,2H),7.32(t,1H),7.15(dd,1H),7.09(d,2H),5.13(s,2H).LC/MS(M+1)=301.
3-(3,4-dimethoxy-phenyl 1)-1H-pyrrolo-[2,3-b] pyridines (34D).
1H NMR DMSO-d6 11.90(s,1H),8.31(d,1H),8.28(d,1H),7.80(s,1H),7.21(m,2H),7.19(dd,1H),7.02(d,1H),3.86(s,3H),3.78(s,3H).LC/MS(M+1)=255.
3-(3,4,5-dimethoxy-phenyl)-1H-pyrrolo-[2,3-b] pyridines (34E).
1H NMR DMSO-d6 11.85(s,1H),8.29(d,1H),8.27(d,1H),7.83(s,1H),7.15(d,1H),6.92(s,2H),3.86(s,6H),3.69(s,3H).LC/MS(M+1)=285.
2-methoxyl group-4-(1H-pyrrolo-[2,3-b] pyridine-3 base)-phenol (34F).
1H NMR DMSO-d6/D
2O 8.25-8.30(m,2H),7.74(s,1H),7.20(d,1H),7.17(dd,1H),7.10(dd,1H),6.86(d,1H),3.88(s,3H).LC/MS(M+1)=241.
Flow process 6
2-methoxyl group-5-[1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-phenyl aldehyde (36)
In test tube, put into boric acid ester 35 (131mg, 500 μ mol) and 3 (175mg, 500 μ mol), yellow soda ash (114mg, 1.08mmol) and tetrakis triphenylphosphine palladium (O) (22mg, 19 μ mol).Add entry (0.9g) and glycol dimethyl ether (2.1g) and make the mixture deoxidation.With test tube sealing and under the magnetic stirring condition, be heated to 110 ℃ and spend the night.With ethyl acetate and water extraction crude product.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain crude product.Be dissolved in solution gradient wash-out in the methyl alcohol via the purification by flash chromatography crude product and with 1: 1 ethyl acetate/hexane-100% ethyl acetate-4/4/1 ethyl acetate/hexane/7N ammoniacal liquor, obtain 36 (98mg, 48%).
2-methoxyl group-5-[1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-benzonitrile (37)
(98mg, 241 μ mol) are dissolved in the tetrahydrofuran (THF) (5ml) with aldehyde 36.To wherein adding 30% ammoniacal liquor (3ml) and iodine (79mg, 313 μ mol).The stirring at room reaction is spent the night.The dilute with water reactant is also used ethyl acetate extraction.With S-WAT (50mg) water (10ml) solution washing organic phase.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain 37 (95.8mg, 98%).
2-methoxyl group-5-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzonitrile (38)
Nitrile 37 (95.8mg, 237 μ mol) is dissolved in two _ alkane (5ml) also with water-soluble solution (250 μ l, the 500 μ mol) processing of 2N sodium hydroxide.With reactant sealing and reflux 2 hours.Reactant is concentrated into dry doubling to extract with ethyl acetate and water.With salt water washing organic phase, dry on sodium sulfate, filter and the concentrated crude product (72.3mg) that obtains.Be dissolved in the solution gradient wash-out of methyl alcohol via the purification by flash chromatography crude product and with 1: 1 ethyl acetate/hexane-100% ethyl acetate-4/4/1 ethyl acetate/hexane/7N ammoniacal liquor, obtain 38 (26.7mg, 45%).
2-methoxyl group-5-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzamide (39)
The nitrile 38 (26.7mg, 107 μ mol) of piptonychia benzenesulfonyl is dissolved in the dimethyl sulfoxide (DMSO) (2.49g).Spend the night to wherein adding salt of wormwood (32.7mg, 237 μ mol) and the solution and the stirring at room reactant of 30% hydrogen peroxide water-soluble (85.5mg).Dilute with water reactant and water, acetonitrile and ether washing gained precipitation obtain end product 39 (25.3mg, 88%).
1H NMRDMSO-d6 11.86(s,1H),8.28(m,1H),8.19(d,1H),8.11(m,1H),7.81(m,2H),7.70(s,1H),7.55(s,1H),7.21(d,1H),7.16(m,1H),3.91(s,3H).LC/MS(M+1)=268
4-bromine 2-HOMOVERATRONITRILE
In the 1L round-bottomed flask, 53.94g (270mmol) 4-bromo-2-fluorine benzonitrile is dissolved among the 500mLTHF.Add sodium methylate (21.99g, 407mmol) and this mixture of reflux up to TLC (SiO
2: CH
2Cl
2) show that initial substance exhausts fully.This mixture is poured among the 1N HCl, and vacuum-evaporation THF.Extract remaining mixture with diethyl ether.Dry (MgSO
4) extract and filter through silica gel plug.Use CH
2Cl
2Wash-out stopper and vacuum-evaporation filtrate obtain 45.56g (80%) white solid product.
1H NMR(500MHz,CDCl
3)δ7.42(d,1H),7.17(dd,1H),7.14(d,1H),3.95(s,3H)。
4-cyano group-3-anisole ylboronic acid (28)
Assembling overhead and nitrogen pipeline on the 1L of 3 necks round-bottomed flask.45.56g (215mmol) 4-bromo-2-HOMOVERATRONITRILE, 64mL (277mmol) three-sec.-propyl borate and 500mL THF pack in flask.In dry ice/acetone batch, solution is cooled to-78 ℃.Via addition funnel drip n-Butyl Lithium (2.5M, 110mL, 275mmol).Stir this mixture 30 minutes and added 2N HCl.Stirred the mixture 1 hour and pour in the water.Use Et
2O extracts mixture.With 1N NaOH reextraction organic solution.Use Et
2O washing water layer is also with dense HCl acidifying.Use Et
2O extracts mixture.Dry organic extract (MgSO
4) and vacuum-evaporation obtain 20.77g (55%) white solid product.
1H NMR(500MHz,d6-DMSO)87.68(d,1H),7.59(s,1H),7.47(d,1H),3.95(s,3H).
Flow process 7:
5-chloro-3-iodo-pyridine-2-base amine (40)
With iodine (16.28g, 64mmol) join 1-amino-5-chloropyridine (8.25g, 64mmol) and Sulfuric acid disilver salt (20g 64mmol) is dissolved in the 400mL alcoholic acid mixture, this mixture of stirring at room 20 hours.On the C ore deposit, filter this mixture and solvent removed in vacuo.Resistates is dissolved among the DCM (600mL) also with the 5%NaOH aqueous solution (500mL), water and salt water washing.Dry organic layer and vacuum concentration obtain solid residue, and it produces 9.8g (60%) 40 through flash chromatography (20%EtOAc-80% hexane).
1H NMR(500MHz,CDCl
3)7.9(s,1H),7.7(s,1H),5.0(bs,2H)。
5-chloro-2-(triethyl-silylation)-1H-pyrrolo-[2,3-b] pyridines (41)
Add 40 (9.5g, 37.3mmol) be dissolved in 320mL DMF and triethylsilyl acetylene (20mL, 112mmol), Pd
2Cl
2(dppf)
2(1.52g, 1.9mmol), lithium chloride (1.58g, 37.3mmol) and 2M Na
2CO
3(7.9mL, mixture 74.7mL) stir this mixture and 90 ℃ and refluxed 15 hours under condition of nitrogen gas.With ethyl acetate-ether mixture (1: 1) dilution and water and salt water washing organic phase, dry then (Na
2SO
4) and vacuum concentration.Make resistates obtain the required product 41 of 4.37g (44%) through flash chromatography (20% EtOAc/80% hexane).
1HNMR(500MHz,CDCl
3)9.4(bs,1H),8.2(s,1H),7.9(s,1H),6.6(s,1H),0.9(t,9H),0.75(q,6H)。
5-chloro-1H-pyrrolo-[2,3-b] pyridines (42)
(4.37g 0.0164mol) is dissolved among the THF with compound 41.Adding molecular sieve (10g3A), then is TBAF (32.75mL, 0.0328).Stirring at room reaction mixture 5 hours.Dilute also water, salt water washing several times with ethyl acetate, dry organic layer and vacuum concentration become oil, and it obtains 0.23g (90%) desired substance 42 through flash chromatography (30% EtOAc-70% hexane).
1H NMR DMSO d
6 11.8(bs,1H),8.2(s,1H),8.1(s,1H),7.5(s,1H),6.5(s,1H)。
1-(tert-butyl-dimethyl-silylation)-5-chloro-1H-pyrrolo-[2,3-b] pyridines (43)
In the spaced sealing test tube of assembling, under nitrogen, (600mg 0.00396mol) is cooled to 0 ℃ with the anhydrous THF of 20mL and with solution to add 42.Add gradually NaH (110mg, 0.00435mol), 0 ℃ was stirred after 15 minutes, add TBSC1 (656mg, 0.00435mol).Replace at interval with the Teflon nut, and the test tube of 80 ℃ of heated sealants 3 hours.Hexane extraction is used in cooling and with ammonium chloride solution neutralization.Dry organic phase and vacuum concentration become oil, and it filters (10% EtOAc-90% hexane) through too short stopper, obtains 871mg (82%) compound 43.
1H NMR(500MHz,CDCl
3)8.2(s,1H),7.8(s,1H),7.25(s,1H),6.4(s,1H),0.9(s,9H),0.6(s,6H)。
Can be according to describing with respect to compound 21 in the previous flow process 3, with compound 43 in C-3 place bromination.
Compound 19 can be used, and for example, uncle-BuLi lithiumation is also used the DMF cancellation, and 5-formyl radical azaindole 44 is provided.Also can be at palladium catalyst, Pd (Ph for example
3P)
4Under the condition that exists, handle compound 19 with carbon monoxide (carbon moxoxide) and methyl alcohol, thereby 5-methoxycarbonyl base azaindole 44 is provided.By standard conversion, functional group is converted to acid, primary, the second month in a season and teritary amide mutually, as 45.Compound 44 can via, for example, Witting reaction homology turns to compound as 49.
Compound 19 can be used, for example, KCN, under the condition that has catalyzer such as copper or palladium to exist, cyaniding in hot DMF, thus 5-cyano group azaindole 46 is provided.
Under the condition that has palladium catalyst to exist, make compound 19 aminations with amine, can provide 5-ammonification azaindole as 48.
Compound 19 can use Suzuki or Stille coupling arylation or heteroarylization, thereby provides compound as 47.
In others, provide other synthesis flow and compound synthetic:
Flow process 9
Embodiment A
5-chloro-3-iodo-pyridine-2-base amine (1): the 5-chloropyridine of in being equipped with the round-bottomed flask of air condenser, packing into-2-base amine (26g, 0.2ml), acetate (78ml) and water (18ml).Then drip the vitriol oil (2.6ml), add gradually periodic acid (9.5g, 0.04mol) and iodine (20g, 0.08mol).80 ℃ of stirred reaction mixtures 6 hours firmly are cooled to room temperature then.
With reaction mixture be poured on ice (~700g) in.With the 5M NaOH aqueous solution with the pH regulator of this suspension to 8-9.Filter brown solid and it is dissolved among the EtOAc (1.21).Use saturated Na
2S
2O
3The aqueous solution, 1M NaOH solution and salt water washing organic phase.At MgSO
4Go up dry organic phase and concentrated.Make resistates recrystallization from hexanaphthene, obtain orange solids (42g, 80%).
1H NMR(CDCl
3):4.8-5.1(2H,brs),7.9(1H,s),8.0(1H,s)。
5-chloro-3-(trimethylammonium-silylation ethynyl)-pyridine-2-base amine (2): under nitrogen, 5-chloro-3-iodo-pyridine-2-base amine (1) (42g packs in the 250ml round-bottomed flask, 165mmol), THF (100ml), cupric iodide (315mg, 1.65mmol) and PdCl
2(PPh
3)
2(1.15g, 1.65mmol), triethylamine (70ml, 0.5mol) and trimethyl silyl acetylene (30ml, 0.21mol).Stirring at room reaction mixture 2 hours.Then reaction mixture is cooled to 0 ℃ and add diethyl ether.By filtering this suspension and thoroughly wash in the C ore deposit with diethyl ether.Concentrated filtrate and make that it is pre--absorb on the silica gel, and use pentane/DCM 10%-100% as eluent, by the column chromatography purifying, provide rice white solid (36g, 100%).
1HNMR(CDCl
3):0.3(9H,s),5.0-5.1(2H,brs),7.6(1H,s),7.9(1H,s)。MS(ES+):225,227。
5-chloro-1H-pyrrolo-[2,3-b] pyridines (3): under the condition of nitrogen gas, (36g, 320mmol) solution that is dissolved in N-Methyl pyrrolidone (70ml) is heated to 80 ℃ with potassium tert.-butoxide.Via dropping funnel Dropwise 5-chloro-3-(trimethylammonium-silylation ethynyl)-pyridine-2-base amine (2) (36g, 160mmol) solution in NMP (200ml).80 ℃ of stirred reaction mixtures are 50 minutes once more.Make reaction mixture be cooled to room temperature.In reaction mixture, add bromine (500ml), and (5 * 200ml) extract with diethyl ether.With salt water washing blended organic layer, dry and vacuum concentration on sal epsom.Use pentane/EtOAc 0%-40% as eluent, by column chromatography purifying resistates, and from hexanaphthene recrystallization, title compound (10g, 41%) is provided.
1H NMR(CDCl
3)6.5(1H,s),7.4(1H,s),8.0(1H,s),8.2(1H,s),10.4-10.6(1H,brs)。MS(ES+)153。
3-bromo-5-chloro-1H-pyrrolo-[2,3-b] pyridines (4): the drips of solution that bromine (3.5ml) is dissolved in chloroform (40ml) is added to 5-chloro-1H-pyrrolo-[2,3-b] pyridines (3), and (10g 65mM) is dissolved in the ice-cold solution of chloroform (260ml).0 ℃ of stirred reaction mixture 60 minutes.Water makes the reaction mixture hydrolysis then, and with the pH regulator to 10 of solution.Remove by filter the gained solid, and use the dichloromethane extraction water.Wash organic layer with water, dry on sal epsom, and vacuum concentration, title compound (10.5g, 69%) is provided.
1H NMR(DMSO-d6)7.8(1H,s),7.9(1H,s),8.3(1H,s)。
3-bromo-5-chloro-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2; 3-b] pyridine (5): under the condition of nitrogen gas; with sodium hydride (2.2g; 54mmol) join 3-bromo-5-chloro-1H-pyrrolo-[2 gradually; 3-b] (10.5g 45mmol) is dissolved in the ice-cold solution of dimethyl formamide (70ml) pyridine (4).After 30 minutes, (8.7g 46mmol) joins in the reaction mixture, and stirring at room reaction mixture 18 hours with toluene sulfonyl chloride.(~150ml) hydrolysis reaction mixture, and filtration obtains brown solid to water, and vacuum-drying provides title compound (14,8g, 85%).
1HNMR(CDCl
3)2.4(3H,s),7.3-7.4(2H,d),7.8-7.9(2H.2s),8.1-8.2(2H,d),8.4(1H,s);MS(ES+)387
5-chloro-3-(4; 4; 5,5-tetramethyl--[1,3; 2] two oxa-boron pentamethylene-2-yls)-1-(toluene-4-alkylsulfonyl)-1H-[2; 3-b] pyridine (6): under condition of nitrogen gas, 3-bromo-5-chloro-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (5) (6.9g packs in the 500ml round-bottomed flask; 18mmol), bispinacolatodiboron (6.9g, 27mmol), PdCl
2(dppf)
2(1.5g, 1.8mmol), potassium acetate (5.3g, 54mmol) and glycol dimethyl ether (100ml).90 ℃ of stirred reaction mixtures 18 hours.Dilute this reaction mixture and use the salt water washing with ethyl acetate (200ml).Dry organic phase and vacuum concentration on sal epsom.Use pentane/EtOAc 0%-20% as eluent,, grind with pentane then, title compound (4g, 50%) is provided by column chromatography purifying resistates.
1HNMR(CDCl
3)1.4(9H,s),2.4(3H,s),7.2(2H,d),8.00-8.05(2H,d),8.10(2H,s),8.3(1H,s)。MS(ES+)433
(6-bromo-pyridine-2-yl)-(4-chloro-benzyl)-amine (7): 4-chlorobenzylamine (700mg packs in the microwave bottle; 5mmol; 5 equivalents) and 2, and the 6-dibromo pyridine (238mg, 1mmol).Under 150 ℃, microwave stirred reaction mixture 3 times 10 minutes (maximum 200W).With diethyl ether (50ml) diluted reaction mixture, with 10% aqueous citric acid solution, saturated sodium bicarbonate aqueous solution and salt water washing.Dry organic phase on sal epsom, after the filtration, vacuum concentration provides buttery title compound (300mg, 100% productive rate).LC/MS:299[M+H]
(4-chloro-benzyl)-[6-(5-chloro-1H-pyrrolo-[2; 3-b] pyridine-3 base)-pyridine-2 base]-amine (8): in the microwave bottle, pack into (6-bromo-pyridine-2-yl)-(4-chloro-benzyl)-amine (300mg; 1mmol), 5-chloro-3-(4; 4; 5; 5-tetramethyl--[1; 3; 2] dioxaborolan-2-yl)-1-(toluene-4-alkylsulfonyl-1H-[2; 3-b] pyridine (7) (215mg; 0.5mmol), tetrakis (triphenylphosphine) palladium (60mg, 0.05mmol), 2M sodium hydroxide (0.75ml) and glycol dimethyl ether (5ml).Make this suspension degassing with nitrogen.130 ℃ of microwave stirred reaction mixtures 10 minutes (maximum 200W).Then with ethyl acetate dilute it (60ml), use the salt solution washed twice, on sal epsom drying also, after the filtration, vacuum concentration.By flash chromatography (eluent: petrol ether/ethyl acetate 60/40) this compound of purifying, the title compound that provides the 50mg tosyl group to protect.This resistates is dissolved in the mixture of methyl alcohol and tetrahydrofuran (THF) (1/3ml).(1ml) joins in the reaction mixture with the 1M sodium hydroxide solution, and stirring at room is 3 hours then.The vacuum concentration reaction mixture is also used the methyl alcohol grinding residues.Filter this suspension, title compound (35mg, 10%) is provided.
1H NMR(DMSO-d6):4.60-4.70(2H,m),6.35-6.40((1H,d),7.05-7.10(1H,d),7.20-7.25(1H,t),7.35-7.45(4H,m),8.15-8.20(2H,m),8.55-8.60(1H,s),12.5(1H,s)。LC/MS:369[M+H],367[M-H]
Below table 3 data of specific illustrative compound are described.Compound number is corresponding with those compounds of description in the table 1."-" expression is not measured.
Table 3
Cmpd# | LC_MASS_ PLUS | NMR_RESULT |
1 | - | 8.9 1H,d;8.35 1H,s;8.25 1H,d;8.1 1H,d;7.2 1H,dd,7.1 1H,d;6.5 1H s |
2 | 309.10 | CDCl3 9.21(m,1H)9.18(s,1H)8.51(s,1H),8.16(dd,J= 5.4,1.0,1H)7.34(dd,J=8.0,5.4,1H),7.25(m 1H)7.19(m, 1H)7.03(m,1H)6.85(s,1H) |
3 | 324.00 | MeOD(500MHz)8.76(s,1H)8.45(s,1H)8.43(s,1H),8.34 (s,1H)7.66(m,1H)7.40(m,1H)7.38(m,1H),7.27(m,2H) |
4 | 288.00 | MeOD,7.2s(1H),7.25t(1H),7.35m(1H),7.5t(2H),7.65 d(2H),8.25s(1H),8.4m(2H),8.7s(1H) |
Cmpd# | LC_MASS_ PLUS | NMR_RESULT |
5 | 310.00 | MeOD,0.6m(2H),1.0m(2H),1.6s(3H),1.8m(1H),2.1 m(1H),2.3d(1H),2.6d(1H),4.3s(1H),6.0m(2H),6.95 s(1H),7.05m(1H),7.5m(2H) |
6 | 212.00 | MeOD,7.05s(1H),7.35m(1H),8.2s(1H),8.4m(2H),8.55 s(1H) |
7 | 302.00 | MeOD,4.8s(2H),7.05s(1H),7.2-7.6m(6H),8.2s(1H),8.4 m(2H),8.55s(1H) |
8 | 240.10 | 1H 8.94,1H 8.19,1H 8.14,2H 7.25,1H 7.02,2H 3.52,,3H 1.31 |
9 | 337.00 | MeOD,2.0bs(2H),2.1s(3H),3.6m(2H),3.8-4.3bm(6H),7.1 d(1H),7.3m(1H),8.2d(1H),8.35m(2H),8.65d(1H) |
10 | 332.00 | MeOD,3.8s(3H),4.7bs(2H),7.0m(3H),7.35m(4H),8.2 s(1H),8.4m(2H),8.6bs(1H) |
11 | 308.00 | MeOD,1.05m(2H),1.3m(3H),1.7m(2H),1.75-1.9m(4H), 3.5d(2H),7.0s(1H),7.3(1H),8.1s(1H),8.35d(1H),8.4 d(1H),8.6s(1H) |
12 | 310.00 | MeOD1.4m(2H),1.7m(2H),2.0m(1H),2.65s(1H),3.45 m(2H),3.6m(1H),4.0d(2H),7.0s(1H),7.35m(1H),8.2 s(1H),8.35d(1H),8.45m(1H),8.6s(1H) |
13 | 240.00 | MeOD;1.3t(3H),3.65m(2H),7.0s(1H),7.3m(1H),8.2 s(1H),8.4d(2H),8.6m(1H) |
14 | 256.00 | MeOD;3.7-3.9dm(4H),7.0s(1H),7.3m(1H),8.1s(1H),8.4 d(2H),8.6bs(1H) |
15 | 360.10 | 1H NMR 500MHz(DMSO-d6)12.35ppm,1H,s;,11.02ppm, 1H,s;8.88ppm,1H,s;8.63ppm,1H,d;,8.42ppm,1H,s; 8.33ppm,2H,m;7.25ppm,2H,m;,6.97ppm,2H,m;6.87 ppm,1H,d;3.78ppm,2H,s;,3.77ppm,3H,s. |
16 | 302.00 | DMSO d 6 8.7(bs,1H);8.4(bs,1H);8.25(d,1H);8.1(d,1H); 7.4(m,2H);7.25(m,3H);7.2(bs,1H);7.15(bs,1H);4.7(bs, 2H) |
17 | 313.00 | DMSO,7.2q(2H),8.3mm(3H),8.6d(2H),8.85dd(2H),9.1 s(1H),12.35bs(2H) |
18 | 336.00 | MeOD,4.8s(2H),7.0s(1H),7.3bs(5H),8.1s(1H),8.3 m(2H),8.6s(1H) |
19 | 295.00 | - |
20 | 337.00 | - |
21 | 347.90 | - |
22 | 347.90 | - |
23 | 365.90 | - |
24 | 422.90 | - |
25 | 343.95 | - |
26 | 328.00 | MeOD,3.1bm(2H),4.0-4.4bd(2H),5.0-5.3bs(2H),7.25 s(1H),7.3-7.35m(4H),7.4m(1H),8.3s(1H),8.4d(1H),8.5 d(1H),8.7s(1H) |
Cmpd# | LC_MASS_ PLUS | NMR_RESULT |
27 | 366.10 | 1H NMR500 MHz (DMSO-d6)12.33ppm,1H,s;11.03ppm, 1H,s;8.86ppm,1H,s;8.62ppm,1H,m;8.43ppm,1H,s; 8.29ppm,2H,m;7.45ppm,2H,m;7.25ppm,1H,m;7.20 ppm,2H,m;3.87ppm,2H,s;. |
28 | 348.00 | 1H NMR 500 MHz(DMSO-d6)12.42ppm,1H,s;11.05ppm, 1H,s;9.72ppm,1H,s;8.89ppm,1H,s;8.63ppm,1H,m; 8.43ppm,1H,s;8.31ppm,2H,m;7.25ppm,6H,m;1H,m; 3.87ppm,2H,s;3.00ppm,3H,s. |
29 | 423.10 | 1H NMR 500 MHz(DMSO-d6)12.33ppm,1H,s;11.00ppm, 1H,s;8.84ppm,1H,s;8.59ppm,1H,m;8.45ppm,1H,s; 8.30ppm,2H,m;7.30ppm,6H,m;3.83ppm,2H,s. |
30 | 330.00 | 1H NMR 500 MHz(DMSO-d6)12.35ppm,1H,s;11.10ppm, 1H,s;8.88ppm,1H,s;8.62ppm,1H,m;8.42ppm,1H,s; 8.31ppm,2H,m;7.30ppm,5H,m;3.90ppm,2H,s; |
31 | 348.00 | 1H NMR 500 MHz(DMSO-d6)12.35ppm,1H,s;11.10ppm, 1H,s;8.88ppm,1H,s;8.62ppm,1H,m;8.42ppm,1H,s; 8.31ppm,2H,m;7.30ppm,5H,m;3.90ppm,2H,s; |
32 | 309.00 | 12.25(s,1H),8.67(d,1H),8.40(s,1H),,8.30(d,1H),8.27(d, 1H),7.23 dd,1H),,7.09(d,1H),4.63(d,2H),3.30(s,2H), 2.80(m,2H),2.45(m,1H),1.07(d,6H),DMSO-d6, |
33 | 351.00 | 12.28(s,1H),8.72(d,1H),8.42(s,1H),,8.31(d,1H),8.28(d, 1H),7.25(dd,1H),,7.14(d,1H),4.71(d,2H),4.10-4.70(m, 2H),3.30(s,1H),3.12(s,2H),2.09(s,3H),,1.21(m, 6H),DMSO-d6, |
34 | 308.00 | 8.90(s,1H),8.60(s,1H),8.39(m,1H),,8.01(m,1H),7.33 (m,2H),4.80(s,10H,solvent),,3.55(m,1H),3.30(m,14H, solvent),1.92(m,2H),1.81(m,3H),1.72(m,1H),,1.25-1.40 (m,3H),1.08-1.25(m,2H),MeOH-d4, |
35 | 385.00 | MeOD,1.8-2.8bm(2H),2.35bm(2H),3.2bm(1H),3.6(2H), 4.5-4.5bs(3H),7.0bs(1H),7.3m(1H),7.s(5H),8.2s(1H), 8.3m(2H),8.6s(1H) |
36 | 367.00 | MeOD,1.25t(3H),1.55q(2H),2.1d(2H),3.1m(2H),4.15 m(4H),4,6m(1H),7.0s(1H),7.3m(1H),8.2s(1H),8.3 d(1H),8.4d(1H),8.6s(1H) |
37 | 337.00 | 12.32(s,1H),9.3-10.5(s,4H),9.01(d,1H),,8.51(s,1H), 8.48(d,1H),8.19(d,1H),,7.53(m,1H),7.25(d,1H),4.82 (m,1/2H),,4.25-4.53(m,21/2H),3.81-3.93(m,1/2H),3.58- 3.71(m,11/2H),3.14-3.58(m,11/2H),,2.12(s,3H),1.18- 1.40(m,3H),CD3CN, |
38 | 337.00 | 12.4(s,1H),8.96(d,1H),,8.48(s,1H),8.40(d,1H),8.12(d, 1H),,7.49(m,1H),7.20(d,1H),4.8(m,1/2H),,4.2-4.5(m,2 1/2H),3.79-3.91(m,1/2H),3.58-3.69(m,11/2H),3.12-3.58 (m,11/2H),,2.1(s,3H),1.12-1.35(m,3H),CD3CN,, |
39 | 351.00 | MeOD,1.4s(1H),1.7t(2H),2.3d(2H),7.0s(1H),7.3m(1H), 8.1s(1H),8.3d(1H),8.35d(1H),8.6s(1H) |
Cmpd# | LC_MASS_ PLUS | NMR_RESULT |
40 | 378.90 | 12.9(s,1H);9.1(s,1H);8.9(s,1H);8.8(s,1H);8.7(bs,2H); 8.5(d,1H);8.3(d,1H);7.6(bs,1H);7.4(m,6H);4.7(s,2H) |
41 | 335.90 | CDCl 3 8.7(bs,2H);8.4(bs,2H);8.3(s,1H);7.4(m,5H); 4.8(s,2H) |
42 | 362.00 | 10.94(m,1H),8.96(d,1H),8.71(s,1H),8.55(s,1H),,8.19 (dd,1H),7.24(d,1H),4.5-6.0(6H),3.7-4.3(m,6H),,3.60(m, 2H),2.1(s,3H) |
43 | 302.00 | MeOD,4.95bs(2H),6.6d(1H),7.2m(1H),7.3-7.5mm(5H), 8.0d(1H),8.3d(1H),8.4s(1H),8.55d(1H) |
44 | 230.10 | 1H 8.45,3H 8.35,2H 7.82,1H 7.25 |
45 | 250.00 | 10.00(s,1H),8.32(m,2H),7.83(s,1H),7.65(d,1H),,7.40 (m,2H),7.20(dd,1H),4.02(s,3H),,CD3CN |
46 | 268.00 | 11.99(s,1H),8.32(d,1H),8.24(m,1H),,8.01(m,1H),7.88 (d,1H),7.59(s,1H),,7.40(s,1H),7.37(m,2H),7.15(dd, 1H),,4.00(s,3H),,DMSO-d6 |
47 | 268.00 | - |
48 | 238.00 | 11.98(s,1H),8.32(d,1H),8.26(m,1H),8.15(s,1H),,8.00 (s,1H),7.91(d,1H),7.82(d,1H),7.71(d,1H),,7.47(t,1H), 7.34(s,1H),7.16(dd,1H),DMSO-d6 |
49 | 238.00 | 11.97(s,1H),8.29(d,1H),8.21(d,1H),7.92(d,1H),,7.85 (d,2H),7.71(d,2H),7.17(s,1H),7.10(dd,1H),DMSO-d6 |
50 | 292.00 | 11.97(s,1H),8.48(s,1H),8.29(m,2H),8.00(d,1H),,7.88 (d,1H),7.71(dd,1H),7.61(s,1H),7.27(d,1H),,7.21(dd, 1H),4.01(s,3H),DMSO-d6 |
51 | 301.00 | - |
52 | 301.00 | - |
53 | 255.00 | - |
54 | 285.00 | - |
55 | 241.00 | - |
Following table 4 is described the data of specific illustrative compound, and compound number is corresponding with those compounds of description in the table 2.Blank expression is measured.
Table4
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
1 | 380.00 | 12.68(m,1H),9.20(s,1H),8.82(s,1H),8.62(m,1H), 8.28(m,1H),8.05(s,1H),7.35(s,1H),7.25(m,1H), 3.6-4.2(m,6H),3.45(m,2H),1.7-2.1(m,5H) DMSO-d6 | 1.45 |
2 | 379.00 | 1.70 | |
3 | 414.00 | 2.30 | |
4 | 335.90 | 2.60 | |
5 | 371.00 | 2.10 | |
6 | MeOD 5.0s(2H),7.1s(1H),7.3m(1H),7.6m(1H),8.1d(1H),8.2 s(1H),8.3-8.4m(2H),8.55d(1H),8.6s(1H),8.7s(1H) | ||
7 | MeOD 5.1s(2H),7.25m(1H),7.35m(1H),7.9d(2H),8.25s(1H), 8.4d(2H),8.65s(1H),8.7d(2H) | ||
8 | 385.00,385.00 | 11.35(s,1H),9.25(s,1H),9.10(s,1H),9.00(s,1H),8.69 (d,1H),7.82(d,1H),5.00(m,2H),4.10(m,2H),2.73(s, 3H),1.91(m,6H)DMSO-d6,12.5(s,1H),8.70(s,1H),8.50 (s,1H),8.31(s,1H), 8.29(d,1H),7.10(d,1H),4.66(d,2H),4.2-4.6(m,2H), 3.15(m,2H),2.09(s,3H),1.20(m 6H) DMSO-d6 | 2.02, 4.63 |
9 | 328.00 | 12.73(s,1H),8.71(s,1H),8.67(s,1H),8.32(s,1H),8.25 (d,1H),7.21(m,1H),3.65-3.95(m,4H),1.82(m,4H), 1.53(m,4H)DMSO-d6 | 2.35 |
10 | 346.00 | 2.23 | |
11 | 328.00 | 12.75(s,1H),8.71(s,1H),8.68(s,1H),8.35(s,1H),8.25 (d,1H),7.22(d,1H),4.62(m,2H),3.10(m,2H),1.75(m, 3H),1.20(m,2H),0.91(m,3H)DMSO-d6 | 2.40 |
12 | 332.00 | DMDO d6 12.6(s,1H);9,5(bs,1H);8.8(s,1H);8.4(s, 1H);8.1(s,1H);7.8(bs,1H):7.4(m,5H);7.1(bs,1H);4.8 (d,2H),3.8(s,3H) | 2.10 |
13 | 346.00 | DMSO d6 12.8(s,1H);9,4(bs,1H);8.8(s,1H);8.3(s, 1H);8.2(s,1H);7.9(bs,1H):7.4(m,5H);7.2(bs,1H);5.2 (bs,1H),3.8(s,3H);1.5(d,3H) | 2.20 |
14 | 346.00 | DMSO d6 12.8(s,1H);9,4(bs,1H);8.8(s,1H);8.3(s, 1H);8.2(s,1H);7.9(bs,1H):7.4(m,5H);7.2(bs,1H);5.2 (bs,1H),3.8(s,3H);1.5(d,3H) | 2.20 |
15 | 413.00 | MeOD 1.2s(3H),1.9m(1H),2.2m(1H),2.55m(1H),2.6s(3H), 3.2-3.4m(2H),3.55m(1H),3.8m(1H),4.5s(2H),5.5 bs(0.7H),7.1s(1H),7.35m(1H),7.5-7.6mm(5H),8.3 s(1H),8.4-8.5mm(2H),8.7s(1H) | 1.31 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
16 | 320.00 | MeOD 4.9s(2H),7.0-7.6mm(7H),8.2s(1H),8.3d(1H),8.7s(1H) | 1.98 |
17 | MeOD 1.2d(3H),1.9m(1H),2.2m(1H),2.4s(1H),2.6m(3H),3.0 s(1H)3.5m(1H),3.8m(1H),7.1s(1H),7.2d(1H),7.35 m(1H),7.7d(1H),8.3s(1H),8.4d(1H),8.5d(1H),8.7 s(1H) | ||
18 | 380.00,380.00 | 11.95(s,1H),10.47(s,3H),8.51(s,1H), 8.17(s,1H),8.09(s,1H),7.77(t,1H), 7.18(d,1H),6.87(d,1H),4.4-4.6(s,2H) 3.99(s,3H),3.32(m,2H),2.13(s,3H),1.35(m,6H) DMSO-d6,9.82(s,1H),8.32(d,1H),8.08(d,1H),7.93(s, 1H),7.58(t,1H),7.20(d,1H),6.66(d,1H),4.2-4.7(m, 4H),3.91(s,3H),3.12(m,2H),2.10(s,3H),1.35(m,6H) CD3CN | 1.98, 2.02 |
19 | 384.00,384.00, 384.00,384.00, 384.00,384.00, 384.00,384.00, 384.00,384.00, 384.00 | 10.75(s,1H),8.46(s,1H),8.39(s,1H), 8.10(s,1H),7.91(t,1H),7.19(d,1H), 7.02(d,1H),6.25-6.75(s,9H),4.4-4.6(s,2H) 4.10(d,2H),3.49(m,2H),2.18(s,3H),1.38(d,6H) DMSO-d6,good,good,good,11-12.2(s,2H),10.6-11.0(s, 1H),8.54(s,1H), 8.35(s,1H),8.05(s,1H),7.69(t,1H),7.11(d,1H), 6.89(d,1H),4.2-4.7(s,2H),4.18(d,2H),3.35(m,2H), 2.17(s,3H),1.38(m,6H) CD3CN,12.20(s,1H),8.71(S,1H),8.25(d,2H),7.55(t, 1H), 7.17(d,1H),6.69(d,1H),4.0-4.5(s,2H),4.29(d,2H), 3.05(m,2H),2.09(s,3H),1.28(m,6H),12.24(s,1H),8.73 (s,1H),8.27(d,2H),7.58(t,1H), 7.18(d,1H),6.71(d,1H),4.2-4.5(m,14H),3.08(m,2H), 2.32(s,3H),2.09(s,3H),1.28(s,6H) DMSO-d6,12.20(s,1H),8.72(s,1H),8.25(d,2H),7.57(t, 1H), 7.19(d,1H),6.71(d,1H),4.3-4.7(s,1H),4.3(d,2H), 3.27(s,9H),3.07(m,2H),2.70(q,1H),2.10(s,3H), 1.29(s,6H) DMSO-d6 DMSO-d6,12.31(s,1H),8.70(s,1H),8.29(m,2H),7.65 (m,1H),7.20(d,1H0,6.80(d,1H),6.5-6.8(s,4H),4.28(d, 2H),4.0-4.6(s,1H),3.15(m,2H),2.41(s,6H),good | 2.39, 2.70, 3.26, 2.42, 3.22, 2.39, 3.35, 3.38, 3.32, 3.32, 3.32 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
20 | 335.00 | 10.55(s,1H),8.38(m,1H),8.30(m,2H), 7.89(t,1H),7.41(m,4H),7.34(m,1H), 7.12(d,1H),6.73(d,1H),4.7-5.7(s,4H) 4.60(s,2H) CD3CN | 2.39 |
21 | 336.00 | MeOD 2.65s(0.3H,DMSO),4.9s(2H),7.1s(1H),7.3-7.5m(6H), 8.2s(1H),8.4-8.5m(2H),8.7s(1H) | 2.20 |
22 | 370.00 | MeOD 4.9s(2H),7.1s(1H),7.3bs(1H),7.6-7.8m(5H),8.2s(1H), 8.4m(2H),8.675s(1H) | 2.60 |
23 | 378.00 | MeOD 2.65s(0.9H,DMSO)4.9s(2H),7.1s(1H),7.3-7.5m(6H), 7.6-7.7m(5H),8.2s(1H),8.4m(2H),8.65s(1H) | 2.60 |
24 | 367.00 | DMSO d6 12.5(bs,1H);8.5(bs,1H);8.2(m,2H);8.0(d, 1H);7.3(d,1H);4.0(bs,2H);3.9(s,3);3.8(bs,2H);3.5 (t,2H);2.5(s,3H);1.9(bs,2H) | 1.70 |
25 | 381.10,381.40 | DMSO d6 12.5(bs,1H);8.4(s,1H);8.3(d,1H);8.25(s, 1H);8.1(s,1H);7.3(d,1H);4.7(appd,2H);3.9(s,3H); 3.2(bd,2H);2.1(s,3H);1.2(bs,6H),DMSO d6 12.3(bs, 1H);8.5(s,1H);8.25(m,2H);8.1(d,1H);7.2(d,1H);4.65 (d,4H);3.9(s,3H);3.2(bd,2H);2.1(s,3H);1.2(bs,6H) | 2.00, 2.00 |
26 | 316.00 | H1 MeOD:1.3m(1H),3.4s(3H),5.1s(2H),7.0s(1H),7.1- 7.4m(7H),8.1s(1H),8.3d(1H),8.6s(1H) | 2.10 |
27 | 320.00 | H1 DMSO:4.7s(2H),7.2t(4H),7.3m(1H),7.55m(2H), 8.3m(3H),8.7s(1H),9.1-9.3bs(0.75H) | 2.00 |
28 | 317.00 | H1 MeOD:1.8bs(2H),4.7s(2H),6.7-6.85mm(4H)7.0-7.2 m(1H),7.3m(1H),8.15s(1H),8.3m(2H),8.6s(1H) | 1.60 |
29 | 338.00 | MeOD 4.9s(2H),6.9m(1H),7.0m(2H),7.2s(1H),7.3m(1H),8.2 s(1H),8.4m(2H),8.65s(1H) | 2.00 |
30 | 403.20 | CD3CN,10.7(bs,1H);8.15(s,1H);8-8.1(m,3H);7(d, 1H);3.8-4.05(bs,4H);3.8(s,3H);3.6(bs,2H);3.3(t,2H); 2.8(s,3H);2.4(s,2H) | 1.90 |
31 | 417.20 | CD3CN,10.7(s,1H);8.15(s,1H);8(m,3H);7(d,1H); 3.8-4(bs,4H);3.85(s,3H);3.6(bs,2H);3.3(m,4H);2.9 (m,2H);1.1(m,3H) | 2.00 |
32 | 427.00 | 12.33(s,1H),8.78(d,1H),8.37(d,1H),8.28(d,1H), 7.87(s,1H),7.69(d,1H),7.49(s,1H),7.44(d,1H), 4.37(s,2H),3.5-4.2(m,14H),3-10(m,2H), 2.08(s,3H),1.32(m,6H) DMSO-d6 | 2.24 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
33 | 397.30 | DMSO-d6 12.25(1H,bs);8.5(1H,s);8.3(1H,d);8.2(1H, d);8.05(1H,d);7.15(1H,bs);4.0(4H,m);3.9(3H,s);3.8- 4.0(H),bm);3.6-3.8(2H,bs);3.4(2H,bs);1.1(3H,bm) | 2.10 |
34 | 411.30 | DMSO-d6 12.25(1H,bs);8.5(1H,s);8.3(1H,d);8.2(1H, d);8.05(1H,d);7.15(1H,bs);3.85(3H,s);3.7-4.0(8H, bm);3.6-3.8(2H,bs);3.4(2H,bs);1.5(2H,bs);0.8(3H, bm) | 2.30 |
35 | 408.30,408.29 | DMSOd6 12.4(s,1H);9.5(s,1H);8.8(s,1H);8.3(s,1H); 7.5(dd,1H);7.2(d,1H);6.7(d,1H);4.6(bs,2H);4.3(d, 2H);3.9(s,3H);3.1(bd,2H);2.1(s,3H);1.2(bs,6H) | 2.90, 2.94 |
36 | 428.00 | 12.41(s,1H),8.78(s,1H),8.41(s,1H),8.29(s,1H), 7.95(d,1H),7.45(d,1H),6.3-7.5(s,1H),4.39(s,2H), 3.69(m,2H),3.23(m,2H),2.05(s,3H),1.29(m,6H) DMSO-d6 | 2.38 |
37 | 465.40,465.30 | DMSOd6 11.9(s,1H);9.4(s,1H);9.2(s,1H);8.2(s,1H); 7.5(dd,1H);7.2(d,1H);6.6(d,1H);4.4(bs,4H);3.1(bs, 2H);2.1(s,3H);1.5(s,9H);1.2(bs,6H) | 3.10, 3.10 |
38 | 365.20 | 8.9(s,1H);8.4(s,1H);8.2(s,1H);7.7(dd,1H);7.2(d, 1H);6.9(d,1H);4.4(bs,4H);3.3(bs,2H);2.2(s,3H);1.4 (bs,6H) | 2.53 |
39 | 315.10 | DMSO-d6:12.3(1H,bs);8.3(2H,m);8.2(1H,bs);7.8 (1H,bs);7.5(6H,m);6.8(1H,bs);4.7(2H,s);4-4.5(1H, bs);2.3(3H,s) | 2.30 |
40 | 350.09 | DMSO-d6:11.9(bs,1H);8.5(d,1H);8.2(s,1H);8.1(s, 1H);7.5(t,1H);7.1(t,1H);6.5(d,1H);3.9-4.5(bs,1H); 4.0(t,1H);3.7(m,4H);3.4(dt,2H);2.4(s,3H);2.1(s, 3H);1.9(m,2H) | 1.90 |
41 | 364.20 | DMSO-d6:11.9(s,1H);8.5(s,1H);8.2(s,1H);8.1(s, 1H);7.6(dd,1H);7.2(d,1H);6.7(d,1H);4.5-5.4(bs, 1H);4.3(d,4H);3.1(bd,2H);2.4(s,3H);2.1(s,3H);1.3 (bs,6H) | 2.40 |
42 | 379.00 | 12.6-13.0(s,1H),12.38(s,1H),8.65(s,1H), 8.61(m,1H),8.40(m,1H),8.21(m,1H),8.06(d,1H), 7.49(d,2H),7.31(t,2H),7.21(t,1H),7.18(d,1H), 6.1-6.9(s,1H),4.88(m,2H),3.4-4.7(s,2H) DMSO-d6 | 3.18 |
43 | 393.00 | 12.39(s,1H),8.60(s,1H),8.50(t,1H),8.41(s,1H), 8.22(s,1H),8.09(d,1H),7.39(m,2H),7.29(m,2H), 7.20(m,1H),6.3-6.8(m,3H),4.90(d,2H),3.85(s,3H) DMSO-d6 | 3.92 |
44 | 379.00 | 12.12(s,1H),8.20(s,1H),8.10(s,1H),7.82(m,2H), 7.32(m,3H),7.21(m,2H),6.50(d,1H),4.60(s,2H), 3.8-4.5(s,8H) DMSO-d6 | 2.20 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
45 | 393.00 | 9.94(s,1H),8.20(d,2H),7.88(d,1H),7.73(s,1H), 7.31-7.42(m,4H),7.26(t,1H),6.44(d,1H), 6.27(m,1H),4.68(d,2H),3.70(s,3H) CD3CN | 2.52 |
46 | 378.00 | mixture | 2.94 |
47 | 394.27 | DMSOD6 12.3(s,1H);9.4(s,1H);8.8(s,1H);8.2(s,1H); 7.5(dd,1H);7.2(d,1H);6.7(d,1H);4.4(d,4H);3.1(bd, 2H);2.1(s,3H);1.2(bs,6H) | 2.47 |
48 | 319.20 | DMSOd6 12.3(bs,1H);8.4(bd,1H);8.3(d,2H);7.6(bs, 1H);7.5(m,4H);7.2(dd,1H);7.1(bd,1H);6.5(bs,1H); 4.5(s,2H) | 2.30 |
49 | 354.30 | DMSOd6 12.2(bs,1H);8.4(appt,1H);8.2(m,2H);7.5 (dd,1H);7.1(dd,1H);6.5(bs,1H);3.9(t,1H);3.8-3.6 (m,4H);3.4(dt,2H);2.1 and 1.8(s,3H);2.0(t,1H) | 2.20 |
50 | 368.40 | DMSO D6 12.1(s,1H);8.5(dd,1H);8.2(s,2H);7.6(dd, 1H);7.2(d,1H);6.8(d,1H);4.3(bd,4H);3.1(db,2H);2.1 (s,3H);1.2(bs,6H) | 2.90 |
51 | 462.00 | 11.60(s,1H),8.70(s,1H),8.48(s,1H),8.11(s,1H), 7.82(t,1H),7.15(d,1H),7.1-8.1(s,4H),6.95(d,1H), 4.55(s,2H),4.14(m,2H),3.68(m,6H),3.39(m,2H), 2.15(s,3H),1.38(m,6H) CD3CN | 1.84 |
52 | 490.00 | 11.29(s,1H),8.90(s,1H),8.50(s,1H),8.61(m,2H),8.11 (s,1H), 7.68(t,1H),7.12(d,1H),6.78(d,1H),4.0-4.5(m,12H), 3.40(m,2H), 3.27(m,4H),2.15(s,3H),1.25-1.45(m,12H) | 1.89 |
53 | 436.40 | DMSO d6 12.4(s,1H);9.4(s,1H);8.8(s,1H);8.3(s,1H); 7.5(t,1H);7.2(d,1H);6.7(d,1H);5.2(sept,1H);4.3(bs, 4H);3.1(bs,2H);2.1(s,3H);1.3(d,6H0;1.2(bs,6H) | 3.40 |
54 | 461.00 | ||
55 | 475.00 | ||
56 | 462.00 | ||
57 | 476.00 | ||
58 | 475.00 | ||
59 | 407.00 | ||
60 | 421.00 | ||
61 | 499.30 | DMSO-d6:11.9ppm(s,1H),10.2(s,1H),9.2(s,1H),8.2 (s,1H),8.15(s,1H),7.5(t,1H),7.15-7.25(dd,4H),7.15(s, 1H),6.7(d,1H),4.2-4.8(bs,4H),3.0(bd,2H),2.5(s,6H), 2.3(s,3H),2.0(s,3H) | 3.40 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
62 | 451.30 | DMSO-d6:11.9ppm(s,1H),9.6(s,1H),9.1(s,1H),8.15 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H), 4.35(m,4H),4.1(t,2H),3.05(bd,2H),2.1(s,3H),1.7(m, 2H),1.3(bs,6H),0.95(t,3H) | 2.90 |
63 | 465.40 | DMSO-d6:11.9ppm(s,1H),9.6(s,1H),9.1(s,1H),8.15 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H), 4.35(m,4H),3.9(d,2H),3.05(bd,2H),2.1(s,3H),1.9(m, 1H),1.3(bs,6H),0.95(d,6H) | 3.20 |
64 | 479.40 | DMSO-d6:11.9ppm(s,1H),9.6(s,1H),9.1(s,1H),8.15 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H), 4.35(m,4H),3.85(s,2H),3.05(bd,2H),2.1(s,3H),1.3 (bs,6H),0.95(s,9H) | 3.40 |
65 | 451.40 | DMSO-d6:11.9ppm(s,1H),9.6(s,1H),9.1(s,1H),8.15 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.9 (q,1H),4.35(m,4H),3.05(bd,2H),2.1(s,3H),1.3(m, 12H) | 2.90 |
66 | 423.30 | DMSO-d6:11.9ppm(s,1H),9.6(s,1H),9.1(s,1H),8.15 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H), 4.35(m,4H),3.7,(s,3H),3.05(bd,2H),2.1(s,3H),1.3 (bs,6H) | 2.40 |
67 | 428.00 | 12.31(s,1H),8.71(d,1H),8.41(d,1H),8.29(d,1H),7.56 (s,1H),7.07(s,1H),4.0-4.8(m,4H),3.3-3.9(m,20H), 3.13(m,2H),2.10(s,3H),1.16(m,6H) | 3.20 |
68 | 427.00 | 12.54(s,1H),8.50(d,1H),8.35(d,1H),8.31(d,1H),8.09 (s,1H),8.07(s,1H),4.0-5.4(m,9H),3.3(m,2H),2.09(s, 3H),1.26(m,6H) | 3.70 |
69 | 485.30 | DMSO d6 11.9(s,1H),10.3(s,1H),9.2(s,1H),8.25(s, 1H),8.15(s,1H),7.5(t,1H),7.45(t,2H),7.25(d,3H), 7.15(d,1H),6.7(d,1H),4.0-4.8(bs,4H),3.0(bd,2H),2.0 (s,3H),1.2(bs,6H) | 3.20 |
70 | 437.30 | DMSO d6 11.8(s,1H),9.6(s,1H),9.1(s,1H),8.2(s,1H), 8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4(m,4H), 4.15(q,2H),3.0(bd,2H),2.0(s,3H),1.25(m,9H) | 3.20 |
71 | 515.30 | DMSO d6 11.9(s,1H),10.2(s,1H),9.2(s,1H),8.2(s, 1H),8.15(s,1H),7.5(t,1H),7.1(m,3H),7.0(d,2H),6.7 (d,1H),4.0-4.8(bs,4H),3.8(s,3H),3.0(bd,2H),2.0(s, 3H),1.2(m,6H) | 3.20 |
72 | 445.00 | 12.17(s,1H),8.41(d,1H),8.27(d,1H),7.88(d,1H),7.77 (s,1H),7.61(s,1H),7.59(s,1H),7.50(s,1H),6.48(s,1H), 4.05(m,2H),3.10(m,2H),2.08(s,3H),1.31(m,6H) DMSO-d6 | 2.84 |
73 | 422.40 | DMSOd6 12.3(bs,1H);9.3(s,1H);8.8(s,1H);8.2(s,1H); 7.5(dd,1H);7.2(d,1H);6.8(d,1H);4.4(q,2H);4.3(bs, 4H);3.1(bs,2H);2.1(s,3H);1.3(t,3H);1.2(bs,6H) | 3.20 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
74 | 450.40 | DMSO d6 12.3(bs,1H);9.4(s,1H);8.9(s,1H);8.2(s,1H); 7.7(dd,1H);7.2(d,1H);6.8(d,1H);4.4(bd,4H);4.1(d, 2H);3.1(bs,2H);2.1(s,3H);2.05(m,1H);1.3(bs,6H); 1.0(d,6H) | 3.70 |
75 | 429.00 | good | 3.70 |
76 | 399.00 | good | 3.17 |
77 | 366.30 | MeOD4 8.4(s,1H);8.1(s,1H);7.9(s,1H);7.6(dd,1H); 7.2(d,1H);6.8(d,1H);4.3(bs,4H);3.2(bs,2H);2.2(s, 3H);1.3(bs,6H) | 2.10 |
78 | 429.00 | ||
79 | 423.00 | ||
80 | 423.00 | ||
81 | 399.00 | 12.43(s,1H),8.48(s,1H),8.33(d,1H),8.06(d,1H), 7.59(d,1H),6.87(d,1H),4.7-6.3(m,4H), 4.2-4.6(m,1H),4.20(m,2H),3.05(m,2H), 2.06(s,3H),1.25(m,6H) DMSO-d6 | 2.21 |
82 | 368.50 | DMSO d6 12.3(s,1H);8.9(s,1H);8.2(s,1H);7.6(s,1H); 7.2(s,1H);6.7(s,1H);4.4(d,1H);3.7-4.1(m,5H);2.9(s, 3H);1.9-2.4(m,5H);1.6(s,1H) | 2.10 |
83 | 386.40 | DMSO d6 12.2 ppm(s,1H),8.7(s,1H),8.26(s,1H),8.23 (s,1H),7.5(t,1H),7.1(d,1H),6.5(d,1H),3.8(m,2H), 3.75(t,2H),3.6(m,2H),3.55(s,1H),3.45(s,1H),3.35 (m,2H),1.9(m,3H) | 3.10 |
84 | 400.40 | DMSO d6 12.2 ppm(s,1H),8.7(s,1H),8.26(s,1H),8.23 (s,1H),7.5(t,1H),7.1(d,1H),6.5(d,1H),4.0(m,1H),3.9 (m,1H),3.8(m,2H),3.75(m,2H),3.65(m,2H),3.35(m, 2H),1.9(m,2H),1.0(dt,3H) | 3.30 |
85 | 369.90 | DMSO-D6:12.2(1H,s);8.7(1H,s);8.25(2H,m);7.6(1H, dd);7.25(1H,d);6.7(1H,d);3.8-3.5(8H,m);2.4(2H,q); 1.05(3H,t). | 2.62 |
86 | 384.00 | DMSO-D6:12.2(1H,s);8.7(1H,s);8.25(2H,m);7.6(1H, dd);7.25(1H,d);6.7(1H,d);3.8-3.5(8H,m);2.4(2H,q); 1.55(2H,sextet);0.95(3H,t). | 2.86 |
87 | 302.90 | DMSO d6:12.2(s,1H),10.3(s,1H),9.3(d,1H),8.3(d, 1H),8.2(d,1H),7.7(t,1H),7.6(m,2H),3.7(s,3H) | 3.20 |
88 | 330.90 | DMSO d6:12.2(s,1H),10.3(s,1H),9.3(s,1H),8.35(s, 1H),8.25(s,1H),7.7(t,1H),7.6(d,1H),7.55(d,1H),4.1 (t,2H),1.7(m,2H),2 0(t,3H) | 3.90 |
89 | 398.00 | DMSO-D6:12.2(1H,s);8.7(1H,s);8.25(2H,m);7.6(1H, dd);7.2(1H,d);6.7(1H,d);3.6-3.3(8H,m);2.3(2H,d); 2.0(1H,m);0.9(6H,d). | 3.08 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
90 | 344.80 | DMSO d6:12.2ppm(s,1H),10.3(s,1H),9.3(s,1H),8.3 (s,1H),8.25(s,1H),7.7(t,1H),7.6(d,1H),7.55(d,1H), 3.95(d,2H),2.0(m,1H),1.0(d,6H) | 4.20 |
91 | 378.80 | DMSO d6:12.2 ppm(s,1H),10.4(s,1H),9.3(s,1H),8.3 (s,1H),8.2(s,1H),7.7(t,1H),7.62(d,1H),7.57(d,1H), 7.5(m,2H),7.4(m,2H),5.2(s,2H) | 4.20 |
92 | 409.00 | 12.56(s,1H),8.73(d,1H),8.52(d,1H),8.32(d,1H),8.05 (d,1H),7.52(d,1H),4.0-4.7(m,4H),3.24(m,2H),2.09(s, 3H),1.36(m,6H) DMSO-d6 | 2.95 |
93 | 409.00 | 12.54(s,1H),8.57(d,1H),8.36(d,1H),8.33(d,1H),7.93 (d,1H),6.92(d,1H),4.0-4.6(m,4H),3.2(m,2H),2.05(s, 3H),1.24(m,6H) DMSO-d6 | 2.82 |
94 | 437.00 | DMSO d6 8.2(s,1H);8.1(s,1H);8.0(s,1H);7.6(dd,1H); 7.1(d,1H);6.8(d,1H);4.5(t,2H);4.4(bs,2H);4.3(d, 2H);3.7(bs,2H);3.1(bs,2H);3.0(s,6H);2.0(s,3H);1.2 (bs,6H) | 1.59 |
95 | 479.00 | DMSO d6 8.2(s,1H);8.1(s,1H);7.9(s,1H);7.5(dd,1H); 7.0(d,1H);6.6(d,1H);4.7(t,2H);4.4(d,2H);4.0-3.8(bs, 6H);3.8(t,2H);3.7-3.5(bs,4H);3.1(bs,2H);3.0(s,6H); 2.0(s,3H);1.2(bs,6H) | 1.63 |
96 | 436.00 | DMSO d6 8.2(s,1H);8.1(s,1H);7.9(s,1H);7.5(dd,1H); 7.0(d,1H);6.6(d,1H);4.7(t,2H);4.4(d,2H);4.0-3.8(bs, 6H);3.8(t,2H);3.7-3.5(bs,4H);3.1(bs,2H);3.0(s,6H); 2.0(s,3H);1.2(bs,6H) | 2.25 |
97 | 427.00 | 12.29(s,1H),8.73(d,1H),8.30(m,2H),8.09(s,1H),7.59 (s,1H),7.52(s,1H),7.06(s,1H),4.1-4.8(m,4H),3.1(m, 2H),2.09(s,3H),1.25(m,6H) DMSO-d6 | 2.35 |
98 | 409.00 | 12.39(s,1H),8.70(d,1H),8.43(d,1H),8.31(s,1H),7.52 (s,1H),7.17(s,1H),4.39(m,4H),3.15(m,2H),2.09(s, 3H),1.25(m,6H) DMSO-d6 | 3.04 |
99 | 300.90 | CDCl3:10.3(s,1H);9.7(s,1H);8.3(s,1H);8.1(s,1H); 7.9(s,1H);7.7(dd,1H);6.8(d,1H);6.5(d,1H);3.05(d, 2H);2.0(m,1H);1.0(d6H). | 2.01 |
100 | 364.90 | DMSO-D6:12.3(br s,1H);8.6(s,1H);8.3(s,1H);8.2(s, 1H);7.5(m,3H);7.3(m,2H);7.2(m 1H);7.1(m,1H);6.5 (br s,1H);5.05(br s 1H);3.75(m,1H);3.7(m,1H). | 1.99 |
101 | 364.90 | CDCl3:10.6(br s,1H);10.25(br s,1H);8.3(s,1H);8.1(s, 1H);7.9(s,1H);7.6(dd,1H);7.3(m,6H);6.8(d,1H);6.25 (d,1H);4.6(m,1H);3.95(m,1H);3.9(m,1H). | 1.98 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
102 | 302.90 | DMSO-D6(~2∶1 rotational mixture):12.6(br s,1H);12.2 (br s,1H);8.7(s,.33H);8.6(s,.67H);8.3(s,.67H);8.25(s, 1H);8.2(s,.33H);7.8(s,.67H);7.5(s,.33H);7.15(d, .67H);7.05(d,.33H);6.8(s,.67H);6.45(s,.33H);4.5(m, 1H);4.1(m,1H);3.6(m,2H);1.3(d,.6H);1.2(d,2.4H). | 1.62 |
103 | 302.90 | DMSO-D6(~2∶1 rotational mixture):12.65(br s,1H); 12.25(br s,1H);8.7(s,.4H);8.6(s,.6H);8.35(s,.67H); 8.3(s,1H);8.25(s,.33H);7.8(s,.67H);7.5(s,.33H);7.2 (d,.67H);7.1(d,.33H);6.8(s,.67H);6.5(s,.33H);4.5(m, 1H);4.05(m,1H);3.5(m,2H);1.3(d,.6H);1.2(d,2.4H). | 1.63 |
104 | 272.80 | DMSO d6 12.3(s,1H);8.4(s,1H);8.3(s,1H);8.1(s,1H); 8.0(d,1H);7.8(d,1H). | 2.61 |
105 | 271.90 | DMSO d6 12.2(s,1H);8.4(s,1H);8.3(s,1H);8.1(s,1H); 7.9(d,1H);7.8(d,1H). | 2.26 |
106 | 273.80 | DMSO d6 12.4(s,1H);9.2(s,1H);8.9(s,1H);8.5(s,1H); 8.3(s,1H);8.2(d,1H);8.0(d,1H). | 2.34 |
107 | 272.90 | DMSO d6 12.3(s,1H);9.1(s,1H);8.9(s,1H);8.5(s,1H); 8.3(s,1H);8.1(d,1H);8.0(bs,1H);7.9(d,1H);7.5(bs, 1H). | 2.01 |
108 | 506.00 | DMSO-d6:12.2(s,1H);9.6(br s,1H);9.25(s,1H);8.8(s, 1H);8.25(s,1H);7.6(dd,1H);7.2(d,1H);6.7(d,1H);4.4 (br s,4H);4.0(m,2H);3.8-3.6(m,6H);3.35(m,2H);3.2 (br s,2H);3.1(br s,2H);2.1(s,3H);1.3(s,6H). | 1.59 |
109 | 533.00 | DMSO-d6:12.2(s,1H);9.2(s,1H);8.75(s,1H);8.6(br s, 1H);8.2(s,1H);7.6(dd,1H);7.2(d,1H);6.75(d,1H);4.4 (br s,4H);3.6-2.7(m,17H);2.1(s,3H);1.9(m,2H);1.3(s, 6H). | 1.46 |
110 | 452.00 | 12.09(s,1H),8.28(d,1H),8.20(d,1H),7.77(d,1H),7.11 (d,1H),6.97(d,1H),4.0-4.7(m,4H),3.30(s,8H),3.18(m, 2H),2.10(s,3H),1.28(m,6H) DMSO-d6 | 2.31 |
111 | 452.00 | 12.32(s,1H),8.76(d,1H),8.37(d,1H),8.31(d,1H),7.71 (s,1H),7.27(s,1H),4.0-4.7(m,4H),3.30(s,6H),3.20(m, 2H),2.09(s,3H),1.29(m,6H) DMSO-d6 | 2.59 |
112 | 366.00 | DMS0 d6 12.2(bs,1H);8.2(s,1H);8.1(s,1H);8.0(s,1H); 7.6(dd,1H);7.1(dd,1H);6.5(dd,1H);4.0(m,1H);3.9(s, 3H);3.8(m,2H);3.75(m,1H);3.7(m,2H);3.5(m,2H); 2.0(s,3H);1.9(m,2H) | 1.90 |
113 | 407.00 | DMSO d6:11.8ppm(s,1H),10(s,1H),9.2(s,1H),8.2(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4(m, 4H),3.05(m,2H),2.1(s,3H),2.08(s,3H),1.3(bs,6H) | 2.10 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
114 | 421.00 | DMSO d6:11.8ppm(s,1H),9.9(s,1H),9.3(s,1H),8.2(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4(m, 4H),3.0(m,2H),2.4(m,2H),2.1(s,3H),1.3(bs,6H),1.1 (t,3H) | 2.20 |
115 | 491.00 | DMSO d6:11.9PPm(s,1H),10(s,1H),9.3(s,1H),8.6 (bs,1H),8.2(s,1H),8.15(s,1H),7.5(t,1H),7.1(d,1H), 6.7(d,1H),4.4(m,4H),3.4(bs,2H),3.2(bs,4H),3.0(m, 2H),2.9(bs,4H),2.1(s,3H),1.3(bs,6H) | 1.50 |
116 | 492.00 | DMSO d6:12ppm(s,1H),10.7(bs,1H),9.3(s,1H),8.22 (s,1H),8.19(s,1H),7.5(t,1H),7.2(d,1H),6.7(d,1H), 4.4(m,4H),4.2(bs,2H),3.8(t,4H),3.1(m,4H),3.0(m, 2H),2.1(s,3H),1.3(bs,6H) | 1.60 |
117 | 435.00 | DMSO d6:11.8ppm(s,1H),9.9(s,1H),9.3(s,1H),8.2(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4(m, 4H),3.0(m,2H),2.6(m,1H),2.1(s,3H),1.3(bs,6H),1.1 (d,6H) | 2.40 |
118 | 419.00 | DMSO d6:11.9ppm(s,1H),10.2(s,1H),9.4(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),6.5 (m,1H),6.3(d,1H),5.8(d,1H),4.4(m,4H),3.0(m,2H), 2.1(s,3H),1.3(bs,6H) | 2.30 |
119 | 493.00 | DMSO d6:11.8ppm(s,1H),10.0(s,1H),9.3(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4 (m,4H),4.0(m,4H),3.0(m,2H),2.6(m,2H),2.1(s,3H), 1.3(bs,6H),1.2(t,3H) | 2.50 |
120 | 452.00 | 8.79(d,1H),8.46(s,1H),8.26(d,1H),8.07(s,1H),7.69 (d,1H),7.40(d,1H),5.71(s,2H),4.91(s,2H),4.20(s, 2H),3.70(s,4H),3.40(m,2H),3.25(s,1H),3.12(s,1H), 3.03(s,1H),2.95(m,2H),1.99(s,3H),1.09(m,6H) CD3CN with 4 drops of DMSO-d6 | 2.43 |
121 | 506.30 | DMSO d6:11.9ppm(s,1H),10.3(S,1H),9.3(S,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4 (m,4H),4.0(d,2H),3.7(t,2H),3.5(m,4H),3.1(m,4H), 3.0(t,2H),2.1(s,3H),1.3(bs,6H) | 1.70 |
122 | 272.90 | DMSO-d6:12.2(br s,1H);8.8(s,1H);8.25(m,2H);7.55 (dd,1H);7.1(d,1H);6.5(d,1H);3.1(s,6H). | 2.05 |
123 | 315.00 | DMSO-d6:12.2(br s,1H);8.8(s,1H);8.25(m,2H);7.5 (dd,1H);7.1(d,1H);6.45(m,1H);3.5(d,2H);3.1(s,3H); 2.15(m,1H);0.95(d,6H). | 3.55 |
124 | 492.00 | DMSO-d6:12.2(br s,1H);9.7(br s,1H);9.2(m,1H);8.8 (s,1H);8.2(s,1H);7.5(m,1H);7.1(m,1H);6.5(m,1H); 4.1-3.5(m,14H);3.4(m,4H);3.2(br s,2H);2.0-1.8(m, 5H). | 2.24 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
125 | 519.10 | DMSO-d6:12.2(br s,1H);9.2(d,1H);8.8(s,1H);8.65(br s,1H);8.2(s,1H);7.5(m,1H);7.1(m,1H);6.5(dd,1H); 4.1-3.1(m,18H);3.0(br s,4H);2.8(s,3H);2.0-1.8(m, 5H). | 1.75 |
126 | 379.90 | DMSO-d6:11.8(br s,1H);9.2(s,1H);8.8(s,1H);8.0(s, 1H);7.5(dd,1H);7.1(d,1H);6.5(dd,1H);4.0(m,1H); 3.8-3.65(m,5H);3.4(m,2H);2.0-1.8(m,5H). | 1.83 |
127 | 477.90 | DMSO d6:11.8ppm(s,1H),9.0(s,1H),8.6(s,1H),8.2(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.3(m, 4H),3.6(t,4H),3.5(t,4H),3.0(m,2H),2.1(s,3H),1.2 (bs,6H) | 2.10 |
128 | 505.00 | DMSO d6:11.9ppm(s,1H),10.3(s,1H),9.3(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4 (m,4H),3.3(m,12H),3.0(m,2H),2.8(m,2H),2.1(3H), 1.3(bs,6H) | 1.50 |
129 | 355.10 | MeOD-D4:8.4(s,1H);8.35(s,1H);8.1(s,1H);8.0(dd, 1H);7.2(d,1H);7.0(d,1H);3.75(m,1H);1.9-1.8(m,3H); 1.7(m,1H);1.55(m,1H);1.3-1.1(m,9H). | 2.40 |
130 | 315.10 | MeOD-D4:8.4(s,1H);8.35(s,1H);8.15(s,1H);8.0(dd, 1H);7.2(d,1H);7.0(d,1H);3.8(m,1H);1.9(m,1H);1.3 (d,3H);1.0(m,6H). | 2.00 |
131 | 367.00 | MeOD-D4:8.3(m,2H);8.1(s,1H);7.9(dd,1H);7.5(m, 2H);7.2(d,1H);7.1(m,2H);6.75(d,1H);5.0(m,1H); 1.65(d,3H). | 2.40 |
132 | 342.80 | DMSO-D6:12.5(br s,1H);8.7(br s,1H);8.35-8.15(m, 2H);7.7(br s,1H);7.1(m,1H);6.8(br s,1H);3.8(br s, 1H);3.7-3.5(m,2H);2.0(m,1H);1.25-0.8(m,8H). | 2.00 |
133 | 360.90 | DMSO-D6:12.3(br s,1H);8.8(br s,1H);8.25(m,2H);7.6 (br s,1H);7.4-7.1(m,5H);6.5(br s,1H);5.6(br s,1H);3.0 (m,1H);2.9(m,1H);2.6(m,1H);1.95(m,1H). | 3.00 |
134 | 330.80 | DMSO-D6:12.5(br s,1H);8.7(br s,1H);8.3-8.25(m, 2H);7.6(br s,1H);7.2(br s,1H);6.7(br s,1H);3.8(br s, 1H);3.65-3.5(m,3H);2.0(m,1H);1.0(m,7H). | 2.00 |
135 | 330.80 | DMSO-D6:12.5(br s,1H);8.6(br s,1H);8.3-8.2(m,2H); 7.7(br s,1H);7.1(br s,1H);6.8(br s,1H);3.8(br s,1H); 3.7-3.5(m,3H);2.0(m,1H);1.0(m,7H). | 2.00 |
136 | 376.90 | DMSO-D6:12.5(br s,1H);8.7(br s,1H);8.3(m,2H);7.4- 7.1(m,5H);5.5(br s,1H);4.7(m,1H);3.2(m,1H);2.9 (m,1H). | 2.40 |
137 | 376.90 | DMSO-D6:12.1(br s,1H);8.8(br s,1H);8.2(m,2H); 7.45-7.05(m,5H);6.5-6.4(m,2H);5.5(br s,1H);4.7(m, 1H);3.15(m,1H);2.9(m,1H). | 2.40 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
138 | 430.00 | DMSO-d6 11.9ppm(s,1H),10.2(s,1H),9.3(s,1H),8.3 (s,1H),8.1(s,1H),7.5(m,1H),7.1(m,1H),6.5(m,2H), 6.3(d,1H),5.8(d,1H),3.5-4.0(m,10H),1.9(m,2H) | 2.30 |
139 | 405.10 | DMSO-d6 11.9ppm(s,1H),10.2(s,1H),9.3(s,1H),8.3 (s,1H),8.1(s,1H),7.5(m,1H),7.1(m,1H),6.5(m,2H), 6.3(s,1H),5.8(s,1H),4.0(t,1H),3.8(dt,2H),3.7(m, 3H),3.4(m,2H),2.0(s,1H),1.9(t,1H),1.8(s,3H) | 2.00 |
140 | 393.10 | DMSO-d6 11.9ppm(s,1H),10.0(s,1H),9.1(s,1H),8.2 (s,1H),8.1(s,1H),7.5(m,1H),7.1(m,1H),6.5(m,2H), 4.0(t,1H),3.8(dt,2H),3.7(m,3H),3.4(m,2H),2.1(s, 3H),2.0(s,1H),1.9(t,1H),1.8(s,3H) | 1.70 |
141 | 407.00 | DMSO-d6 11.8ppm(s,1H),9.9(s,1H),9.1(s,1H),8.2(s, 1H),8.1(s,1H),7.5(m,1H),7.1(m,1H),6.5(m,2H),4.0 (t,1H),3.8(dt,2H),3.7(m,3H),3.4(m,2H),2.4(q,2H), 2.0(s,1H),1.9(t,1H),1.8(s,3H),1.1(t,3H) | 1.90 |
142 | 334.80 | DMSOD6 12.2(bs,1H);8.3(s,1H);8.15(s,1H);8.0(s, 1H);7.6(d,2H);7.5(dd,2H);7.4(dd,2H);7.3(d,2H); 6.95(d,1H);5.1(s,2H) | 4.60 |
143 | 287.80 | DMSO D6 12.1(bs,1H);8.3(s,2H);7.9(s,1H);7.55(d, 1H);7.4(dd,2H);7.2(d,1H);2.95(hept,1H);1.25(d,6H) | 4.60 |
144 | 271.90 | DMSO D6 12.1(bs,1H);8.3(s,2H);7.9(s,1H);7.3(d, 1H);7.2(bs,2H);6.8(appd,1H);2.9(s,6H) | 2.60 |
145 | 333.80 | 4.10 | |
146 | 382.90 | DMSO d6 12.1(bs,1H);8.3(s,1H);8.25(s,1H);8.0(s, 1H);7.3(dd,1H);7.2(m,2H);6.9(s,1H);4.2(bs,2H);3.6 (d,2H);2.8(bs,2H);2.0(s,3H);1.3(bs,6H) | 3.70 |
147 | 378.10 | 3.00 | |
148 | 288.10 | 2.00 | |
149 | 395.10 | DMSO-D6:12.4(s,1H);8.7(d,1H);8.4(s,1H);8.25(s, 1H),7.5(s,1H);6.9(d,1H);4.0-3.65(m,6H);3.4(m,2H); 2.0-1.8(m,5H). | 3.30 |
150 | 326.00 | DMSO-D6:12.3(s,1H);8.9(s,1H);8.4(s,1H);8.25(s, 1H),7.35(s,1H);7.25(m,1H);6.6(s,1H);3.2(m,2H); 2.0(m,1H);1.0(d,6H). | 3.70 |
151 | 353.00 | DMSO-D6:12.4(s,1H);8.75(br s,1H)8.7(s,1H);8.45(s, 1H);8.3(s,1H),7.6(s,1H);7.0(s,1H);4.0(m,2H);3.8 (m,2H);3.35(m,2H);3.2(m,2H);2.1(m,2H). | 1.80 |
152 | 519.20 | DMSO d6:11.9 ppm(s,1H),10.1(s,1H),9.3(s,1H),9.0 (bs,1H),8.2(s,1H),8.1(s,1H),7.5(t,1H),7.15(d,1H), 6.7(d,1H),4.3(m,4H),3.0-3.8(m,14H),3.1(m,2H),2.1 (s,3H),2.0(q,2H),1.3(bs,6H) | 1.40 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
153 | 520.20 | DMSO d6:11.9ppm(s,1H),10.1(s,1H),9.3(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.3 (m,4H),4.0(d,2H),3.7(t,4H),3.5(d,2H),3.2(m,2H), 3.1(m,4H),2.1(s,3H),2.0(q,2H),1.3(bs,6H) | 1.60 |
154 | 433.10 | DMSO d6:11.9ppm(s,1H),9.9(s,1H),9.3(s,1H),8.3(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),5.9(s, 1H),5.5(s,1H),4.4(m,4H), 3.0(m,2H),2.1(s,3H),2.0(s,3H),1.3(bs,6H) | 2.20 |
155 | 473.10 | DMSO d6:11.8ppm(s,1H),9.6(s,1H),9.3(s,1H),8.3(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.75(t,1H),6.7(d, 1H),4.4(m,4H),3.0(m,2H),2.3(m,2H),2.2(m,2H),2.1 (s,3H),1.7(m,2H),1.6(m,2H),1.3(bs,6H) | 2.60 |
156 | 469.10 | DMSO d6:11.9ppm(s,1H),10.3(s,1H),9.4(s,1H),8.4 (s,1H),8.1(s,1H),8.0(d,2H),7.6(m,4H),7.2(d,1H), 6.7(d,1H),4.4(m,4H),3.1(m,2H),2.1(s,3H),1.3(bs, 6H) | 2.50 |
157 | 459.10 | DMSO d6:11.9ppm(s,1H),9.7(s,1H),9.3(s,1H),8.3(s, 1H,8.1(s,1H),7.5(t,1H),7.1(d,1H),6.75(s,1H),6.7 (d,1H),4.4(m,4H),3.1(m,2H),2.6(dt,4H),2.1(s,3H), 1.9(q,2H),1.3(bs,6H) | 2.40 |
158 | 475.20 | DMSO d6:11.8ppm(s,1H),9.8(s,1H),9.3(s,1H),8.15 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4 (m,4H),3.1(m,2H),2.4(m,1H),2.1(s,3H),1.8(dd,4H), 1.4(q,2H),1.3(bs,10H) | 2.60 |
159 | 379.00 | 12.03(s,1H),8.7-9.8(s,5H),8.40(s,1H),8.08(s,1H), 7.96(s,1H),7.77(t,1H),7.15(d,1H),6.90(d,1H),4.15- 4.7(m,4H),3.31(m,2H),2.95(s,3H),2.16(s,3H),1.37 (m,6H) CD3CN | 1.70 |
160 | 440.90 | DMSO d6 12.3(bs,1H);10.0(bs,1H);8.6(s,1H);8.2(s, 1H);8.1(s,1H);7.3(s,1H);7.1(s,1H);4.4(bs,2H);4.2 (d,2H);3.1(bd,2H);2.05(s,3H);2.01(s,3H);1.3(bs, 6H) | 2.40 |
161 | 447.00 | DMSO d6:11.8ppm(s,1H),9.7(s,1H),9.3(s,1H),8.3(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),6.5(q, 1H),4.4(m,4H),3.1(m,2H),2.1(s,3H),1.9(s,3H),1.8 (d,3H),1.2(bs,6H) | 2.40 |
162 | 475.90 | DMSO d6:11.9ppm(s,1H),10.5(s,1H),9.4(s,1H),9.3 (s,1H),8.5(s,1H),8.45(s,1H),8.1(s,1H),7.6(t,1H),7.1 (d,1H),6.7(d,1H),4.3(m,4H),3.1(m,2H),2.1(s,3H), 1.3(bs,6H) | 2.30 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
163 | 470.00 | DMSO d6:11.9ppm(s,1H),10.6(s,1H),9.4(s,1H),9.3 (s,1H),9.2(s,1H),8.8(d,1H),8.4(s,1H),8.4(d,1H),8.2 (s,1H),7.7(q,1H),7.6(t,1H),7.2(d,1H),6.7(d,1H),4.4 (m,4H),3.1(m,2H),2.1(s,3H),1.3(bs,6H) | 2.10 |
164 | 471.00 | DMSO d6:11.9ppm(s,1H),10.9(s,1H),9.5(s,1H),9.3 (s,1H),9.0(s,1H),8.8(s,1H),8.5(s,1H),8.2(s,1H),7.6 (t,1H),7.1(d,1H),6.7(d,1H),4.4(m,4H),3.0(m,2H), 2.1(s,3H),1.3(bs,6H) | 2.30 |
165 | 433.00 | DMSO d6:11.8ppm(s,1H),10.2(s,1H),9.3(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.3 (bd,4H),3.0(bd,2H),2.1(s,1H),1.8(m,1H),1.3(bs, 6H),0.8(m,4H) | 2.30 |
166 | 461.10 | DMSO d6:11.8ppm(s,1H),9.9(s,1H),9.3(s,1H),8.2(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4 (bd,4H),3.0(bd,2H),2.8(q,1H),2.1(s,1H),1.9(m,1H), 1.8(m,1H),1.7(m,1H),1.6 (m,1H),13 (bs,6H) | 2.60 |
167 | 460.00 | DMSO d6:12.0ppm(s,1H),10.9(s,1H),9.3(s,1H),8.8 (s,1H),8.4(s,1H),8.2(s,1H),7.6(t,1H),7.2(s,1H),7.15 (d,1H),6.7(d,1H),4.4(bd,4H),3.1(bd,2H),2.1(s,3H), 1.3(bs,6H) | 2.30 |
168 | 483.00 | DMSO d6:11.9ppm(s,1H),10.3(s,1H),9.4(s,1H),8.4 (s,1H),8.2(s,1H),7.85(s,1H),7.8(d,1H),7.6(t,1H),7.4 (s,2H),7.4(q,1H),7.2(d,1H),6.7(d,1H),4.4(bd,4H), 3.1(bd,2H),2.4(s,3H),2.1(s,3H),1.3(bs,6H) | 2.70 |
169 | 487.00 | DMSO d6:11.9ppm(s,1H),10.4(s,1H),9.4(s,1H),8.4 (s,1H),8.2(s,1H),7.9(d,1H),7.8(d,1H),7.6(q,1H), 7.55(t,1H),7.45(t,1H),7.2(d,1H),6.7(d,1H),4.4(bd, 4H),3.1(bd,2H),2.1(s,3H),1.3(bs,6H) | 2.70 |
170 | 437.00 | DMSO d6:11.9ppm(s,1H),9.8(s,1H),9.3(s,1H),8.3(s, 1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.7(d,1H),4.4 (bd,4H),4.1(s,2H),3.4(s,1H),3.0(bd,2H),2.1(s,3H), 1.3(bs,6H) | 2.10 |
171 | 476.00 | DMSO d6:12.0ppm(s,1H),10.5(s,1H),9.0(s,1H),8.3 (s,1H),8.2(s,1H),7.6(t,1H),7.1(d,1H),6.7(d,1H),4.4 (bd,4H),3.3(m,2H),3.0(bd,2H),2.3(m,2H),2.1(s,3H), 1.5-1.9(m,4H),1.3(bs,6H) | 1.70 |
172 | 487.00 | DMSO d6:11.9ppm(s,1H),10.4(s,1H),9.4(s,1H),8.3 (s,1H),8.2(s,1H),7.7(t,1H),7.6(q,1H),7.5(t,1H),7.4 (q,2H),7.2(d,1H),6.7(d,1H),4.4(bd,4H),3.1(bd,2H), 2.1(s,3H),1.3(bs,6H) | 2.60 |
173 | 502.90 | DMSO d6:11.9ppm(s,1H),10.5(s,1H),9.4(s,1H),8.3 (s,1H),8.2(s,1H),7.4-7.7(m,5H),7.2(d,1H),6.7(d, 1H),4.4(bd,4H),3.1(bd,2H),2.0(s,3H),1.3(bs,6H) | 2.60 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
174 | 502.90 | DMSO d6:11.9ppm(s,1H),10.5(s,1H),9.4(s,1H),8.4 (s,1H),8.2(s,1H),8.0(d,1H),7.7(s,1H),7.6(t,1H),7.5 (t,1H),7.2(d,1H),6.7(d,1H),4.4(bd,4H),3.1(bd,2H), 2.1(s,3H),1.3(bs,6H) | 2.90 |
175 | 307.00 | DMSO d6 12.4(bs,1H);8.4(s,1H);8.3(s,1H);8.2(s, 1H);7.95(d,2H);7.9(s,1H) | 2.80 |
176 | 253.70 | DMSO d6 12.4(bs,1H);8.5(s,1H);8.3(s,1H);8.2(s, 1H);8.0(d,2H);7.9(d,2H) | 3.10 |
177 | 350.95 | DMSO d6 12.4(bs,1H);8.35(s,1H);8.3(s,1H);8.2(m, 2H);8.1(s,1H);7.9(s,1H) | 3.16 |
178 | 287.01 | DMSO d6 12.2(bs,1H);8.4(s,1H);8.3(s,1H);8.0(s, 1H);7.65(s,1H);7.6(dd,1H);7.4(dd,1H);7.2(dd,1H); 3.8(S,2H) | 2.69 |
179 | 494.00 | DMSO d6:11.9ppm(s,1H),10.5(s,1H),9.4(s,1H),8.45 (s,1H),8.4(s,1H),8.3(d,1H),8.2(s,1H),(8.1(d,1H),7.8 (t,1H),7.6(t,1H),7.2(d,1H),6.7(d,1H),4.4(bd,4H), 3.1(bd,2H),2.1(s,3H),1.3(bs,6H) | 2.60 |
180 | 449.10 | DMSO d6:11.8ppm(s,1H),9.9(s,1H),9.3(s,1H),8.2(s, 1H),8.1(s,1H),7.6(t,1H),7.1(d,1H),6.7(d,1H),4.4 (bd,4H),3.1(bd,2H),2.4(m,1H),2.1(s,3H),1.6(m,1H), 1.4(m,1H),1.3(bs,6H),1.1(d,3H,0.9(t,3H) | 2.50 |
181 | 433.00 | DMSO d6:11.9ppm(s,1H),10.0(s,1H),9.3(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.1(d,1H),6.8(m,1H),6.7 (d,1H),6.2(d,1H),4.4(bd,4H),3.1(bd,2H),2.1(s,3H), 1.9(d,3H),1.3(bs,6H) | 2.30 |
182 | 474.90 | DMSO d6:11.9ppm(s,1H),10.3(s,1H),9.3(s,1H),8.4 (s,1H),8.2(s,1H),8.0(d,1H),7.9(d,1H),7.6(t,1H), 7.25(t,1H),7.2(d,1H),6.7(d,1H),4.4(bd,4H),3.1(bd, 2H),2.1(s,3H),1.3(bs,6H) | 2.50 |
183 | 228.80 | DMSO d6 12.2(bs,1H);8.3(s,1H);8.25(s,1H);8.0(s, 1H);7.7(d,2H);7.4(dd);7.2(dd,1H) | 3.40 |
184 | 230.10 | DMSO d6 12.2(bs,1H);8.3(s,1H);8.25(s,1H);8.0(s, 1H);7.7(d,2H);7.4(dd);7.2(dd,1H) | 1.60 |
185 | 243.10 | DMSO d6 12.2(bs,1H);8.3(s,1H);8.25(s,1H);7.9(s, 1H);7.5(dd,2H);7.3(dd,1H);7.1(d,1H);2.3(s,3H) | 3.40 |
186 | 334.10 | DMSO d6 12.2(bs,1H);8.25(s,1H);8.2(s,1H);8.0(s, 1H);7.5(d,1H);7.4(dd,2H);7.3(d,1H);7.05(dd,2H); 6.7(d,2H);6.55(dd,1H);4.3(s,2H) | 2.60 |
187 | 401.80 | DMSO d6 12.2(bs,1H);8.3(s,1H);8.05(s,1H);8.0(s, 1H);7.5(m,5H);7.3(dd,1H);7.2(s,1H);7.1(s,1H);6.8 (s,1H);4.4(s,2H) | 3.90 |
188 | 291.02 | 2.30 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
189 | 487.00 | DMSO d6:11.9ppm(s,1H),10.3(s,1H),9.3(s,1H),8.4 (s,1H),8.15(s,1H),8.1(m,2H),7.5(t,1H),7.4(t,2H), 7.15(d,1H),6.7(d,1H),4.4(bd,4H),3.1(bd,2H),2.1(s, 3H),1.3(bs,6H) | 2.60 |
190 | 460.00 | DMSO d6:11.9ppm(s,1H),10.6(bs,1H),9.3(s,1H),8.5 (s,1H),8.2(s,1H),7.5(t,1H),7.1(d.1H),6.7(d,1H),4.4 (bd,4H),3.1(bd,2H),2.1(s,3H),1.2(bs,6H) | 2.00 |
191 | 445.00 | DMSO d6:11.9ppm(s,1H),10.2(bs,1H),9.4(s,1H),8.3 (s,1H),8.1(s,1H),7.5(t,1H),7.2(m,1H),7.1(d.1H),6.7 (d,1H),6.6(m,1H),6.3(d,1H),5.7(d,1H),5.5(d,1H), 4.4(bd,4H),3.1(bd,2H),2.1(s,3H),1.2(bs,6H) | 2.40 |
192 | 452.90 | DMSO d6:11.9ppm(s,1H),10.3(s,1H),9.3(s,1H),8.2 (s,1H),8.1(s,1H),7.5(t,1H),7.4(d,1H),7.1(d.1H),6.7 (d,1H),6.7(s,1H),4.4(bd,4H),3.1(bd,2H),2.1(s,3H), 1.2(bs,6H) | 2.50 |
193 | 456.10 | DMSO-d6:11.9(bs,1H);8.3(s,1H);8.1(m,2H);7.55(dd, 1H);7.45(d,2H);7.4(dd,2H);7.3(m,1H);7.15(d,1H); 6.7(d,1H);5.2(s,2H);4.2(d,4H);3.1(m,2H);2.05(s, 3H);1.25(s,6H). | 3.00 |
194 | 451.20 | DMSO-d6:11.9(bs,1H);8.25(s,1H);8.1(s,1H);8.05(s, 1H);7.55(dd,1H);7.15(d,1H);6.7(d,1H);4.3(d,4H); 4.15(m,2H);3.25(m,2H);3.05(m,2H);2.8(s,6H);2.15 (m,2H);2.05(s,3H);1.25(s,6H). | 1.60 |
195 | 279.80 | (d4-methanol,free base)8.87(s,1H),8.70(s,1H),8.50(s, 1H),8.38(s,1H),8.20(d,1H),8.18(d,1H),8.10(m,1H), 7.96(m,1H) | 2.86 |
196 | 311.80 | (d4-methanol,salt)8.88(s,1H),8.25(m,2H),7.86(s,1H), 7.34(m,1H),2.72(s,3H) | 3.95 |
197 | 293.80 | (d4-methanol,salt)8.71-7.45(m,8H),2.90(s,3H) | 2.33 |
198 | 293.90 | (d4-methanol,salt)8.53-7.82(m,7H),7.41(s,1H),4.34(s, 3H) | 2.33 |
199 | 278.90 | (d4-methanol,salt)8.39(dd,1H),8.25(s,1H),8.11(s,1H), 7.94-7.79(m,5H),7.51-7.44(m,2H) | 3.87 |
200 | 279.90 | (d4-methanol,salt)9.16-7.99(m,9H) | 3.87 |
201 | 259.90 | (d4-methanol,salt)8.86(d,1H),8.23(s,1H),8.09(s,1H), 7.99(m,1H),7.70(d,1H),7.39(dd,1H),6.65(d,1H),4.17 (s,3H) | 3.46 |
202 | 279.80 | (d4-methanol,salt)9.01(d,1H),8.98(d,1H),8.32(s,1H), 8.31(s,1H),8.28(d,1H),8.17(d,1H),8.01-7.97(m,2H), 7.94(s,1H) | 2.50 |
203 | 287.90 | (CDCl3)10.00(br s,1H),8.49(s,1H),8.27(s,1H),8.00s, 1H),7.71(m,1H),7.48(m,1H),7.20(m,1H),7.19(d,1H), 1.97(s,OH,1H),1.57(s,6H) | 2.56 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
204 | 412.90 | DMSO d6 12.2(bs,1H);8.7(t,1H);8.4(s,1H);8.2(s, 1H);8.1(s,1H);8.0(s,1H);4,8(q,1H);3.9(s,3H);3.85 (m,2H);1.15(d,3H) | 1.90 |
205 | 394.20 | 2.10 | |
206 | 408.10 | 2.20 | |
207 | 420.20 | 2.30 | |
208 | 493.20 | 1.70 | |
209 | 452.20 | 2.20 | |
210 | 343.00 | 1H NMR(CDCl3)0.30(9H,s),7.33-7.54(8H,m),7.59- 7.68(2H,m),8.05-8.08(1H,m),8.61-8.65(1H,m),9.70 (1H,brs). | |
211 | 349.10 | (400 MHz,DMSO-d6)7.30-7.43(8H,br m),7.48(2H,m), 7.98(1H,d),8.34(1H,d),12.36(1H,br m). | |
212 | 364.40 | (400 MHz,DMSO-d6)7.00(2H,d),7.23(2H,d),7.34(3H, m),7.49(2H,dd),7.97(1H,s),8.33(1H,d) and 12.38(1H, s). | |
213 | 271.00 | 1H NMR(CDCl3)7.30-7.57(6H,m),7.60-7.77(5H,m), 8.44-8.48(1H,m),8.65-8.70(1H,m),11.21(1H,brs). | |
214 | 301.00 | 1H NMR(DMSO)3.84(3H,s),6.80-6.88 91H,m),7.25- 7.30(1H,m),7.32-7.41(3H,m),7.45-7.54(2H,m),7.72- 7.81(2H,m),7.90-7.98(1H,m),8.39-8.43 91H,m),8.54- 8.60(1H,m),12.04(1H,brs). | |
215 | 315.00 | 1H NMR(DMSO)1.36(3H,t,J=6.9Hz),4.10(2H,q,J= 6.9Hz),6.80-6.86(1H,m),7.22-7.29(1H,m),7.30-7.41 (3H,m),7.45-7.55(2H,m),7.73-7.80(2H,m),7.91-7.98 (1H,m),8.38-8.41(1H,m),8.53-8.59(1H,m),12.02 91H, brs). | |
216 | 331.00 | 1H NMR(DMSO)3.70-3.80(6H,m),6.81-6.90(1H,m), 7.02-7.15(2H,m),7.32-7.40(1H,m),7.42-7.51(2H,m), 7.66-7.79(3H,m),8.11-8.16(1H,m),8.50-8.56(1H,m), 11.95(1H,brs). | |
217 | 436.70 | (400 MHz,DMSO-d6)12.31(1H,s),8.32(1H,d),7.94(1H, d),7.52(2H,d),7.33(3H,m),7.10(2H,d),6.98(2H,d), 3.75(4H,dd)and 3.15(4H,dd). | |
218 | 349.00 | 1H NMR(DMSO)3.30(3H,s),7.34-7.45(1H,m),7.49- 7.83(6H,m),8.16(1H,s),8.18-8.28(2H,m),8.45-8.49 91H,m),8.58-8.62(1H,m),12.21(1H,brs). | |
219 | 342.00 | 1H NMR(DMSO)3.00(6H,s),7.35-7.42(1H,m),7.45- 7.68(4H,m),7.75-7.90(4H,m),8.03(1H,s),8.45-8.50 (1H,m),8.56-8.60(1H,m),12.11(1H,brs). |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
220 | 370.00 | 1H NMR(DMSO)0.91(3H,t,J=7.4Hz),1.30-1.42(2H, m),1.49-1.59(2H,m),3.25-3.34(2H,m),7.35-7.42(1H, m),7.46-7.58(3H,m),7.68-7.81(3H,m),7.92-8.03(2H, m),8.19-8.22(1H,m),8.44-8.49(1H,m),8.50-8.61(2H, m),12.10(1H,brs). | |
221 | 367.00 | 1H NMR(DMSO)3.36(3H,s),7.28-7.39(2H,m),7.50- 7.88(5H,m),8.10-8.26(3H,m),8.43-8.46(1H,m),8.57- 8.59(1H,m),12.25(1H,brs). | |
222 | 349.00 | 1H NMR(DMSO)3.79(3H,s),3.86(3H,s),7.00-7.05 (1H,m),7.26-7.37(4H,m),7.78-7.89(2H,m),8.35-8.40 (1H,m),8.50-8.56(1H,m),11.93(1H,brs). | |
223 | 307.00 | 1H NMR(DMSO)7.22-7.37(4H,m),7.78-7.88(4H,m), 7.92(1H,brs),8.36-8.41 91H,m),8.51-8.58(1H,m),12.02 (1H,brs). | |
224 | 319.00 | 1H NMR(DMSO)3.80(3H,s),6.99-7.06(2H,m),7.26- 7.36(2H,m),7.68-7.84(5H,m),8.33-8.39(1H,m),8.50- 8.57(1H,m),11.91(1H,brs). | |
225 | 452.00 | 1H NMR(DMSO)3.30-3.80(8H,m),7.25-7.32(1H,m), 7.50-7.63(2H,m),7.80(1H,s),7.88-7.99(2H,m),8.05 (1H,s),8.49-8.54(1H,m),8.60-8.68(1H,m),12.20(1H, brs). | |
226 | 410.00 | 1H NMR(DMSO)1.16(3H,t),3.20-3.42(2H,m),7.50- 7.76(3H,m),7.88-7.95(2H,m),7.98-8.06(2H,m),8.20 (1H,s),8.51-8.66(3H,m),12.18(1H,brs). | |
227 | 332.00 | 1H NMR(DMSO)7.28-7.39(3H,m),7.79-8.03(7H,m), 8.09(1H,brs),8.48-8.51(1H,m),8.53-8.59(1H,m),12.14 (1H,brs). | |
228 | 332.00 | 1H NMR(DMSO)7.30-7.48(3H,m),7.42(1H,brs),7.50- 7.58(1H,m),7.70-7.86(3H,m),7.92-8.11(3H,m),8.20 (1H,brs),8.41-8.49(1H,m),8.54-8.59(1H,m),12.09(1H, brs). | |
229 | 299.00 | 1H NMR(DMSO)7.38-7.43 91H,m),7.48-7.55(2H,m), 7.78-7.83(2H,m),7.97 92H,d,J=8.2Hz),8.09(2H,d,J= 8.2Hz),8.21(1H,s),8.54-8.62 92H,m),10.00 91H,s), 12.30(1H,brs). | |
230 | 342.00 | 1H NMR(DMSO)1.90 93H,s),4.20-4.30 92H,m),7.27- 7.40(3H,m),7.45-7.51 92H,m),7.70-7.80(4H,m),7.85- 7.91(1H,m),8.30-8.41(2H,m),8.51-8.60(1H,m),12.00 (1H,brs). | |
231 | 313.00 | 1H NMR(DMSO)2.60(3H,s),7.36-7.42(1H,m),7.47- 7.55(2H,m),7.76-7.83(2H,m),7.95-8.08(4H,m),8.15 (1H,s),8.50-8.56(1H,m),8.58-8.63 91H,m),12.24(1H, brs). |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
232 | 286.00 | 1H NMR(DMSO)5.08(2H,brs),6.63-6.70(2H,m),7.30- 7.52 95H,m),7.60-7.66(1H,m),7.70-7.80(2H,m),8.30- 8.35(1H,m),8.50-8.55(1H,m),11.75(1H,brs). | |
233 | 1H NMR(DMSO)2.40-2.48(3H,m),7.36-7.55(4H,m), 7.78-7.85(4H,m),8.02-8.09(2H,m),8.15(1H,s),8.52- 8.56(1H,m),8.59-8.62(1H,m),12.25(1H,brs). | ||
234 | 364.00 | 1H NMR(DMSO)3.00(3H,s),7.25-7.54(5H,m),7.70- 7.90(5H,m),8.40-8.48(1H,m),8.52-8.60(1H,m),9.73 (1H,brs),12.00(1H,brs). | 8.93 |
235 | 304.00 | 1H NMR(DMSO)7.15(1H,s),7.35(1H,brs),7.78(1H,s), 7.85-8.08(7H,m),8.31(1H,s),8.49 91H,brs),8.61(1H, brs),12.08(1H,brs). | 7.68 |
236 | 320.00 | 1H NMR(DMSO)7.30(1H,s),7.60-7.76(2H,m),7.82- 8.10(7H,m),8.55(1H,brs),8.70(1H,s),12.10(1H,brs). | 8.14 |
237 | 370.00 | (400 MHz,MeOH-d4):4.70-4.85(2H,brs),6.35-6.45(1H, s),7.30-7.50(5H,m),8.05-8.15(1H,d),8.20-8.25(1H,s), 8.60-8.70(1H,brs) | 4.87 |
238 | 388.00 | 1H NMR(DMSO-d6):3.33(1H,s),4.75-4.80(2H,m), 7.35-7.45(4H,m),8.15(1H,s),8.20-8.25(2H,m),8.28- 8.35 1H,m),8.50(1H,s) | 4.87 |
239 | 344.00 | 1H NMR(DMSO)3.85(3H,s),6.91-7.00(1H,m),7.26- 7.49(4H,m),7.85-8.10(6H,m),8.50(1H,brs),8.60(1H, brs),12.15(1H,brs). | 8.38 |
240 | 308.24 | 1H NMR(DMSO-d6):7.22(1H,m),7.47(2H,m),7.85 (1H,s),8.21(1H,s),8.64(1H,s),11.19(1H,br s) | 4.93 |
241 | 299.38 | 1H NMR(CDCl3):2.04(4H,s),3.53(4H,s),6.22(1H,d), 6.86(1H,d),7.44(1H,t),7.81(1H,s),8.17(1H,s),8.87 (1H,s) | 5.15 |
242 | 369.00 | 1H NMR (DMSO-d6):4.60-4.70(2H,m),6.35-6.40(1H, d),7.05-7.10(1H,d),7.20-7.25(1H,t),7.35-7.45(4H,m), 8.15-8.20(2H,m),8.55-8.60(1H,s),12.5(1H,s) | 4.99 |
243 | 321.00 | 1H NMR(DMSO-d6):6.70-6.75(1H,d),6.90-6.95(1H,t), 7.30-7.35(3H,qd),7.50-7.65(3H,m),8.25-8.30(2H,m), 8.80(1H,s),9.05(1H,s),12.5(1H,s) | 4.84 |
244 | 401.49 | 1H NMR(DMSO-d6):4.63(2H,d),5.20(1H,br s),6.45 (1H,d),7.08(1H,d),7.27(1H,t),7.37(2H,s),7.43(1H,t), 7.64(1H,s),8.16(2H,d),8.39(1H,s),12.48(1H,br s) | 5.20 |
245 | 513.00 | (d6-DMSO,400MHz)3.16(3H,s),5.30(2H,s),7.52(1H, d), 7.60(2H,d),7.70(1H,d),7.81(1H,t),7.91(2H,d), 8.17(1H,d),8.28(1H,d),8.36(1H,s),12.31(1H,s) | 4.89 |
246 | 245.00 | (d6-DMSO,400MHz)5.98(2H,brs),6.25(1H,d), 7.01(1H,d),7.37(1H,t),8.18(1H,s),8.24(1H,d), 8.96(1H,d),12.12(1H,s) | 3.80 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
247 | 413.00 | (d6-DMSO,400MHz)3.15(3H,s),4.71(2H,s),6.38(1H, d), 7.06(1H,d),7.42(1H,t),7.65(2H,d),7.88(2H,d), 8.18(2H,s),8.53(1H,s),12.12(1H,s) | 4.00 |
248 | 372.00 | 1H NMR(DMSO-d6):7.05-7.10(1H,t),7.35-7.40(1H, m),7.60-7.65(1H,t),7.70-7.80(3H,m),7.82-7.88(1H,d), 7.95(1H,s),8.25(1H,s),8.40(1H,s),12.5(1H,s) | 5.22 |
249 | 349.00 | (d6-DMSO,400MHz)7.56-7.60(2H,m),7.63(1H,d), 7.69(1H,d),7.82(1H,t),7.97(1H,s),8.00(2H,d), 8.27(1H,s),8.42(1H,s),9.28(1H,s),10.81(1H,s), 12.29(1H,s) | 4.59 |
250 | 345.00 | (d6-DMSO,400MHz)1.53(9H,s),7.56(2H,dd), 7.69(1H,t),8.25(1H,d),8.36(1H,s),9.30(1H,s), 10.06(1H,s),12.22(1H,s) | 4.90 |
251 | 405.00 | NMR(DMSO)4.6(2H,d,CH2),6.4(H,d,ar),7.05(H,d, ar),7.3(H,m,ar),7.4(H,d,ar),7.45(H,t,ar),7.6(H,d, ar),7.65(H,s,ar),8.15(2H,s,ar),8.5(H,s,NH) and 12.15 (H,s,NH). | 5.15 |
252 | 349.00 | 1H NMR(DMSO-d6):1.50-1.55(3H,d),5.05-5.15(2H, m),6.30-3.35(1H,d),6.95-7.05(1H,d),7.10-7.15(1H,d), 7.15-7.20(1H,t),7.25-7.40(3H,m),7.45-7.50(2H,d), 8.15(1H,s),8.20(1H,s),8.75(1H,s),12.5(1H,s) | 4.93 |
253 | 315.70 | CDCl3 3.23(6H,m),6.45(1H,d),7.03(1H,d),7.43(1H, m), 7.5-7.57(3H,m),7.70-7.73(2H,m),7.88(1H,s),8.65(1H, s), 9.10(1H,s),9.25(1H,s). | 10.37 |
254 | 349.00 | NMR(DMSO)2.2(3H,s,CH3),4.5(2H,s,CH2),6.3(H, s,ar),6.8-7.4(7H,m,ar),8.1-8.3(2H,m,ar) and 8.7(H,s, NH). | 5.03 |
255 | 407.00 | 1H NMR(DMSO)3.01(3H,s),7.28-7.39(3H,m),7.70- 8.10(8H,m),8.45(1H,brs),8.55(1H,brs),9.80(1H,brs), 12.14(1H,brs). | |
256 | 407.00 | 1H NMR(DMSO)2.45(3H,brs),7.31(1H,brs),7.51(1H, brs),7.80-8.15(10H,m),8.60(1H,brs),8.67(1H,brs), 12.21(1H,brs). | |
257 | 414.53 | 1H NMR(DMSO-d6):1.44(9H,s),3.41(4H,s),3.57 (4H,d),6.69(1H,d),7.22(1H,d),7.57(1H,t),8.27(2H, s),8.67(1H,s),12.25(1H,s | 2.50 |
258 | 365.40 | 1H NMR(DMSO-d6):3.70(3H,s),6.35(1H,d),6.88(2H, d),7.03(1H,d),7.11(1H,t),7.34(2H,d),7.37(1H,t),8.18 (1H,s),8.21(1H,d),8.76(1H,s),12.13(1H,s) | 4.78 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
259 | 329.70 | CDCl3 1.05(3H,t),1.7-1.8(2H,m),3.4-3.5(2H,m),4.6 (1H,s), 6.32(1H,d),7.03(1H,d),7.45(1H,m),7.5-7.6(3H,m), 7.75(2H,d),7.78(1H,s),8.65(1H,s),8.97(1H,s),9.12 (1H,s) | 4.99 |
260 | 349.00 | (400MHz,MeOH-d4):1.55-1.60(3H,d),5.05-5.15(1H, m),6.30-6.35(1H,d),6.95-7.05(1H,d),7.10-7.15(1H,m), 7.15-7.20(1H,t),7.25-7.40(3H,m),7.45-7.50(2H,d), 7.95(1H,s)8.15(1H,s),8.75(1H,s) | 4.93 |
261 | 445.00 | NMR(DMSO)4.7(2H,d,CH2),6.35(H,d,ar),7.15(H,d, ar),7.2(H,t,ar),7.3-7.55(7H,m,ar),7.6(s,H,ar),8.2(H, s,ar),8.5(H,s,NH)and 8.9(H,s,NH). | 5.30 |
262 | 391.00 | NMR(DMSO)2.2(3H,s,Me),4.6(2H,d,CH2),6.3(H,d, ar),7.05-7.1(4H,m,ar),7.25(2H,,d,ar),7.3-7.45(4H,m, ar),7.6(2H,d,ar),8.15(H,s,ar),8.5(H,s,NH)and 9.05 (H,s,NH). | 5.14 |
263 | 355.00 | 1H NMR(DMSO-d6):6.70-6.80(1H,d),7.10-7.20(1H,t), 7.30-7.40(2H,m),7.50-7.60(2H,m),7.80-7.90(1H,d), 8.15(1H,s),8.25(1H,s),8.50(2H,s),12.2(1H,s) | 4.92 |
264 | 349.00 | 1H NMR(DMSO-d6):2.95-3.00(2H,t),3.55-3.60(2H, m),6.30-6.35(1H,d),6.65-6.70(1H,t),7.05-7.10(1H,d), 7.15-7.20(1H,t),7.30(4H,m),7.32-7.40(1H,t),8.17(1H, s),8.20(1H,s),8.85(1H,s),12.2(1H,s) | 4.67 |
265 | 363.00 | NMR(DMSO)6.7(H,d,ar),6.9(H,t,ar),7.35-7.4(2H,m, ar),7.4-7.5(4H,m,ar),7.5-7.75(5H,m,ar),8.25(H,s,ar), 8.6(H,s,ar),8.9(H,s,ar),9.3(H,s,NH)and 12.1(1H,s, NH). | 4.64 |
266 | 397.00 | NMR(DMSO)6.8(H,d,ar),7.0(H,m,ar),7.2(H,m,ar), 7.2-7.6(7H,m,ar),7.65(H,m,ar),8.0(H,m,ar),8.2(H,s, ar),8.4(H,m,NH),8.5 (H,s,ar),8.7(H,s,ar)and 12.1(H, brs,NH). | 5.20 |
267 | 314.43,314.00 | 1H NMR(DMSO-d6):3.11(4H,s),3.88(4H,d),6.78 (1H,d),7.30(1H,d),7.65(1H,t),8.30(2H,d),8.63(1H, s),8.77(2H,br s),12.30(1H,s),DMSO D6 2.82-2.93(4H, m),3.48-3.55(4H,m),6.65(1H,d),7.15(1H,d),7.55(1H, t),8.25-8.30(2H,m),8.69(1H,s) | 3.42,2.7 5 |
268 | 287.60 | CDCl3 4.48(2H,s),6.45(1H,d),7.12(1H,d),7.42(1H,t), 7.5-7.6(3H,m),7.75(2H,t),7.88(1H,s),8.7(1H,s),8.88 (1H,s), 9.52(1H,s) | 2.79 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
269 | 377.60 | CDCl3 4.7(2H,d),5.0(1H,s),6.35(1H,d),7.08(1H,d), 7.3-7.4(9H,t), 7.5-7.6(3H,m),7.68(2H,d),7.88(1H,s),8.65(1H,s), 8.95(1H,s), 9.43(1H,s) | 5.00 |
270 | 289.00 | 1H NMR(DMSO-d6):3.45-3.50(2H,m),3.60-3.65(2H, m),4.70-4.77(1H,t),6.25-6.30(1H,d),6.50-6.55(1H,t), 7.00-7.05(1H,d),7.30-7.40(1H,t),8.20(1H,s),8.25(1H, s),8.85(1H,s),12.2(1H,s) | 3.79 |
271 | 330.00 | 1H NMR(DMSO-d6):2.00-2.10(2H,m),2.80-2.85(6H, s),3.20-3.30(2H,m),3.40-3.50(2H,m),6.25-6.30(1H, m),6.60-6.80(1H,m),7.00-7.05(1H,d),7.30-7.40(1H,t), 8.20-8.30(2H,m),8.85(1H,s),12.2(1H,s) | 3.34 |
272 | 225.00 | (d6-DMSO)2.90(3H,d),6.24(1H,d),6.42-6.44(1H,m), 7.00(1H,d),7.14(1H,dd),7.37(1H,t),8.08(1H,s), 8.23(1H,d),8.85(1H,d),11.87(1H,s) | 3.32 |
273 | 355.00 | 1H NMR(DMSO-d6):6.60-6.65(1H,m),6.70-6.80(1H, d),7.00-7.10(1H,m),7.15-7.30(1H,m),7.20-7.30(1H, m),7.55-7.65(2H,m),7.90(1H,s),8.15(1H,s),8.30(1H, s),8.60(1H,s),8.90-8.95(1H,m),12.2(1H,s) | |
274 | 349.48 | 1H NMR(DMSO-d6):3.14(3H,s),4.92(4H,s),6.42 (1H,d),7.09(1H,d),7.23(1H,t),7.31(4H,m),7.48(1H, t),8.11(1H,s),8.21(1H,s),8.55(1H,s),12.20(1H,br s) | 5.25 |
275 | 328.46 | 1H NMR(DMSO-d6):2.24(3H,s),3.31(4H,s),3.56(4H, s),6.67(1H,d),7.19(1H,d),7.54(1H,t),8.27(2H,s),8.69 (1H,s),12.23(1H,s) | 4.37 |
276 | 354.64 | 1H NMR(DMSO-d6):2.07(3H,s),3.57(8H,m),6.70 (1H,d),7.23(1H,d),7.58(1H,t),8.28(2H,s),8.68(1H, s),12.25(1H,s) | 4.25 |
277 | 331.70 | DMSO 3.55(1H,m),3.65(1H,m),4.82(1H,m),6.35 (1H,d),6.52(1H,m), 7.05(1H,d),7.4(1H,t),7.55(1H,t),7.75(1H,d),8.15 (1H,s), 8.58(1H,s),9.08(1H,s) | 4.24 |
278 | 301.70 | DMSO 2.92(3H,s),6.30(1H,d),6.51(1H,m),7.08(1H,d), 7.35-7.42(2H,m),7.5-7.6(2H,m),7.72(2H,d),8.13(1H,s), 8.65(1H,s),9.18(1H,s) | 4.62 |
279 | 315.00 | NMR(DMSO)1.1(6H,d,iPr),2.85(H,m,CH),3.3(H, brs,NH),7.55(H,d,ar),7.65(H,t,ar),7.85(H,t,ar),8.2 (H,s,ar),8.3(H,s,ar),9.1(H,s,ar) and 10.3(H,s,NH). | 4.47 |
280 | 363.00 | NMR(DMSO)3.85(2H,s,CH2),7.15(5H,m,ar),7.6(H, d,ar),7.7(H,t,ar),7.9(h,d,ar),8.3(H,s,ar),84(H,s,ar), 9.1(H,s,ar),10.6(H,s,NH) and 12.3(H,brs,NH). | 4.72 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
281 | 383.00 | (DMSO)7.45-7.7(3H,m,ar),7.7-7.8(2H,m,ar),7.8(H,t, ar),8.0(H,m,ar),8.25(H,s,ar),8.4(H,s,ar),9.2(H,s, ar),11.1(H,s,NH),and 12.3(H,s,NH). | 4.68 |
282 | 383.00 | DMSO)6.6(H,m,ar),7.7(2H,dar),7.85(H,t,ar),8.0(H, m,ar),8.1(H,s,ar),8.25(H,s,ar),8.45(H,s,ar),9.3(H, s,ar),10.8(0.5H,s,NH) and 12.3(0.5H,s,NH). | 4.95 |
283 | 287.00 | (DMSO)2.2(3H,s,Me),7.55(H,m,ar),7.7(H,m,ar), 7.85(H,m,ar),8.2(H,m,ar),8.4(H,m,ar),10.4(H,s, NH) and 12.3(H,s,NH) | 4.05 |
284 | 335.00 | 1H NMR(DMSO-d6):3.50-3.55(3H,m),6.40-6.45(1H, m),7.25-7.30(2H,m),7.32-7.37(2H,m),7.45-7.55(3H, m),8.15(1H,s),8.30(1H,s),8.45(1H,s),12.2(1H,s) | 5.27 |
285 | 386.46 | 1H NMR(CDCl3):1.69(3H,d,J=6.9 Hz),5.29(1H,m), 5.42(1H,6.8 Hz),7.07(2H,m),7.44(2H,m),8.04(1H, m),8.09(1H,m),8.27(1H,m),8.65(1H,m),8.87(1H,br s) | 4.97 |
286 | 368.46 | 1H NMR(CDCl3):1.69(3H,d,J=6.8),5.33(1H,m),5.45 (1H,m),7.38(2H,m),7.47(2H,m),8.04(1H,d),8.08(1H, d),8.27(1H,d),8.70(2H,m) | 4.90 |
287 | 369.80 | DMSO 1.1-1.3(6H,m),1.6-1.7(2H,m),2.0-2.08(2H,m), 4.0(1H,m), 6.26(1H,d),6.35(1H,d),7.0(1H,d),7.3-7.4(2H,m),7.52 (2H,t), 7.7(2H,d),8.15(1H,s),8.55(1H,s),9.1(1H,s) | 5.27 |
288 | 355.00 | (DMSO)1.1-1.5(5H,m,cyhex),1.6-1.9(5H,m,cyhex), 2.65(1H,m,cyhex),7.6(H,d,ar),7.75(H,t,ar),7.95 (H, d,ar),8.3(H,s,ar),8.4(H,s,ar),9.15(H,s,ar),10.35(H, s,NH) and 12.2(H,s,NH). | 4.95 |
289 | 313.45 | 1H NMR(DMSO-d6):1.55(6H,m),2.01(2H,s),4.20 (1H,m),6.27(1H,d),6.54(1H,d),7.01(1H,d),7.34(1H, t),8.23(1H,s),8.30(1H,s),8.96(1H,s),12.13(1H,s) | 5.09 |
290 | 327.45 | 1H NMR(DMSO-d6):1.27(3H,m),1.45(2H,m),1.69 (1H,d),1.81(2H,d),2.09(2H,d),3.81(1H,m),6.24(1H, d),6.39(1H,d),6.97(1H,d),7.31(1H,t),8.20(2H,s), 8.88(1H,s),12.20(1H,br s) | 5.25 |
291 | 341.49 | 1H NMR(DMSO-d6):1.51(6H,m),1.67(4H,m),2.01 (2H,2),4.02(1H,s),6.26(1H,d),6.44(1H,d),6.98(1H, d),7.33(1H,t),8.19(1H,s),8.24(1H,s),8.93(1H,s), 12.13(1H,br s) | 5.37 |
292 | 273.38 | 1H NMR(DMSO-d6):2.94(3H,s),3.53(3H,s),6.56(1H, s),7.05(1H,s),7.58(1H,s),8.31(1H,s),8.36(1H,s),8.78 (1H,s) | 4.59 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
293 | 341.55 | 1H NMR(CDCl3):2.04(4H,m),3.61(4H,m),6.24(1H,d, J=8.3),6.98(1H,d,J=7.4),7.39(1H,m),7.48-7.52(3H, m),7.70(2H,m),7.88(1H,m),8.61(1H,s),9.16(1H,s), 9.33(1H,br s) | 5.32 |
294 | 350.00 | DMSO)7.7-7.8(2H,m,ar),7.9(H,t,ar),8.05(H,d,ar), 8.15(H,t,ar),8.25(H,d,ar),8.3(H,s,ar),8.45(H,s,ar), 8.8(H,d,ar),9.0(H,s,ar),10.6(H,s,NH) and 12.4(H,s, NH). | 4.85 |
295 | 383.00 | (400MHz,MeOH-d4):7.85-7.95(2H,d),8.05-8.10(2H, d),8.25-8.30(2H,s),8.35-8.37(1H,s),8.70(1H,s) | 3.98 |
296 | 350.00 | (DMSO)7.6-7.7(H,m,ar),7.75(H,m,ar),7.85(H,m,ar), 8.0(H,m,ar),8.3(H,m,ar),8.4(H,m,ar),8.8(H,s,ar), 9.15(h,s,ar),9.3(H,s,ar),11.0(H,s,ar)and 12.35(H,s, NH) | 4.22 |
297 | 395.55 | 1H NMR(DMSO-d6):3.69(6H,d),4.41(2H,br s),6.34 (1H,s),6.88(2H,m),6.94(2H,s),7.02(1H,m),7.36(1H, t),8.19(2H,m),8.76(1H,s),12.13(1H,s) | 4.64 |
298 | 257.59 | 1H NMR(DMSO-d6):2.89(3H,s),6.26(1H,d),6.54(1H, d),7.03(1H,d),7.38(1H,t),8.21(1H,s),8.24(1H,s),8.94 (1H,s),12.14(1H,s) | 4.40 |
299 | 354.00 | (400MHz,MeOH-d4):2.35-2.40(3H,s),7.30-7.45(4H, m),8.05-8.15(3H,m),8.20-8.25(1H,s) | 4.87 |
300 | 368.00 | (400MHz,DMSO-d6):2.20(6H,s),7.25(3H,m),7.70- 7.80(1H,s),8.05(1H,m),8.15(1H,m),8.30(1H,m),9.10 (1H,s),12.2(1H,s) | 4.93 |
301 | 406.00 | (400MHz,DMSO-d6):7.80-7.85(1H,m),7.90-7.95(2H, d),8.05-8.10(2H,d),8.15-8.35(3H,m),8.50(1H,s),8.60 (1H,s),9.50-9.55(1H,s),9.85-9.90(1H,s),12.2(1H,s) | 4.53 |
302 | (400MHz,MeOH-d4):2.10-2.0(1H,m),2.70-2.80(1H, m),2.95-3.05(1H,m),3.10-3.20(1H,m),5.90-6.00(1H,t), 7.20-7.40(4H,m),8.05-8.10(1H,s),8.15-8.20(2H,d), 8.85(1H,s) | ||
303 | 342.60 | (DMSO)2.9-3.1(4H,m),7.0-7.5(6H,m),7.7-7.8(2H,m), 7.8-8.2(6H,m),11.9(0.7H,s) | 4.30 |
304 | 346.50 | (DMSO)7.1-7.2(3H,m),7.2-7.4(3H,m),7.8-7.9(2H,m), 7.9-8.1(3H,m),8.1-8.2(1H,s),8.4(1H,s),8.5(1H,s),12.3- 12.4(0.7H,s) | 4.34 |
305 | 398.00 | (400MHz,CDCl3):1.65-1.70(3H,d),5.25-5.30(1H,m), 5.40-5.45(1H,m),6.80-6.85(1H,d),7.0(1H,s),7.05-7.10 (1H,d),7.30-7.35(1H,t),8.05-8.10(2H,m),8.30(1H,s), 8.70(1H,s),9.20-9.50(1H,brs) | 4.87 |
306 | 384.00 | (400MHz,MeOH-d4):1.65-1.70(3H,d),5.40-5.50(1H, m),6.65-6.80(1H,d),6.95(1H,s),7.00-7.05(1H,d),7.15- 7.20(1H,t),8.00-8.10(2H,m),8.20(1H,s),8.70(1H,s) | 4.45 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
307 | 410.80 | CDCl3 1.7(3H,d),3.97(3H,s),5.42(1H,br s),5.57 (1H,m), 7.03(2H,t),7.5-7.6(2H,m),8.12(1H,s),8.2(1H,s),9.1 (1H,s) ,9.52(1H,s),10.15(1H,br s) | 4.64 |
308 | 405.00 | (d6-DMSO,400MHz)4.73(2H,s),7.38(2H,d),7.54(2H, d),8.30(1H,d), 8.50(1H,s),8.62(2H,d) | 5.50 |
309 | 409.80 | DMSO 1.62(3H,d),2.88(3H,m),5.58(1H,d),7.1(2H,m), 7.62(2H,m),8.1-8.25(3H,m),8.55(1H,m),8.72(1H,s), 9.15(1H,s),12.3(1H,s) | 3.95 |
310 | 413.51 | 1H NMR(DMSO-d6):1.58(3H,d),5.50(1H,t),7.67(2H, d),7.79(2H,d),8.16(3H,m),8.21(2H,d),8.37(1H,s) | 4.82 |
311 | 402.48 | 1H NMR(DMSO-d6):1.71(3H,d),5.43(1H,m),7.28 (1H,s),7.54(2H,d),7.61(2H,d),7.66(1H,s),7.94(1H, s),8.26(1H,s),8.47(1H,s),12.49(1H,s) | 4.89 |
312 | 388.42 | 1H NMR(DMSO-d6):4.74(2H,d),7.28(1H,t),7.38(2H, m),7.48(1H,s),8.19(1H,s),8.23(2H,m),8.33(1H,t), 8.52(1H,s),12.33(1H,s) | 4.95 |
313 | 383.50 | 1H NMR(DMSO-d6):1.66(3H,d),5.45(1H,q),6.85 (2H,d),7.31(1H,s),8.20(1H,d),8.23(1H,s),8.54(2H, d) | 4.64 |
314 | 389.00 | (d6-DMSO,400MHz)5.69(2H,s),7.49(2H,d),7.59(2H, d), 8.32(1H,s),8.42(1H,s),8.65-8.67(2H,m),12.56(1H,s) | 5.32 |
315 | 306.46 | 1H NMR(DMSO-d6):4.48(1H,m),8.23(1H,s),8.35 (2H,m),8.68(1H,s),12.59(1H,s) | 4.80 |
316 | 355.46 | 1H NMR(DMSO-d6):4.87(2H,d),7.36(1H,m),7.51 (1H,d),7.87(1H,m),8.12(1H,s),8.24(1H,s),8.29(1H, d),8.43(1H,s),8.62(2H,d),12.39(1H,s) | 4.10 |
317 | 355.46 | 1H NMR(DMSO-d6):4.86(2H,d),7.73(1H,m),8.26 (2H,s),8.30(1H,d),8.44(1H,s),8.54(1H,s),8.65(1H, d),8.86(1H,s)12.43(1H,s) | 4.10 |
318 | 355.46 | 1H NMR(DMSO-d6):4.93(2H,d),7.90(2H,d),8.16 (1H,s),8.23(2H,d),8.31(1H,s),8.55(1H,s),8.78(2H, d),12.37(1H,s) | 4.00 |
319 | 231.38 | 1H NMR(DMSO-d6):7.27(1H,t),8.32(1H,s),8.41(1H, s),8.80(3H,m) | 4.20 |
320 | 455.00 | 1H NMR(DMSO-d6):1.55-1.60(3H,d),2.15-2.20(6H, s),2.55-2.60(2H,m),3.95-4.00(2H,m),5.35-5.40(1H, m),6.60-6.40(1H,m),7.00-7.10(2H,m),7.15-7.20(1H,t), 8.05-8.10(1H,m),8.15-8.20(2H,m),8.25(1H,s),8.60 (1H,s),12.2(1H,s) | 4.49 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
321 | 453.00 | 1H NMR(DMSO-d6):1.60-1.70(3H,d),2.20-2.30(2H, m),3.4-3.5(4H,m),5.15-5.20(1H,m),5.55-5.62(1H,m), 6.85-6.90(1H,d),7.05-7.10(1H,s),7.18-7.23(1H,d), 7.35-7.40(1H,t),8.30-8.35(3H,m),8.50(1H,s) | 4.25 |
322 | 382.00 | NMR(DMSO)1.65(3H,d,CH3),2.15(3H,s,CH3),5.55 (H,m,alpha),7.1(H,d,ar),7.1-7.2(2H,m,ar),7.6(2H,m, ar),8.05(1H,s,ar),8.2(1H,s,ar),8.3(1H,s,ar),8.63(1H, s,ar)and 12.3(1H,s,ar) | 4.99 |
323 | 412.00 | NMR(DMSO)1.5(3H,d,CH3),5.4(H,m alpha),7.0(H, s,ar),7.1-7.25(2H,,m,ar),7.5-7.6(2H,m,ar),8.3(H,s, ar),8.4(2H,brs,ar),8.65(H,s,ar) and 12.4(H,s,ar). | 4.10 |
324 | 382.00 | NMR(DMSO)1.5(3H,s,CH3),2.25(3H,s,CH3),5.3(H, m,alpha),6.2(H,m,ar),7.3(2H,m,ar),7.5(2H,m,ar), 7.75(H,m,ar),8.2(H,m,ar),8.3(H,m,ar),8.65(H,m, ar) and 12.3(H,m,ar) | 4.92 |
325 | 361.44 | 1H NMR(DMSO-d6):1.53(3H,m),1.81(2H,m),1.98 (1H,m),2.90(1H,m),3.31(1H,m),3.43(1H,m),3.58 (2H,m),7.85(1H,s),8.30(2H,d),8.36(1H,s),8.68(1H, d),8.84(1H,s),12.52(1H,s) | 3.70 |
326 | 361.44 | 1H NMR(DMSO-d6):1.34(1H,m),1.60(1H,m),1.92 (2H,m),2.20(1H,m),2.78(2H,m),3.24(3H,m),3.54 (1H,m),7.99(1H,s),8.23(1H,m),8.30(2H,d),8.60(1H, d),8.70(1H,s),12.45(1H,s) | 3.59 |
327 | 361.44,361.00 | 1H NMR(DMSO-d6):1.41(2H,m),1.92(2H,m),2.08 (1H,m),2.83(2H,m),3.29(2H,m),3.44(2H,m),7.97 (1H,s),8.20(1H,s),8.25(1H,s),8.30(1H,s),8.48(1H, d),8.71(1H,s),12.43(1H,s),1H NMR(DMSO-d6):1.41 (2H,m),1.92(2H,m),2.08(1H,m),2.83(2H,m),3.29 (2H,m),3.44(2H,m),8.20(1H,s),8.25(1H,s),8.30(1H, s),8.48(1H,d),8.71(1H,s),12.43(1H,s) | 3.57, 3.55 |
328 | 347.40 | 1H NMR(DMSO-d6):1.94(1H,m),1.96(2H,m),2.14 (1H,m),3.20(2H,m),3.71(2H,m),3.83(1H,m),7.89 (1H,s),8.30(4H,m),8.69(1H,s),8.91(1H,s),12.58(1H, s) | 3.67 |
329 | 347.40 | 1H NMR(DMSO-d6):1.77(1H,m),2.12(1H,m),2.77 (1H,m),3.00(1H,m),3.17(1H,m),3.34(2H,m),3.60 (2H,m),7.98(1H,s),8.23(1H,d),8.31(2H,m),8.71(3H, m),12.53(1H,s) | 3.54 |
330 | 394.45 | 1H NMR(DMSO-d6):2.04(4H,m),2.84(2H,m),3.33 (1H,s),5.61(1H,m),7.18(3H,m),7.27(1H,d),8.00(1H, d),8.21(1H,t),8.23(1H,s),8.26(1H,s),8.68(1H,s), 12.34(1H,s) | 5.28 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
331 | 483.00 | (d6-DMSO,400MHz)1.44(9H,s),1.54(3H,d),5.34- 5.37(1H,m), 7.11(1H,brs),7.19(2H,d),7.63(1H,s),8.10-8.12(2H, m),8.18(1H,d), 8.23(1H,d),8.54(1H,d),9.27(1H,brs),12.29(1H,brs) | 4.95 |
332 | 264.00 | NMR(DMSO)7.3(2H,brs,NH2),8.1(1H,s,ar),8.2(1H, s,ar),8.3(1H,s,ar),8.95(1H,s,ar)and 12.35(1H,s,NH). | 3.87 |
333 | 383.00 | (d6-DMSO,400MHz)1.55(3H,d),5.36-5.40(1H,m), 6.76(1H,brs), 6.98(1H,brs),7.21(2H,brs),8.16(1H,d),8.23(1H,d), 8.26(2H,d), 8.58(1H,s),12.36(1H,s) | 4.42 |
334 | 382.80 | DMSO 1.58(3H,d),4.65(2H,d),5.28(1H,t),5.5-5.6 (1H,m),7.15(2H,m),7.6(2H,m),8.05(1H,m),8.2(1H,s), 8.26(1H,m),8.68(1H,s),11.95(1H,s) | 3.90 |
335 | 456.00 | 1H NMR (MeOD-d4):1.60-1.70(3H,d),3.60(3H,s),4.65 (2H,s),5.40-5.45(1H,m),6.70-6.75(1H,d),7.03(1H,s), 7.12-7.18(1H,d),7.25-7.30(1H,t),8.00-8.07(2H,m), 8.15(1H,s),8.60(1H,s) | 4.70 |
336 | 442.00 | 1H NMR(DMSO-d6):1.35-1.40(3H,d),4.00-4.05(2H, s),5.25-5.35(1H,m),6.50-6.55(1H,d),6.95-7.00(2H,m), 7.05-7.15(1H,m),8.05-8.13(3H,m),8.18(1H,s),8.55 (1H,s),12.5(1H,s) | 3.82 |
337 | 363.00 | 1H NMR(CD3OD):1.60-1.70(3H,d),3.10-3.20(3H,s), 3.35-3.45(3H,s),5.30-5.35(1H,m),8.15-8.20(2H,m), 8.30-8.35(1H,s),8.75-8.80(1H,s) | 4.07 |
338 | 375.00 | 1H NMR(DMSO-d6):0.30-0.40(1H,m),0.42-0.47(1H, m),1.35-1.40(3H,d),2.55-2.60(1H,m),4.40-4.50(1H, m),7.58-7.63(1H,d),8.15-8.25(3H,m),8.28(1H,s),8.65 (1H,s),12.0(1H,s) | 3.84 |
339 | 398.47 | 1H NMR(CDCl3):1.63(3H,m),3.44(1H,s),4.57(2H, m),5.31(1H,br s),6.02(1H,br s),7.06(2H,m),7.39(2H, m),8.19(1H,m),8.30(1H,m),8.76(1H,br s),8.93(1H,br s) | 4.59 |
340 | 349.00, 349.00 | 1H NMR(DMSO-d6):1.35-1.40(3H,d),2.55-2.60(3H, m),4.40-4.50(1H,m),7.58-7.63(1H,d),8.00-8.05(1H, m),8.15-8.25(2H,m),8.28(1H,s),8.65(1H,s),12.0(1H, s),1H NMR(DMSO-d6):1.35-1.40(3H,d),2.55-2.60(3H, m),4.40-4.50(1H,m),7.58-7.63(1H,d),8.00-8.05(1H, m),8.15-8.25(2H,m),8.28(1H,s),8.65(1H,s),12.0(1H, s) | 3.59, 2.84 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
341 | 428.00 | 1H NMR(DMSO-d6):1.35-1.40(3H,d),3.6-3.7(2H,m), 3.954.00(2H,m),4.80-4.90(1H,m),5.4-5.5(1H.m),6.7- 6.8(1H,m),7.00-7.10(2H,m),7.20-7.25(1H,m),8.10- 8.25(3H,m),8.65(1H,s),12.0(1H,s) | 4.47 |
342 | (400MHz,DMSO)1.57(3H,d),5.50-5.57(1H,m),7.11- 7.15(2H,m),7.57-7.60(2H,m),8.20(1H,d),8.25(1H,d), 8.36(1H,s),9.15(1H,d),9.45(1H,d),12.90(1H,brs). | ||
343 | (400MHz,DMSO)1.55(3H,d),4.85(2H,s),5.45-5.53 (1H,m),7.09-7.14(2H,m),7.55-7.58(2H,m),7.62(1H,s), 7.72(1H,d),7.87(1H,s),7.95(1H,d),8.10(1H,d),11.55 (1H,s). | ||
344 | 333.00 | 1H NMR(CD3OD):2.40-2.50(2H,m),2.6-2.7(2H,m), 3.50-3.60(3H,m),3.7-3.8(1H,m),5.2-5.3(1H,m),8.40 (1H,s),8.50(1H,m),8.55(1H,s),8.75(1H,s) | 3.54 |
345 | 347.00,347.40 | 1H NMR(DMSO-d6):1.80-1.90(2H,m),2.1-2.2(2H,m), 3.05-3.15(2H,m),3.4-3.5(2H,m),4.30-4.40(1H,m), 7.65-7.70(1H,m),8.30-8.35(2H,m),8.40-8.50(1H,s), 8.60-8.70(1H,s),8.75-8.80(1H,m),12.0(1H,s),1H NMR (DMSO-d6):1.84(2H,m),2.33(2H,m),3.14(2H,m), 3.44(2H,m),4.36(1H,m),7.88(1H,s),8.25(1H,s),8.30 (2H,d),8.37(1H,m),8.60(1H,m),8.69(1H,s),12.44 (1H,s) | 3.50, 3.50 |
346 | 423.56 | 1.73(3H,d,J 6.8,Me),3.06(3H,br s,Me),3.24(3H,br s,Me),5.53-5.47(1H,m,CH),5.75(1H,br s,NH),7.07- 7.03(2H,m,2x ArH),7.46-7.43(2H,m,2x ArH),8.14(1 H,d,J 3.7,ArH),8.46(1H,d,J 1.8,ArH),8.77(2 H,s,2x ArH). | 4.02 |
347 | 347.47 | 1H NMR(DMSO-d6):1.66(1H,m),1.85(1H,m),1.98 (1H,m),2.11(1H,m),2.90(2H,m),3.32(1H,m),3.47 (1H,m),4.46(1H,m),7.57(1H,d),8.31(3H,m),8.66(3H, m),12.47(1H,s) | 3.68 |
348 | 348.44 | 1H NMR(DMSO-d6):1.67(2H,m),1.96(2H,d),3.49 (2H,t),3.96(2H,d),4.30(1H,m),7.62(1H,d),8.18(1H, s),8.22(1H,s),8.29(1H,s),8.72(1H,s),12.36(1H,s) | 4.42 |
349 | 360.46 | 1H NMR(DMSO-d6):1.17(5H,m),1.70(6H,m),2.67 (2H,d),8.27(1H,s),8.42(2H,s),8.72(1H,s),12.57(1H, s) | 5.39 |
350 | 396.46 | (DMSO,D6);1.55(3H,d,J 6.8,Me),5.53(1H,t,J 6.8, CH),7.13-7.09(2H,m,2x ArH),7.63-7.60(2H,m,2x ArH),8.15-8.14(1H,m,NH),8.22-8.19(2H,m,2x ArH), 8.83(1H,s,ArH),9.30(1H,s,ArH). | 3.27 |
351 | 392.00 | 1H NMR(DMSO-d6):1.35-1.40(9H,s),1.50-1.55(3H, d),4.10-4.15(1H,m)4.40-4.50(1H,m),7.95-8.00(1H,d), 8.20(1H,s),8.30(1H,m),8.35(1H,m),8.75(1H,s) | 4.87 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
352 | 347.00 | (d6-DMSO,400MHz)1.86-1.94(1H,m),2.28(3H,s), 2.33(1H,brs), 2.53-2.57(1H,m),2.60-2.67(2H,m),2.84-2.88(1H, m),4.62(1H,brs), 7.67(1H,d),8.17(1H,d),8.21(1H,s),8.28(1H,d),12.35 (1H,s) | 4.00 |
353 | 255.00 | DMSO D6 7.60(1H,d),8.32(1H,s),8.43(1H,s),8.56 (1H,s),8.82-8.86(2H,m)12.55(1H,s). | 4.52 |
354 | 382.46 | 1H NMR(DMSO-d6):0.95(3H,t),1.85(1H,m),1.97 (1H,m),7.19(1H,t),7.34(2H,t),7.53(2H,d),8.08(1H, d),8.16(2H,s),8.26(1H,s),8.66(1H,s),12.31(1H,s) | 4.92 |
355 | 374.50 | 1H NMR(DMSO-d6):1.15(8H,m),1.28(2H,m),1.72 (2H,m),1.84(2H,m),4.23(1H,m),7.43(1H,d),8.12(1H, s),8.18(1H,s),8.27(1H,s),8.73(1H,s),12.32(1H,s) | 5.47 |
356 | 346.43 | 1H NMR(DMSO-d6):0.85(1H,m),1.48(4H,m),1.68 (1H,d),1.81(2H,m),2.04(2H,m),4.03(1H,m),7.49(1H, d),8.13(1H,s),8.19(1H,s),8.29(1H,s),8.73(1H,s), 12.21(1H,s) | 5.25 |
357 | 432.70 | CDCl3 0.8(3H,d),5.45(1H,m),5.6(1H,br s),7.1(2H,m), 7.45(2H,m),8.15(1H,s),8.4(1H,s),8.5-8.6(1H,br s),8.78 (1H,s),9.65(1H,br s) | 5.00 |
358 | 439.00 | (DMSO)1.27(3H,t,J 7.1),1.56(3H,d,J 7.0),4.17(2H, q,J 7.1),5.64(1H,t,J 7.0),7.10(2H,t,J 8.9),7.60-7.56 (2H,m),8.04-8.00(2H,m),8.15(1H,d,J 3.8),8.22(1H, d,J2.1),8.96(1H,br s),9.65(1H,br s),11.96(1H,br s). | 4.39 |
359 | 425.51 | 1H NMR(DMSO):1.52(3H,m),2.85(3H,m),5.33(1H, m),7.00(1H,s),7.15(2H,m),7.48(2H,m),8.24(2H,m), 8.49(1H,s),8.66(1H,s),8.87(1H,m),12.4(1H,br s) | 4.82 |
360 | 336.00 | 1H NMR(DMSO-d6):1.45-1.50(3H,d),4.50-4.60(1H, m),8.05-8.25(5H,m),8.60(1H,m),12.3-12.4(1H,s), 12.50-1.270(1H,brs) | 3.20 |
361 | 363.00 | 1H NMR(CD3OD):1.10-1.20(3H,t),1.90-2.20(2H,m), 2.85(3H,s),4.65-4.70(1H,m),8.25-8.35(3H,m),8.65 (1H,s) | 3.92 |
362 | 377.00 | 1H NMR(CD3OD):1.10-1.20(6H,m),2.3-2.4(1H,m), 2.80(3H,s),4.70-4.75(1H,d),8.25-8.35(3H,m),8.80 (1H,s) | 4.27 |
363 | 377.00 | 1H NMR(CD3OD):1.05-1.15(6H,m),1.50-1.60(3H,m), 3.95-4.05(1H,m),4.50-4.65(1H,m),8.10-8.25(3H,m), 8.80(1H,s) | 4.07 |
364 | 391.00 | 1H NMR(CD3OD):0.70-0.80(6H,m),1.55-1.60(3H,d), 1.70-1.80(1H,m),2.85-2.95(1H,m),3.10-3.15(1H,m), 4.50-4.65(1H,m),8.10-8.25(3H,m),8.80(1H,s) | 4.22 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
365 | 381.00 | 1H NMR(CD3OD):1.55-1.60(3H,d),3.45-3.55(2H,m), 4.25-4.35(1H,m),4.40-4.45(1H,m),4.55-4.65(1H,m), 8.10-8.25(3H,m),8.80(1H,s) | 3.79 |
366 | 362.00 | (d6-DMSO,400MHz)1.23-1.33(2H,m),1.72(2H,d), 1.99-2.04(1H,m), 3.27(2H,t),3.41(2H,t),3.85-3.89(2H,m),7.80(1H,t), 8.14(1H,d), 8.21(1H,s),8.28(1H,d),8.74(1H,d),12.35(1H,brs) | 4.50 |
367 | 363.00 | 1H NMR(DMSO-d6):0.95-1.05(3H,t),1.35-1.40(3H,d), 3.00-3.10(2H,m),4.45-4.55(1H,m),7.55-7.60(1H,d), 8.05-8.10(1H,m),8.18-8.22(2H,m),8.28(1H,s),8.70 (1H,s), | 3.92 |
368 | 456.00,456.07 | 1H NMR(DMSO-d6):1.40-1.50(3H,d),2.80(3H,s), 2.85-3.05(2H,m),3.15-3.25(2H,m),4.50-4.60(1H,m), 7.00-7.05(1H,m),7.60-7.65(1H,d),8.12-8.17(1H,m), 8.19(1H,m),8.22(1H,m),8.28(1H,s),8.70(1H,s),,1H NMR(DMSO):1.45(3H,d),2.89(2H,m),3.15(2H,m), 3.31(3H,s),4.55(1H,m),7.04(1H,s),7.69(1H,d),8.19 (2H,m),8.26(1H,s),8.67(1H,s),12.35(1H,s) | 3.57, 2.84 |
369 | 417.00, 416.90 | 1H NMR(CD3OD):1.55-1.60(3H,d),3.85-4.00(2H,m), 4.70-4.80(1H,m),8.10-8.25(3H,m),8.80(1H,s),DMSO d6 12.4(bs,1H);8.8(t,1H);8.7(s,1H);8.3(s,2H);8.2(s, 1H);7.9(bs,1H);4.7(q,1H);4.0(m,2H);1.3(d,3H) | 4.09, 2.30 |
370 | 412.44 | 1H NMR(DMSO):1.60(3H,m),5.51(1H,br s),7.08-7.21 (2H,m),7.49-7.53(2H,m),8.29(1H,m),8.39(1H,m), 8.53(1H,m),8.79(2H,m),12.6(1H,s) | 4.22 |
371 | 436.48 | 1H NMR(CDCl3):1.64(3H,m),5.31(1H,m),5.77(1H, m),7.05(2H,m),7.40(2H,m),7.95(1H,m),8.32(1H,br s),8.58(1H,m),8.94(1H,m) | 5.17 |
372 | 375.00 | (d6-DMSO,400MHz)1.14-1.24(2H,m),1.75-1.80(5H, m),2.11(3H,s), 2.75(2H,d),3.40(2H,t),7.80(1H,t),8.13(1H,d),8.20 (1H,s),8.28(1H,d),8.73(1H,d),12.35(1H,s) | 3.95 |
373 | 348.00 | (d6-DMSO,400MHz)1.66-1.74(1H,m),1.99-2.08(1H, m),2.67-2.74(1H,m),3.49-3.51(2H,m),3.58-3.67 (2H,m),3.73(1H,t),3.79-3.84(1H,m),7.88(1H,t),8.16 (1H,d),8.22(1H,s),8.29(1H,d),8.74(1H,d),12.36(1H, brs) | 3.27 |
374 | 376.70 | CDCl3 1.75(3H,d),3.23(1H,s),5.30-5.35(1H,m),5.5-5.56 (1H,m),7.08-7.18(2H,m),7.5-7.58(2H,m),8.22(2H,m), 8.55(1H,br s),8.9(1H,s),10.65(1H,br s) | 3.54 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
375 | 1H NMR(CD3OD):1.68-1.73(3H,d),4.50(2H,s),5.40- 5.50(1H,m),6.7-6.8(1H,m),7.05-7.10(1H,m),7.15-7.20 (1H,d),7.30-7.40(1H,t),8.30-8.40(2H,m),8.45(1H,s), 8.50(1H,s) | 3.25 | |
376 | 455.00 | 1H NMR(CD3OD):1.68-1.73(3H,d),2.75-2.80(3H,s), 4.50(2H,s),5.40-5.50(1H,m),6.8-6.9(1H,m),7.05-7.10 (1H,m),7.15-7.20(1H,d),7.30-7.40(1H,t),8.05-8.10 (2H,m),8.20(1H,s),8.60(1H,s) | 3.38 |
377 | 469.00 | 1H NMR(CD3OD):1.68-1.73(3H,d),2.15-2.20(2H,m), 2.90-2.95(6H,s),3.10-3.20(2H,m),4.05-4.10(2H,m), 5.50-5.60(1H,m),6.8-6.9(1H,m),7.05-7.10(1H,m), 7.15-7.20(1H,d),7.30-7.40(1H,t),8.20-8.24(1H,d), 8.25-8.30(2H,m),8.60(1H,s) | 3.29 |
378 | 406.75 | CDCl3 1.75(3H,d),3.55(1H,s),4.65(2H,s),5.30-5.35 (1H,m),5.42-5.48(1Hm),7.1-7.18(2H,m),7.45-7.52 (2H,m),8.1-8.18(2H,m),8.45(1H,br s),8.78(1H,s),9.4 (1H,br s) | 3.15 |
379 | 347.47 | 1H NMR(CDCl3/MeOD):0.83(2H,m),1.94(1H,m), 2.32(1H,m),3.00(1H,m),3.30(1H,m),3.36(2H,m), 3.46(1H,m),3.60(1H,m),3.87(1H,m),8.15(1H,s),8.24 (1H,s),8.29(1H,s),8.68(1H,s) | 3.54 |
380 | 333.51 | 1H NMR(DMSO-d6):2.15(1H,m),2.30(2H,m),3.35 (2H,m),3.58(1H,m),4.77(1H,m),7.87(1H,s),8.29(3H, m),8.81(1 H,s),8.94(2H,br s),12.45(1H,s) | 5.00 |
381 | 333.40 | 1H NMR(DMSO-d6):2.17(1H,m),234(1H,m),3.34 (3H,m),3.58(1H,m),4.79(1H,m),7.87(1H,d),8.27(3H, m),8.68(1H,s),8.81(2H,br s),12.45(1H,s) | 5.00 |
382 | 302.37 | 1H NMR(DMSO-d6):3.16(1H,s),4.29(2H,m),8.29(4H, m),8.88(1H,s),12.40(1H,s) | 3.22 |
383 | 403.48 | 1HNMR(DMSO-d6):0.82(2H,m),1.11(1H,m),1.22 (1H,m),1.85(2H,t),1.98(3H,s),2.07(1H,br s),3.00 (1H,t),3.51(1H,s),3.83(1H,m),4.40(1H,d),8.40(1H, s),8.44(1H,d),8.65(1H,s),8.88(1H,s),9.20(1H,br s), 12.91(1H,s) | 3.18 |
384 | 420.80 | CDCl3 1.72(3H,d),3.55(3H,s),4.45(2H,s),5.32-5.36 (1H,m),5.47-5.53(1H,m),7.05-7.1(2H,m),7.45-7.5 (2H,m),8.15(2H,m),8.5(1H,br s),8.85(1H,s),10.05(1H, br s) | 3.59 |
385 | 391.00 | 1H NMR(CD3OD):1.15-1.20(9H,s),2.80(3H,s),4.70- 4.75(1H,s),8.05-8.10(1H,m),8.12-8.15(2H,m),8.85 (1H,s) | 3.50 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
386 | 396.53 | 1H NMR(DMSO):1.18(3H,t),1.55(3H,d),2.56(2H, q),5.51(1H,m),7.07-7.15(3H,m),7.52(2H,m),7.98 (1H,s),8.14(1H,s),8.23(1H,d),8.60(1H,d),12.22(1H, s) | 3.88 |
387 | 365.00 | (d6-DMSO,400MHz)2.61(3H,d),3.82-3.83(2H,m), 4.60(1H,dd),5.02(1H,t),7.32(1H,d),8.05(1H,d),8.20 (1H,s),8.24(1H,d),8.27(1H,d),8.66(1H,d),12.36(1H, brs) | 2.55 |
388 | 379.00 | (d6-DMSO,400MHz)2.61(3H,d),3.30(3H,s),3.74(2H, brs),4.82(1H,dd),7.54(1H,d),8.13(1H,d),8.23(2H, brs),8.27(1H,s),8.66(1H,s),12.36(1H,brs) | 2.82 |
389 | 441.00 | 1H NMR(CD3OD):1.68-1.73(3H,d),2.80-2.85(3H,s), 3.10-3.25(2H,m),3.35-3.55(2H,m),4.55-4.60(1H,m), 8.10(1H,m),8.15(1H,s),8.20(1H,s),8.75(1H,s) | 2.68 |
390 | 453.00 | 1H NMR(CD3OD):1.68-1.73(3H,d),2.10-2.50(2H,m), 2.90-3.20(4H,m),4.50-4.60(2H,m),8.10-8.15(2H,m), 8.20(1H,s),8.80(1H,s) | 1.74 |
391 | 379.00 | 1H NMR(CD3OD):1.68-1.73(3H,d),3.35-3.40(2H,m), 3.50-3.60(2H,m),4.60-4.70(1H,m),8.10(1H,m),8.15 (1H,s),8.20(1H,s),8.80(1H,s) | 2.63 |
392 | 393.00 | 1H NMR(CD3OD):1.68-1.73(3H,d),3.15-3.20(3H,s), 3.30-3.60(4H,m),4.60-4.70(1H,m),8.10(1H,m),8.15 (1H,s),8.20(1H,s),8.80(1H,s) | 2.80 |
393 | 391.00 | (d6-DMSO,400MHz)0.89(3H,d),0.94(3H,d),1.58- 1.81(3H,m),2.60(3H,d),4.61-4.67(1H,m),7.59(1H, d),8.03(1H,d),8.21(1H,d),8.22(1H,s),8.27(1H,d) 8.68(1H,d),12.36(1H,s) | 3.33 |
394 | (400MHz,DMSO)1.56(3H,d),5.41-5.48(1H,m),7.15 (2H,t),7.56(2H,dd),8.17(1H,d),8.21(1H,d),8.28(1H, s),8.64(1H,d),8.84(1H,d),12.75(1H,brs). | ||
395 | 367.00 | (400MHz,DMSO)1.50(3H,d),5.10-5.14(1H,m),6.32 (1H,d),6.99(1H,d),7.08-7.14(3H,m),7.34(1H,t),7.46- 7.49(2H,m),8.14(1H,s),8.20(1H,d),8.64(1H,s),12.11 (1H,brs).,MeOD-D4:8.35(m,2H);8.1(s,1H);7.95(dd, 1H);7.5(m,2H);7.2(d,1H);7.15(m,2H);6.8(d,1H);5.0 (m,1H);1.65(d,3H). | 2.50 |
396 | (400MHz,DMSO)1.60(3H,d),3.88(3H,s),7.15(2H,t), 7.46-7.49(2H,m),7.98(1H,d),8.25-8.30(2H,m),8.34 (1H,d),8.56(1H,s),12.65(1H,brs). | ||
397 | (400MHz,DMSO)1.51(3H,s),5.31-5.36(1H,m),7.12 (2H,t),7.41-7.46(3H,m),7.80-8.08(2H,m),8.17(1H,d), 11.98(1H,brs). |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
398 | (400MHz,DMSO)1.51(3H,d),5.33-5.38(1H,m),7.14 (2H,t),7.42-7.45(2H,m),7.70-7.76(3H,m),7.88(1H,d), 8.21(1H,s),12.20(1H,brs). | ||
399 | 339.00 | DMSO D6 2.78-2.92(4H,m),3.50-3.62(4H,m),7.05 (1H,s),7.54(1H,s),8.27(1H,s),8.45(1H,s),8.68(1H,s) | 1.24 |
400 | 403.00 | (d6-DMSO,40OMHz)3.90-3.95(2H,m),4.12(2H,d), 7.97(1H,t),8.15(1H,s),8.24(1H,d),8.27(1H,d),8.63 (1H,d),8.75(1H,t),12.34(1H,brs) | 2.93 |
401 | 350.00 | NMR(DMSO)1.3(3H,d,CH3),2.6-2.8(2H,m,CH2), 4.65(H,m,alpha),7.15(H,m,ar),8.15(H,m,ar),8.25 (2H,s,ar),8.7(H,s,NH),12.1-12.5(2H,NH and COOH, brs x2) | 2.59 |
402 | 363.00 | NMR(DMSO)1.25(3H,d,CH3),1.75(3H,m,CH3),3.0 (2H,CH2,m),4.65(H,m,alpha),7.5 (H,d,ar),8.0 (H,m, NH),8.1(H,d,ar),8.15(H,s,ar),8.25(H,s,ar),8.7(H,s, NH) and 12.45(H,s,NH). | 2.90 |
403 | 379.38 | 1H NMR(DMSO-d6):1.73(2H,m),1.99(2H,m),2.84 (2H,m),4.55(1H,m),7.74(2H,br s),7.95(1H,d),8.19 (1H,s),8.28(2H,m),8.73(1H,s),12.38(1H,s),12.99 (1H,brs) | 2.21 |
404 | 418.49 | 1H NMR(DMSO-d6):1.74(3H,m),5.82(1H,m),7.20 (2H,m),7.61(2H,m),7.70(1H,s),7.84(1H,s),7.99(1H, s),8.39(1H,s),8.54(1H,s),8.66(1H,s),8.79(1H,br s), 9.82(1H,br s),13.08(1H,br s) | 3.85 |
405 | 344.00 | 2.82-2.88(4H,m),3.47-3.52(4H,m),4.50(2H,s),5.31 (1H,br s),6.61(1H,s),7.15(1H,s),8.20(1H,s),8.25(1H, s),8.70(1H,s),12.25(1H,br s) | 2.34 |
406 | 417.00 | 1H NMR(CD3OD):1.1-1.4(6H,m),1.6-2.0(7H,m),3.0- 3.15(1H,m),3.65-3.80(1H,m),5.6-5.7(1H,m),8.15(1H, m),8.20-8.25(2H,m),8.80(1H,s) | 3.37 |
407 | 429.00 | 1H NMR(DMSO-d6):1.45-1.50(3H,d),3.80-4.00(5H, m),4.60-4.65(1H,m),6.80-6.85(1H,m),7.95(1H,s),8.10 (1H,s),8.25(1H,s),8.70(2H,m),12.2(1H,s) | 3.13 |
408 | 443.00 | 1H NMR(DMSO-d6):1.37-1.47(6H,m),3.85-4.05(2H, m),4.10-4.20(2H,qd),4.60-4.65(1H,m),6.65-6.70(1H, d),7.95(1H,s),8.10(1H,s),8.25(1H,s),8.70-8.80(2H, m),12.2(1H,s) | 3.33 |
409 | 342.80 | DMSO D6 3.22-3.30(4H,m),3.86-3.91(4H,m),7.22 (1H,s),7.69(1H,s),8.33(1H,s),8.46(1H,s),8.68(1H,s), 10.07(1H,s),12.48(1H,s) | 2.80 |
410 | 457.00 | 1H NMR(DMSO-d6):1.35-1.40(6H,m),1.45-1.50(3H, d),3.80-4.10(2H,m),4.60-4.65(2H,m),6.50-6.60(1H, m),7.95(1H,s),8.10(1H,s),8.25(1H,s),8.70-8.80(2H, m),12.5(1H,s) | 3.46 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
411 | 423.00 | 1H NMR(DMSO-d6):1.45-1.50(3H,d),3.80-4.00(2H, m),4.50-4.60(1H,m),4.75(1H,s),8.05(1H,m),8.30-8.40 (2H,m),8.50-8.60(1H,m),8.95-9.000(1H,m),9.20(1H, m),12.5(1H,s) | 3.22 |
412 | 338.70 | DMSO D6 2.80-2.90(4H,m),3.48-3.61(4H,m),4.43 (1H,s),6.66(1H,s),7.25(1H,s),8.27(1H,s),8.35(1H,s), 8.66(1H,s),12.28(1H,br s). | 3.16 |
413 | 399.00 | 1H NMR(CD3OD):1.5-1.6(3H,d),3.85-4.10(2H,m), 4.60-4.75(1H,m),6.40-6.50(1H,s),8.15(1H,d),8.20- 8.25(2H,m),8.90(1H,s) | 2.93 |
414 | 497.00 | 1H NMR(CD3OD):1.5-1.6(3H,d),3.00-3.10(3H,s), 3.30-3.60(6H,bm),3.90-4.05(2H,m),4.45-4.55(1H,m), 6.50-6.60(1H,s),8.20(1H,s),8.30(1H,s),8.50(1H,s), 8.70-8.80(1H,m) | 3.08 |
415 | 583.00 | 1H NMR(DMSO-d6):1.30-1.35(3H,d),1.40(9H,s), 3.35-3.40(4H,m),3.65-3.72(4H,m),3.9-4.0(2H,m), 4.40-4.50(1H,m),6.35-6.40(1H,s),7.10-7.20(1H,m), 8.15(1H,s),8.25(1H,s),8.50(1H,s),8.60-8.70(1H,m), 12.5(1H,s) | 3.69 |
416 | 483.00 | 1H NMR(CD3OD):1.50-1.60(3H,d),3.40-3.45(4H,m), 3.95-4.05(2H,m),4.10-4.20(2H,m),4.6-4.7(1H,m),6.55 (1H,s),8.35(1H,s),8.40(2H,m),8.90(1H,s) | 2.73 |
417 | 458.00 | 1H NMR(CD3OD):1.40-1.50(3H,d),3.50-3.55(2H,m), 3.75-3.85(2H,m),3.95-4.05(2H,m),4.10-4.20(2H,m), 4.45-4.55(1H,m),6.30-6.35(1H,s),8.00-8.05(1H,s), 8.25(2H,m),8.75(1H,s) | 2.88 |
418 | 467.74 | 1H NMR(DMSO-d6):1.43(3H,d),3.93(2H,m),4.56 (1H,m),8.04(1H,s),8.35(1H,d),8.39(1H,d),8.57(1H, m),8.66(1H,m),8.99(1H,s),12.67(1H,s) | 3.35 |
419 | 485.00 | 1H NMR(CDCl3):1.50-1.55(3H,d),2.25-2.30(6H,s), 2.5-2.7(2H,m),3.50-3.60(2H,m),3.80-4.10(2H,m), 4.50-4.60(1H,m),5.55-5.60(1H,m),5.90(1H,s),7.60- 7.90(2H,m),8.20(1H,s),8.45-8.55(1H,brs),10.5-10.8 (1H,brs) | 2.82 |
420 | 424.80 | 1H NMR(DMSO):1.44(3H,d),3.91(2H,m),4.58(1H, m),8.38(1H,m),8.66-8.72(3H,m),9.20(1H,d) | 3.12 |
421 | 453.77 | 1H NMR(DMSO-d6):3.92(2H,m),4.06(2H,s),8.06(1H, s),8.33(1H,d),8.44(1H,s),8.59(2H,m),8.95(1H,s), 12.76(1H,s) | 3.22 |
422 | 413.02 | 1H NMR(DMSO):1.68(3H,d),5.67(1H,m),7.19(2H, m),7.61(2H,m),8.32(1H,s),8.47(2H,m),8.85(1H,m), 9.18(1H,s),12.83(1H,br s) | 3.90 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
423 | 383.76 | 1H NMR(DMSO):1.65(2H,m),5.56(1H,m),5.75(1H, br s),7.22(2H,m),7.50(2H,m),7.56(1H,s),8.35(2H,s), 8.39(1H,m),12.75(1H,br s),13.5(1H,s) | 3.45 |
424 | 481.00 | 1H NMR(DMSO-d6):1.45-1.50(3H,d),3.05-3.20(3H, m),3.80-4.00(2H,m),5.30-5.50(1H,m),8.00-8.10(1H, m),8.30-8.40(1H,m),8.50-8.80(2H,m),12.5(1H,s) | 3.67 |
425 | 439.81 | 1H NMR(DMSO):1.52(3H,d),2.99(6H,m),5.36(1H, m),6.43(1H,br s),7.16(2H,m),7.49(2H,m),8.11(1H, m),8.22(2H,m),8.51(1H,br s),12.36(1H,s) | 3.56 |
426 | 478.00 | 1H NMR(DMSO-d6):1.28(9H,s),1.40-1.50(3H,d), 2.90-3.15(4H,m),4.50-4.60(1H,m),6.70-6.80(1H,m), 7.60-7.65(1H,d),8.08-8.13(1H,m),8.15-8.20(2H,m), 8.25(1H,m),8.70(1H,s),12(1H,s) | 3.23 |
427 | 435.82 | 1H NMR(DMSO-d6):3.92(2H,m),4.24(2H,s),7.43(1H, m),7.59(1H,m),7.77(2H,m),8.22(2H,s),8.78(1H,m), 8.81(1H,m),8.92(1H,s),12.35(1H,s) | 3.28 |
428 | 293.63 | 1H NMR(DMSO-d6):1.25(3H,t),2.93(2H,q),8.34(1H, s),8.37(1H,s),8.57(1H,s),8.07(1H,s),12.84(1H,br s) | 3.28 |
429 | 441.00 | 1H NMR(CD3OD):1.30-1.50(6H,dd),1.60-1.70(3H,d), 3.05-3.15(1H,m),3.85-4.05(2H,m),4.80-4.90(1H,m), 8.10(1H,s),8.20-8.25(2H,m),8.80(1H,s) | 3.45 |
430 | 359.00 | 1H NMR(CD3OD):1.30-1.40(6H,d),2.88(3H,s),2.95- 3.05(1H,m),4.20-4.25(2H,m),8.05(1H,s),8.20-8.25 (2H,m),8.80(1H,s) | 3.00 |
431 | 378.73 | 1H NMR(CD3OD):1.70-1.75(3H,d),2.90-3.15(2H,m), 3.5-3.6(2H,m);3.80-3.85(1H,m),8.35-8.45(3H,m), 8.60-8.70(1H,m) | 2.54 |
432 | 470.19 | 1H NMR(CD3OD):1.30-1.40(6H,d),1.60(3H,d),2.95 (3H,s),3.85-4.20(2H,m),4.80-4.90(1H,qd),7.60(1H,s), 8.05(1H,s),8.20(1H,s) | 3.43 |
433 | 439.00 | 1H NMR(CD3OD):1.45-1.55(3H,d),1.80-1.90(2H,m), 2.65-2.80(2H,m);4.50-4.60(1H,m),7.00-7.10(5H,m), 8.10-8.20(3H,m),8.80(1H,s) | 3.33 |
434 | 443.00 | 1H NMR(CD3OD):1.65-1.75(3H,d),2.90-2.95(2H,m), 3.50-3.60(2H,m);3.70-3.80(3H,m),4.90-5.00(1H,m), 7.30(1H,s),8.40-8.45(2H,m),8.50(1H,s),8.60(1H,s), 8.80(1H,s) | 2.77 |
435 | 448.00 | 1H NMR(CD3OD):1.75-1.85(3H,d),3.05-3.15(2H,m), 3.25-3.30(2H,m);3.45-3.55(2H,m),3.60-3.80(4H,m), 3.90-4.00(2H,m),4.95-5.00(1H,m),8.40-8.45(2H,m), 8.50(1H,s),8.60(1H,s) | 2.81 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
436 | 432.00 | 1H NMR(CD3OD):1.75-1.85(3H,d),2.90-2.10(4H,m), 3.00-3.10(2H,m);3.20-3.30(2H,m),3.55-3.75(4H,m), 4.95-5.00(1H,m),8.40-8.45(2H,m),8.50(1H,s),8.60 (2H,s) | 2.64 |
437 | 478.19 | 1H NMR(CD3OD):1.65-1.70(3H,d),2.90-3.00(2H,m), 3.50-3.70(2H,m),4.80-4.90(1H,m),6.80-6.90(1H,t), 6.95-7.05(3H,m),7.20-7.25(1H,d),7.35-7.40(1H,d), 8.35-8.40(3H,m),8.50(1H,m) | 3.18 |
438 | 440.00 | 1H NMR(CD3OD):1.65-1.70(3H,d),3.70-3.90(4H,m), 4.80-4.90(1H,m),7.80-7.85(1H,t),7.90-7.95(1H,t), 8.35-8.45(3H,m),8.50(2H,s),8.60(1H,m) | 2.93 |
439 | 446.00 | 1H NMR(CD3OD):1.75-1.85(3H,d),1.90-2.10(6H,m), 2.80-2.90(2H,m);3.00-3.10(2H,m),3.40-3.75(4H,m), 4.95-5.00(1H,m),8.40-8.45(2H,m),8.50(1H,s),8.60 (2H,s) | 2.59 |
440 | 435.14 | 1H NMR(CD3OD):1.00-1.05(6H,d),1.75-1.85(3H,d), 3.20-3.40(5H,m),4.60-4.70(1H,m),8.10-8.30(3H,m), 8.80(1H,s) | 3.15 |
441 | 447.00 | 1H NMR(CD3OD):1.75-1.85(3H,d),3.10-3.80(8H,m), 4.95-5.00(1H,m),8.40-8.45(2H,m),8.50(1H,s),8.60 (1H,s) | 2.66 |
442 | 443.00 | 1H NMR(CD3OD):1.75-1.85(3H,d),2.05-2.15(2H,m), 3.55-3.60(1H,m);3.75-3.80(1H,m),4.10-4.20(2H,m), 4.95-5.00(1H,m),7.50(2H,s),8.35(1H,s),8.40-8.60(3H, m),8.63(1H,s),8.87(1H,s) | 2.75 |
443 | 428.00 | 1H NMR(CD3OD):1.60-1.70(3H,d),3.40-3.50(1H,m), 3.70-3.80(1H,m);4.00-4.05(2H,m),4.80-4.90(1H,m), 5.90(1H,s),6.60(1H,s),8.35-8.55(7H,m),8.6(2H,s), | 3.16 |
444 | 420.09 | 1H NMR(DMSO-d6):1.26(3H,d),1.68(3H,s),3.05(4H, m),4.54(1H,m),7.78(2H,m),8.13(1H,s),8.27(3H,m), 8.66(1H,s),12.40(1H,s) | 2.68 |
445 | 470.12 | 1H NMR(CDCl3+CD3OD drops):1.19(5H,m),1.66 (3H,d),2.76(2H,m),3.06(2H,m),4.69(1H,m),8.10(1H, s),8.18(1H,s),8.30(1H,s),8.64(1H,s) | 2.88 |
446 | 518.19 | 1H NMR(CDCl3+CD3OD drops):2.83(2H,t),3.33(1H, s),3.40(1H,m),3.58(1H,m),4.05(2H,m),4.59(1H,m), 6.94(1H,br s),7.06(2H,d),7.56(2H,d),7.92(1H,s),8.03 (1H,s),8.12(1H,s),8.12(1H,s),8.71(1H,s) | 2.88 |
447 | 423.00 | 1H NMR(CD3OD):1.05-1.10(3H,t),1.60-1.70(3H,d), 2.35-2.40(2H,m),2.45-2.55(2H,m);3.40-3.50(2H,m), 4.55-4.60(1H,m),8.10(1H,s),8.15(1H,s),8.20(1H,s), 8.80(1H,s) | 3.23 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
448 | 446.00 | 1H NMR(CD3OD):1.60-1.70(4H,m),1.90-2.05(2H,m), 2.10-2.20(1H,m),2.25-2.40(1H,m);2.70-2.80(3H,m), 2.90-3.00(1H,m),3.05-3.10(1H,m),3.35-3.45(2H,m), 3.50-3.60(2H,m),3.65-3.75(2H,m),4.90-5.00(1H,m), 8.35-8.40(2H,m),8.50(1H,s),8.60-8.65(1H,s) | 2.62 |
449 | 440.00 | 1H NMR(CD3OD):1.65-1.70(3H,d),3.70-3.90(4H,m), 4.80-4.90(1H,m),7.80-7.85(1H,t),8.35-8.45(3H,m), 8.45-8.55(2H,s),8.60(1H,s),8.75(1H,s) | 2.90 |
450 | 452.00 | (d6-DMSO,400MHz)1.36(3H,d),2.28(3H,s),2.78(3H, s),2.79-2.99(2H,m),3.15-3.25(2H,m),4.50(1H,brs), 6.22(1H,brs),7.05(1H,brs),7.38(1H,d),8.13(1H,brs), 8.22(1H,s),8.26(1H,d),8.77(1H,brs),12.30(1H,s) | 2.76 |
451 | 492.00 | 1H NMR(CD3OD):1.40-1.45(9H,s),1.65-1.70(3H,d), 2.80-2.85(3H,m),2.95-3.00(1H,m),3.05-3.10(1H,m), 3.40-3.50(2H,m),4.60-4.70(1H,m),8.15(1H,s),8.25 (1H,s),8.30(1H,s),8.80(1H,s) | 3.42 |
452 | 392.00 | 1H NMR(CD3OD):1.65-1.70(3H,d),3.20-3.40(2H,m), 3.70(3H,s),3.75-3.80(2H,m),4.50-4.60(1H,m),6.25- 6.30(1H,d),6.35-6.40(1H,t),6.55-6.65(2H,m),7.90(1H, s),8.05(1H,s),8.15(1H,s),8.55(1H,s) | 2.59 |
453 | 485.00 | 1H NMR(CD3OD):1.65-1.70(3H,d),3.20-3.40(2H,m), 3.70(3H,s),3.75-3.80(2H,m),4.50-4.60(1H,m),6.25- 6.30(1H,d),6.35-6.40(1H,t),6.55-6.65(2H,m),7.90(1H, s),8.05(1H,s),8.15(1H,s),8.55(1H,s) | 3.13 |
454 | 484.00 | 1H NMR(CD3OD):1.08-1.13(6H,m),1.55-1.60(3H,d), 2.85-3.05(2H,m),3.10-3.25(2H,m),3.35-3.40(1H,m), 4.60-4.70(1H,m),8.10(1H,s),8.15(1H,s),8.20(1H,s), 8.80(1H,s) | 2.94 |
455 | 468.00 | (d6-DMSO,400MHz)1.39(3H,brs),2.70-2.96(5H,m), 3.16-3.26(2H,m),3.84(3H,s),4.31-4.36(1H,m),6.60 (1H,s),7.03(1.4H,brs),7.43(0.6H,brs),8.01(1H,t),8.26 (1H,s),8.41(1H,s),8.70(0.4H,brs),9.09(0.6H,brs), 12.39(1H,s) | 2.96 |
456 | 420.00 | (d6-DMSO,400MHz)1.81-1.88(1H,m),1.94-1.98(1H, m),2.15(6H,s),2.24-2.28(1H,m),2.38-2.44(1H,m), 2.86(3H,s),3.23(3H,s),5.38-5.40(1H,m),7.83(1H,d), 8.15(1H,s),8.20(1H,d),8.28(1H,d),8.72(1H,d),12.35 (1H,s) | 2.90 |
457 | 455.13 | 1H NMR(DMSO):1.47(3H,d),3.36(1H,m),3.51(1H, m),3.80(2H,m),6.64(2H,d),6.82(1H,t),7.09(2H,t), 8.07(1H,br s),8.28(4H,m),8.66(1H,s),12.50(1H,s) | 3.29 |
458 | 512.22 | 1H NMR(DMSO):1.45(3H,d),3.07(4H,m),4.55(1H, m),4.93(2H,m),7.21(1H,m),7.29(5H,m),8.01(1H,br s),8.17(1H,m),8.28(3H,m),8.65(1H,s),12.44(1H,s) | 3.34 |
Cmpd No. | LC_MASS _PLUS M+1(obs) | NMR_RESULT(1H NMR) | RT (mins) |
459 | 479.16 | 1H NMR(DMSO+CD3OD drops):1.41(3H,d),3.27(2H, m),3.58(1H,m),3.60(1H,m),4.53(1H,m),7.42(2H,m), 7.60(2H,m),8.13(1H,s),8.24(2H,m),8.43(1H,s),8.51 (1H,s) | 3.09 |
460 | 460.17 | 1H NMR(DMSO):1.48(5H,m),1.75(2H,m),2.10(2H, t),2.92(2H,m),3.05(4H,m),4.53(1H,m),7.90(1H,br s),8.04(1H,m),8.28(3H,m),8.66(1H,s),12.41(1H,s) | 2.86 |
461 | 388.04 | 1H NMR (DMSO):1.46(3H,d),2.59(2H,m),3.35(1H, m),4.57(1H,m),7.95(1H,br s),8.23(1H,s),8.28(2H,s), 8.47(1H,t),8.65(1H,s) | 2.84 |
462 | 555.18 | 1H NMR(DMSO):1.45(3H,d),2.60(2H,m),3.26(2H, m),3.85(2H,d),4.56(1H,m),7.22(1H,t),7.37(2H,d), 7.69(1H,d),8.21(4H,m),8.66(1H,s),12.31(1H,s) | 3.59 |
463 | 419.00 | 1H NMR(CD3OD):0.70-0.75(3H,t),1.05-1.15(7H,m), 1.35-1.45(2H,m),1.55-1.60(3H,d),3.90-4.00(1H,m), 4.60-4.65(1H,m),8.10(1H,s),8.15(1H,s),8.20(1H,s), 8.80(1H,s) | 3.50 |
464 | 405.00 | 1H NMR(CD3OD):0.70-0.75(6H,t),1.30-1.40(2H,m), 1.40-1.50(1H,m),1.55-1.60(3H,d),2.90-3.00(1H,m), 3.15-3.20(1H.m),4.70-4.75(1H,m),8.10(1H,s),8.15 (1H,s),8.20(1H,s),8.80(1H,s) | 3.40 |
465 | 391.00 | 1H NMR(CD3OD):0.70-0.75(3H,t),1.05-1.10(3H,d), 1.35-1.45(2H,m),1.55-1.60(3H,d),3.80-3.90(1H,m), 4.70-4.75(1H,m),8.10(1H,s),8.15(1H,s),8.20(1H,s), 8.80(1H,s) | 3.30 |
466 | 407.00 | 1H NMR(CD3OD):1.55-1.60(3H,d),2.40-2.50(2H,m), 3.35-3.55(2H.m),4.65-4.70(1H,m),8.25(1H,s),8.30- 8.40(2H,m),8.70(1H,s) | 2.50 |
467 | 420.00 | 1H NMR(CD3OD):1.55-1.60(3H,d),2.30-2.40(2H,m), 3.35-3.60(5H,m),4.60-4.70(1H,m),8.15(1H,s),8.20 (1H,s),8.25(1H,s),8.80(1H,s) | 2.80 |
468 | 448.00 | 1H NMR(CD3OD):1.00-1.10(6H,m),1.55-1.60(3H,d), 2.30-2.40(2H,m),3.35-3.50(3H,m),3.80-3.90(2H,m), 4.60-4.70(1H,m),8.15(1H,s),8.20(1H,s),8.25(1H,s), 8.80(1H,s) | 3.00 |
469 | 484.00 | 1H NMR(CD3OD):0.90-1.00(6H,m),1.55-1.60(3H,d), 2.95-3.05(1H,m),3.10-3.25(2H.m).3.50-3.60(1H.m), 3.70-3.80(1H,m),4.65-4.70(1H,m),8.10(1H,s),8.30- 8.40(2H,m),8.70(1H,s) | 3.00 |
B) biological data
Embodiment 1:JAK3 suppresses assay method
Use standard radioactivity enzyme assay SCREENED COMPOUND suppresses the ability of JAK3.The DMSO stoste (concentration is 667 μ M-46nM) that will contain the The compounds of this invention of serial dilution is inoculated on the 96 hole polycarbonate flat boards with 1.5 μ L/ holes.Add in flat board with 50 μ L/ holes and to contain 2 μ M poly-(Glu)
4The kinase buffer liquid of Tyr and 10 μ M ATP (100mM HEPES (pH 7.4), 100mM MgCl
2, 25mM NaCl, 1mM DTT and 0.01% bovine serum albumin (BSA)).In order to begin reaction, add the 50 μ L kinase buffer liquid that contain 2nM JAK3 enzyme.Whole ATP concentration be 5 μ M[γ-
33P] ATP (200 μ Ci
33P ATP/ μ mol ATP (Perkin Elmer, Cambridge, MA)).Room temperature (25 ℃) is after 20 minutes, by add 50 μ L20% Tricholroacetic Acid (TCA)/0.4mM ATP and termination reaction in every hole.Using TomTek CellHarvester that whole inclusion in each hole are transferred to 96 hole glass fibre then filters in the flat board.After the washing, add 60 μ L flicker fluid and use Perkin Elmer TopCount to detect
33P mixes.After removing the average background value of all data points, thereby use Prism software fitting data to obtain K
i(app).Except eventually poly-(Glu)
4Tyr concentration is that 15 μ M and whole ATP concentration are outside the 12 μ M, the inhibition of measuring JAK2 as mentioned above.
Embodiment 2:ROCK suppresses assay method
Use standard coupling enzyme system people such as (, (1998) Protein Sci.7,2249) Fox SCREENED COMPOUND suppresses the ability of ROCK I (AA 6-553).Be reflected at and contain 100mM HEPES (pH7.5), 10mM MgCl
2, 25mM NaCl, 2mM DTT and 1.5%DMSO solution in carry out.In the mensuration final concentration of substrate be 45 μ M ATP (Sigma Chemicals, St Louis, MO) and 200 μ M peptides (American Peptide, Sunnyvale, CA).Be reflected under 30 ℃ and the 45nMROCK I condition and carry out.The final concentration of each component of coupling enzyme system is 2.5mM phosphoenolpyruvic acid, 350 μ M NADH, 30 μ g/ml pyruvate kinases and 10 μ g/ml serum lactic dehydrogenases.
Use standard radioactivity enzyme system SCREENED COMPOUND suppresses the ability of ROCK.Mensuration is to contain 100mM HEPES (pH 7.5), 10mM MgCl
2, 25mM NaCl, 2mM DTT and 1.5%DMSO solution in carry out.In the mensuration final concentration of substrate be 13 μ M[γ-
33P] ATP (25mCi
33P ATP/mmol ATP, Perkin Elmer, Cambridge, MA/Sigma Chemicals, St Louis is MO) with 27 μ M myelin basic protein (MBP).Whole enzyme concn in the mensuration is 5nM ROCK.Room temperature is measured.The DMSO stoste (concentration is 10 μ M-2.6nM) that 1.5 μ L is contained the The compounds of this invention of serial dilution is inoculated on the 96 hole flat boards.In flat board, add 50 μ L solution 1 (100mM HEPES (pH7.5), 10mMMgCl
2, 26mM[γ-
33P] ATP).By adding 50 μ L solution 2 (100mM HEPES (pH7.5), 10mM MgCl
2, 4mM DTT, 54mM MBP and 10nM ROCK) and begin reaction.After 2 hours, (TCA Fisher) finishes reaction with 50 μ L, 30% Tricholroacetic Acid that contains 9mM ATP.The reactant transfer that 140 μ L are finished to glass fibre filter dull and stereotyped (Corning, Cat.No.3511) in, then with 5%TCA washing 3 times.Add 50 μ L Optima Gold scintillating liquids (Perkin Elmer) and last to plate count at Top Count (Perkin Elmer).After removing the average background value of all data points, use Prism software fitting data, thereby obtain K
i(app).
Embodiment 3:Aurora suppresses assay method
Use standard coupling enzyme system (people such as Fox,
Protein Sci.7,2249 (1998)) SCREENED COMPOUND suppresses the ability of Aurora-A (AA 1-403).Be reflected at and contain 100mMHEPES (pH 7.5), 10mM MgCl
2, 25mM NaCl, 300 μ M NADH, 1mM DTT and 3%DMSO solution in carry out.In the mensuration final concentration of substrate be 200 μ M ATP (SigmaChemicals, St Louis, MO) and 800 μ M peptides (LRRASLG, American Peptide, Sunnyvale, CA).Be reflected under 30 ℃ and the 35nM Aurora-A condition and carry out.The final concentration of each component of coupling enzyme system is 2.5mM phosphoenolpyruvic acid, 200 μ M NADH, 60 μ g/ml pyruvate kinases and 20 μ g/ml serum lactic dehydrogenases.
Preparation contains the mensuration stoste buffered soln of top listed all preparations except ATP and target test compound.Under 30 ℃, in 96 hole flat boards, use the target test compound of 2 μ l0.002 μ M-30 μ M final concentrations to cultivate this mensuration stoste buffered soln (60 μ l) 10 minutes.Usually, the DMSO of the test compound by preparing serial dilution (from 1mM compound stoste) in sub-flat board carries out 12 titration.Begin reaction by adding 5 μ l ATP (final concentration 200 μ M).Under 30 ℃, (Sunnyvale CA) obtained speed of reaction in 10 minutes to use Molecular Devices Spectramax flat bed reader.Use computerized non-linear regression (Prism 3.0, Graphpad software, San Diego, CA), by determining the Ki value as the speed data of inhibitor concentration function.Use Aurora-C albumen, the activity of screening Aurora-C in a similar manner.Use Aurora-B albumen and radioactivity measurement method, described in embodiment 1 and 2, screening Aurora-B activity.
Below table 5 enzyme of describing specific illustrative compound suppress data (K
i).Compound number is corresponding with those compounds of description in the table 1.
Below table 6 enzyme of describing specific illustrative compound suppress data (K
i).Compound number is corresponding with those compounds of description in the table 2.
In table 5 and 6, with regard to specifying enzyme, " A " representative is lower than the K of 0.5 μ M
i, " B " represents the K between the 0.5-5.0 μ M
i, " C " representative is greater than the K of 5.0 μ M
iIf measured a more than K
iValue is then represented average K
iIf the value of providing is not measured K so
iWith regard to ROCK, enzyme-Lian assay method has been used in term " enzyme " expression; Term "
33P " expression used the radioactivity measurement method.
The enzyme of table 5. table 1 compound suppresses data
Compound number | AuroraA | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||
1 | A | A | |||
2 | B | A | |||
3 | A | A | A | B | |
4 | B | A | A | ||
5 | B | C | A | ||
6 | B | B | A | ||
7 | B | A | A | A |
Compound number | AuroraA | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||
8 | B | A | A | A | |
9 | B | B | B | B | |
10 | A | A | A | ||
11 | A | A | A | ||
12 | A | B | B | ||
13 | B | B | A | ||
14 | A | A | A | ||
15 | A | ||||
16 | A | A | A | A | |
17 | B | A | B | B | |
18 | B | A | A | A | |
19 | A | A | A | ||
20 | A | A | A | ||
21 | A | A | |||
22 | A | ||||
23 | A | ||||
24 | A | ||||
25 | B | A | |||
26 | B | B | B | ||
27 | A | ||||
28 | A | ||||
29 | A | ||||
30 | A | A | |||
31 | A | A | |||
32 | B | A | A | ||
33 | B | A | A | A | |
34 | A | A | A | ||
35 | B | C | B | ||
36 | B | B | B | ||
37 | A | A | A | ||
38 | B | A | A | A | |
39 | C | C | B | ||
40 | A | A | A | ||
41 | A | A | B | ||
42 | A | A | B | ||
43 | B | A | A | A | |
44 | B | B | B | A | |
45 | B | B | B | ||
46 | B | A | A | ||
47 | B | B | B | ||
48 | B | B | B | ||
49 | B | A | B | ||
50 | B | B | B | ||
51 | B | B | A | A |
Compound number | AuroraA | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||
52 | C | C | B | ||
53 | C | B | B | ||
54 | C | C | B | ||
55 | B | B | A |
The enzyme of table 6 table 2 compound suppresses data
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
1 | A | A | B | ||||
2 | A | A | B | ||||
3 | A | A | A | ||||
4 | A | A | A | A | |||
5 | A | A | B | ||||
6 | A | A | A | ||||
7 | B | B | B | ||||
8 | A | A | A | A | |||
9 | A | A | B | ||||
10 | A | A | A | A | |||
11 | A | A | B | ||||
12 | A | A | A | ||||
13 | A | A | B | ||||
14 | B | A | A | A | |||
15 | B | B | B | ||||
16 | A | A | A | ||||
17 | B | B | A | ||||
18 | B | A | A | B | B | ||
19 | A | A | A | A | A | ||
20 | A | A | A | B | |||
21 | A | A | A | ||||
22 | A | A | A | ||||
23 | B | B | A | ||||
24 | B | A | A | A | |||
25 | A | A | A | A | |||
26 | A | A | A | ||||
27 | A | A | A | ||||
28 | A | A | A | ||||
29 | A | A | A | ||||
30 | A | A | A | A | |||
31 | A | A | A | ||||
32 | A | A | A | B | |||
33 | A | A | A | A | A | ||
34 | A | A | A | B | |||
35 | A | A | A | A | A |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
36 | A | A | A | B | B | ||
37 | A | A | B | A | |||
38 | B | A | A | B | B | ||
39 | A | A | A | B | |||
40 | A | A | B | ||||
41 | A | A | A | B | |||
42 | A | A | A | B | |||
43 | A | B | B | B | |||
44 | A | B | B | B | |||
45 | A | A | A | B | |||
46 | A | A | A | B | |||
47 | B | A | A | B | |||
48 | A | A | A | B | |||
49 | B | A | A | B | |||
50 | B | A | A | A | |||
51 | B | B | B | ||||
52 | B | C | C | B | |||
53 | A | A | A | A | |||
54 | A | B | B | B | |||
55 | B | B | |||||
56 | B | C | B | ||||
57 | B | C | B | B | |||
58 | B | A | A | B | |||
59 | B | A | A | B | |||
60 | B | B | B | B | |||
61 | A | A | B | ||||
62 | A | A | A | ||||
63 | A | A | A | ||||
64 | A | A | B | ||||
65 | A | A | B | ||||
66 | B | A | A | B | |||
67 | A | A | A | B | |||
68 | A | A | A | B | |||
69 | B | A | A | B | |||
70 | B | A | A | B | |||
71 | A | A | B | ||||
72 | A | B | A | B | |||
73 | A | A | A | ||||
74 | A | A | A | ||||
75 | A | A | A | A | |||
76 | A | A | A | B | |||
77 | A | A | B | ||||
78 | A | A | A | B | |||
79 | A | A | A | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
80 | A | A | A | B | |||
81 | A | B | B | B | |||
82 | A | A | A | ||||
83 | A | A | B | ||||
84 | A | A | B | ||||
85 | A | A | B | ||||
86 | A | A | B | ||||
87 | A | A | B | ||||
88 | A | A | B | ||||
89 | A | A | B | ||||
90 | A | A | B | ||||
91 | B | B | B | ||||
92 | A | A | A | A | |||
93 | A | A | A | B | |||
94 | B | B | B | ||||
95 | B | B | B | B | |||
96 | B | A | A | B | |||
97 | A | A | A | B | |||
98 | A | A | A | B | |||
99 | A | A | A | B | |||
100 | A | A | A | B | |||
101 | A | A | A | B | |||
102 | B | A | A | B | |||
103 | B | A | A | B | |||
104 | A | A | B | ||||
105 | A | A | B | ||||
106 | A | A | B | ||||
107 | A | A | B | ||||
108 | A | A | B | ||||
109 | A | A | B | ||||
110 | B | B | B | B | |||
111 | A | A | B | ||||
112 | A | A | B | ||||
113 | B | A | A | B | |||
114 | B | A | A | B | |||
115 | A | A | B | ||||
116 | A | A | B | ||||
117 | B | A | A | B | |||
118 | B | A | A | B | |||
119 | B | A | A | B | |||
120 | A | A | A | B | |||
121 | B | A | A | B | |||
122 | B | A | A | B | |||
123 | B | A | A | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
124 | B | A | A | B | |||
125 | B | A | A | B | |||
126 | C | B | B | ||||
127 | A | A | B | ||||
128 | B | A | A | B | |||
129 | B | A | B | ||||
130 | A | A | A | B | |||
131 | A | A | A | B | |||
132 | A | A | A | B | |||
133 | A | A | B | ||||
134 | A | A | B | ||||
135 | A | A | A | ||||
136 | A | A | A | ||||
137 | A | A | B | ||||
138 | A | A | R | ||||
139 | A | A | B | ||||
140 | A | A | B | ||||
141 | A | A | B | ||||
142 | B | A | B | ||||
143 | B | A | B | ||||
144 | A | A | B | ||||
145 | A | A | B | ||||
146 | A | A | B | ||||
147 | A | A | B | ||||
148 | B | A | A | ||||
149 | A | A | B | ||||
150 | B | A | A | B | |||
151 | A | A | A | A | |||
152 | B | A | A | B | |||
153 | B | A | A | B | |||
154 | B | A | A | B | |||
155 | B | A | A | B | |||
156 | B | A | A | A | |||
157 | B | A | A | B | |||
158 | B | A | A | B | |||
159 | B | A | A | B | |||
160 | A | A | B | ||||
161 | B | A | A | B | |||
162 | B | A | A | B | |||
163 | B | A | A | B | |||
164 | B | A | A | B | |||
165 | B | A | A | B | |||
166 | B | A | A | B | |||
167 | B | A | A | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
168 | B | A | A | B | |||
169 | B | A | A | B | |||
170 | B | A | A | B | |||
171 | A | A | B | ||||
172 | B | A | A | A | |||
173 | A | A | A | ||||
174 | A | A | |||||
175 | A | A | |||||
176 | A | A | |||||
177 | A | A | A | B | |||
178 | B | B | B | ||||
179 | B | A | A | B | |||
180 | A | A | B | ||||
181 | B | A | A | B | |||
182 | B | A | A | B | |||
183 | A | A | B | ||||
184 | B | A | B | ||||
185 | B | A | |||||
186 | A | A | A | ||||
187 | B | A | |||||
188 | C | B | |||||
189 | A | A | B | ||||
190 | B | A | A | B | |||
191 | B | A | A | A | |||
192 | B | A | A | A | |||
193 | A | A | A | ||||
194 | A | A | B | ||||
195 | B | A | B | ||||
196 | C | B | B | ||||
197 | B | A | B | ||||
198 | C | B | B | ||||
199 | B | A | B | ||||
200 | B | A | B | ||||
201 | A | A | B | ||||
202 | B | B | B | ||||
203 | A | A | B | ||||
204 | A | B | |||||
205 | A | B | |||||
206 | A | B | |||||
207 | A | B | |||||
208 | A | B | |||||
209 | A | B | |||||
210 | B | ||||||
211 | A | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
212 | A | B | B | ||||
213 | A | B | |||||
214 | B | B | |||||
215 | B | B | |||||
216 | A | B | |||||
217 | A | B | B | ||||
218 | A | A | A | ||||
219 | A | B | B | ||||
220 | B | B | |||||
221 | A | A | |||||
222 | A | A | |||||
223 | B | B | |||||
224 | A | A | |||||
225 | B | B | |||||
226 | B | ||||||
227 | A | A | |||||
228 | A | A | |||||
229 | A | B | |||||
230 | B | B | |||||
231 | A | A | |||||
232 | A | B | |||||
233 | B | ||||||
234 | A | ||||||
235 | A | A | |||||
236 | A | ||||||
237 | A | A | A | B | |||
238 | A | A | A | B | |||
239 | A | A | |||||
240 | A | B | |||||
241 | B | ||||||
242 | A | B | A | B | |||
243 | A | B | |||||
244 | B | B | |||||
245 | A | ||||||
246 | B | B | |||||
247 | A | B | |||||
248 | A | B | |||||
249 | A | B | |||||
250 | A | B | |||||
251 | A | B | |||||
252 | A | A | B | ||||
253 | A | A | |||||
254 | A | B | |||||
255 | A | A |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
256 | A | A | |||||
257 | B | B | |||||
258 | A | B | |||||
259 | A | A | |||||
260 | A | A | B | ||||
261 | B | B | |||||
262 | B | B | |||||
263 | A | B | |||||
264 | A | B | |||||
265 | A | B | |||||
266 | A | B | |||||
267 | A | A | |||||
268 | B | ||||||
269 | A | ||||||
270 | B | B | |||||
271 | A | B | |||||
272 | B | ||||||
273 | A | B | |||||
274 | A | B | |||||
275 | B | B | |||||
276 | A | B | |||||
277 | A | A | |||||
278 | A | A | |||||
279 | B | ||||||
280 | A | ||||||
281 | A | ||||||
282 | A | ||||||
283 | B | ||||||
284 | B | B | |||||
285 | A | A | A | B | |||
286 | A | B | |||||
287 | A | ||||||
288 | A | ||||||
289 | A | B | |||||
290 | A | B | B | B | |||
291 | A | B | B | ||||
292 | C | B | |||||
293 | B | B | |||||
294 | A | B | |||||
295 | A | B | |||||
296 | A | B | |||||
297 | A | B | |||||
298 | B | B | |||||
299 | A | A | A |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
300 | A | A | A | ||||
301 | B | B | |||||
302 | A | A | B | ||||
303 | A | ||||||
304 | B | ||||||
305 | A | A | B | ||||
306 | A | A | A | B | |||
307 | A | A | |||||
308 | B | B | |||||
309 | B | B | |||||
310 | A | A | B | ||||
311 | A | B | |||||
312 | A | A | A | B | |||
313 | A | B | |||||
314 | B | ||||||
315 | A | B | B | ||||
316 | A | A | A | B | |||
317 | A | A | A | B | |||
318 | A | B | |||||
319 | B | ||||||
320 | A | ||||||
321 | A | B | A | B | |||
322 | A | A | B | ||||
323 | A | A | A | B | |||
324 | A | A | A | B | |||
325 | A | A | A | B | |||
326 | A | A | A | A | |||
327 | A | A | A | A | |||
328 | A | A | A | B | |||
329 | A | A | A | A | |||
330 | A | A | B | ||||
331 | A | A | B | ||||
332 | A | ||||||
333 | A | A | A | B | |||
334 | A | ||||||
335 | A | A | |||||
336 | A | B | |||||
337 | A | B | |||||
338 | A | B | |||||
339 | A | A | A | B | |||
340 | A | A | A | B | |||
341 | A | A | B | ||||
342 | A | B | |||||
343 | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
344 | A | A | |||||
345 | A | B | B | A | |||
346 | B | ||||||
347 | A | B | B | A | |||
348 | A | A | A | B | |||
349 | A | A | A | B | |||
350 | B | ||||||
351 | A | B | |||||
352 | A | ||||||
353 | B | ||||||
354 | A | A | B | ||||
355 | A | A | A | B | |||
356 | A | A | A | B | |||
357 | A | B | |||||
358 | B | ||||||
359 | A | A | A | B | |||
360 | B | B | |||||
361 | A | A | A | B | |||
362 | A | A | A | B | |||
363 | A | B | |||||
364 | A | B | |||||
365 | A | B | |||||
366 | A | B | |||||
367 | A | B | |||||
368 | A | A | A | B | |||
369 | A | A | A | A | B | ||
370 | A | A | A | B | |||
371 | A | A | A | A | B | ||
372 | A | B | |||||
373 | A | B | |||||
374 | A | A | A | B | |||
375 | A | A | B | ||||
376 | A | B | |||||
377 | A | B | |||||
378 | A | B | |||||
379 | A | A | |||||
380 | A | A | B | ||||
381 | A | A | |||||
382 | A | B | |||||
383 | A | B | |||||
384 | A | B | |||||
385 | A | A | B | ||||
386 | A | A | A | A | B | ||
387 | A | A | A | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
388 | A | A | B | ||||
389 | A | B | |||||
390 | B | B | |||||
391 | A | A | A | B | |||
392 | A | B | |||||
393 | A | B | |||||
394 | A | B | |||||
395 | A | A | A | A | B | ||
396 | A | B | |||||
397 | A | A | B | ||||
398 | A | B | |||||
399 | A | A | |||||
400 | A | A | B | ||||
401 | A | B | |||||
402 | B | B | |||||
403 | B | ||||||
404 | A | B | B | ||||
405 | A | ||||||
406 | A | B | B | ||||
407 | A | A | B | ||||
408 | A | B | |||||
409 | A | A | |||||
410 | A | B | |||||
411 | A | A | B | ||||
412 | A | ||||||
413 | A | A | B | ||||
414 | B | B | B | ||||
415 | A | A | B | ||||
416 | A | B | B | ||||
417 | A | A | B | ||||
418 | A | A | B | ||||
419 | B | B | |||||
420 | A | A | A | B | |||
421 | A | B | B | ||||
422 | A | A | B | ||||
423 | A | A | B | ||||
424 | A | A | B | ||||
425 | A | A | B | ||||
426 | A | A | B | ||||
427 | A | B | B | B | |||
428 | A | B | B | ||||
429 | A | B | B | B | |||
430 | A | B | B | B | |||
431 | A | A | A | B |
Compound number | Aurora A | Aurora B | Aurora C | JAK2 | JAK3 | ROCK | |
Enzyme | 33P | ||||||
432 | B | B | B | ||||
433 | B | B | B | ||||
434 | B | B | B | ||||
435 | B | B | B | ||||
436 | B | A | B | ||||
437 | A | B | B | ||||
438 | B | B | B | ||||
439 | A | A | B | ||||
440 | B | B | B | ||||
441 | B | B | B | B | |||
442 | A | B | B | B | |||
443 | A | A | A | A | B | ||
444 | A | A | A | B | B | ||
445 | A | B | A | ||||
446 | A | A | A | B | B | ||
447 | A | B | B | B | |||
448 | B | B | B | ||||
449 | A | B | B | ||||
450 | A | A | A | B | B | ||
451 | B | B | B | ||||
452 | A | A | A | B | |||
453 | B | B | B | ||||
454 | A | B | B | B | |||
455 | A | B | B | B | |||
456 | A | B | B | ||||
457 | B | B | |||||
458 | A | A | A | ||||
459 | B | B | |||||
460 | B | B | |||||
461 | A | A | A | ||||
462 | B | B | |||||
463 | A | B | |||||
464 | B | ||||||
465 | A | ||||||
466 | B | ||||||
467 | A | ||||||
468 | A | ||||||
469 | A |
Claims (66)
1. the compound of formula (I):
Or its pharmacologically acceptable salts, wherein:
R
1Be T-R ' or-Si (R ')
3
R
2, R
3, and R
4Independently be halogen, CN, NO separately
2, or V-R ';
X
1, X
2And X
3Independently be N or CH separately, wherein the hydrogen atom of CH is optional by R
5Replace;
X is 1,2,3 or 4;
R
5Each appearance independently be halogen, CN, NO
2, or U-R ', wherein at least one R
5Not H;
T, V and U independently are valence link or the optional C that replaces separately
1-C
6Alkylidene chain, wherein this chain at the most optional the and independent quilt-NR ' of two methylene units-,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR '-,-NR ' CO-,-NR ' CO
2-,-SO
2NR '-,-NR ' SO
2-,-CONR ' NR '-,-NR ' CONR '-,-OCONR '-,-NR ' NR '-,-NR ' SO
2NR '-,-SO-,-SO
2-,-PO-,-PO
2-or-POR '-replacement; And
The each appearance of R ' independently is hydrogen or the optional group that replaces, and is selected from: C
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, condition is:
If a) R
1Be the cyclopentyl that replaces, x is 1, X
1And X
3Be CH, X so
2Not C-R
5, R wherein
5Be fluorine or OMe;
B) if R
2And R
3Be H and R simultaneously
1And R
4Independently be selected from H or Me, x is 1, X
1And X
3Be CH, X so
2Not C-R
5, R wherein
5Be OMe, NO
2, or fluorine;
C) if R
1, R
2, R
3And R
4Be H simultaneously, x is 1, R
5Be-SMe NH
2Or the optional NH-piperidines that replaces, and X
1And X
2Be N, X so
3Not CH;
D) if R
2, R
3And R
4Be H simultaneously, X
1, X
2And X
3Be CH, and two R
5Form the optional dicyclo that replaces of condensed, R so with the ring that links to each other with them
1Not CH
2CH
2N (Me)
2
E) if R
2And R
3Be H simultaneously, R
4Be NH
2, and X
1, X
2And X
3Be CH, R so
1It or not the phenyl that replaces;
F) if R
2, R
3And R
4Be H, R so simultaneously
1Not Si (R ')
3With
G) if R
1, R
2And R
4Be H and (i) X simultaneously
2And X
3Be CH or CR
5Or (ii) X
1, X
2Or X
3In any one is N, R so
3It or not phenyl or by O-phenyl or N (Me)
2The phenyl that replaces.
2. compound according to claim 1, wherein:
A) R
1Be T-R ', wherein T is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO
2-or-CO-replaces, and R ' is hydrogen, C
1-C
4-alkyl, or the optional 5-that replaces or 6-unit's aryl or heteroaryl; Or
R
1Be-Si (R ')
3, R ' is hydrogen, C
1-C
4-alkyl, or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle.
3. compound according to claim 1, wherein R
1Be hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3
4. compound according to claim 1, wherein R
1Be hydrogen, methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, p-toluenesulfonyl (Ts), t-butyldimethylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).
5. compound according to claim 1, wherein R
2, R
3, and R
4Independently be hydrogen, R ', halogen, CN, NO separately
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR ' (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2, or-O (CH
2)
4N (R ')
2
6. compound according to claim 1, wherein R
2, R
3, and R
4Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-O (CH
2)
2OCH
3,-CONH
2,-COOCH
3,-OH ,-CH
2OH ,-NHCOCH
3,-SO
2NH
2,-SO
2N (Me)
2, or the optional group that replaces, be selected from C
1-C
4Alkyl, C
1-C
4Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
7. compound according to claim 1, wherein:
A) R
2, R
3, and R
4Each is hydrogen naturally;
B) R
2, R
3, or R
4In one be hydrogen;
C) R
2, R
3, or R
4In two be hydrogen;
D) R
2And R
4All be hydrogen, and R
3Be halogen, CN, NO
2, or V-R ';
E) R
2And R
4All be hydrogen, and R
3It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5;
F) R
2And R
4All be hydrogen, and R
3Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring; Or
G) R
2And R
4All be hydrogen, and R
3Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, _ azoles base, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group or _ di azoly.
8. compound according to claim 1, wherein R
2, R
3, and R
4Optional separately by R
6Occur to replace for z time, wherein z is 0-5 and R
6Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or Z-R ", wherein Z is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
9. compound according to claim 8, wherein z is 0,1,2 or 3, and R
6Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
10. compound according to claim 8, wherein z is 1,2 or 3 and R
6Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2, or-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and wherein aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
11. compound according to claim 1, wherein X
1, X
2, or X
3In two be N, and X
1, X
2, or X
3In remaining one be CH, wherein the hydrogen atom of CH is optional by R
5Replace.
12. compound according to claim 1, wherein X
1, X
2, or X
3In one be N, and X
1, X
2, or X
3In remaining two be CH, wherein the hydrogen atom of CH is optional by R
5Replace.
13. compound according to claim 1, wherein X
1, X
2And X
3Each is CH naturally, and wherein the hydrogen atom of CH is optional by R
5Replace.
15. compound according to claim 1, wherein R
5Each appearance independently be hydrogen, R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' or-NR ' (CH
2)
4OR '.
16. compound according to claim 1, wherein x is 1,2 or 3, and R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2) N (R ')
2, or-NR ' (CH
2)
2N (R ')
2
17. compound according to claim 1, wherein x is 1,2 or 3, and R
5at least once occur be-OR '.
18. compound according to claim 1, wherein x is 1,2 or 3, and R
5at least once occur be-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R '.
19. compound according to claim 1, wherein x is 1,2 or 3, and R
5At least once to occur be the optional C that replaces
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
20. compound according to claim 1, wherein x is 1 or 2, and R
5Each appearance independently be halogen, R ', CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2, CON (R ')
2,-CH
2CON (R ')
2,-(CH
2)
2CON (R ')
2, COOR ' ,-CH
2COOR ' ,-(CH
2)
2COOR ' ,-SO
2N (R ')
2,-CH
2SO
2N (R ')
2,-(CH
2)
2SO
2N (R ')
2,-NR ' SO
2R ' ,-CH
2NR ' SO
2R ' ,-(CH
2)
2NR ' SO
2R ', NR ' CON (R ')
2,-CH
2NR ' CON (R ')
2,-(CH
2)
2NR ' CON (R ')
2,-NR ' SO
2N (R ')
2,-CH
2NR ' SO
2N (R ')
2,-(CH
2)
2NR ' SO
2N (R ')
2,-COCOR ' ,-CH
2COCOR ' ,-(CH
2)
2COCOR ' ,-N (R ')
2,-CH
2N (R ')
2,-(CH
2)
2N (R ')
2,-OR ' ,-CH
2OR ' ,-(CH
2)
2OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-CH
2NR ' COR ' or-(CH
2)
2NR ' COR '.
21. compound according to claim 20, wherein R
5Be CN ,-CH
2CN ,-(CH
2)
2CN ,-NO
2,-CH
2NO
2,-(CH
2)
2NO
2, OR ' ,-CH
2OR ' ,-CON (R ')
2,-SO
2N (R ')
2,-N (R ')
2, or R '.
22. compound according to claim 20, wherein R
5Each appearance independently be hydrogen, halogen, CN ,-CH
2CN ,-(CH
2)
2CN, NO
2,-CH
2NO
2,-(CH
2)
2NO
2,-CONH
2,-CON (C
1-C
4Alkyl) ,-SO
2NH
2,-SO
2N (C
1-C
4Alkyl), NH
2,-N (C
1-C
4Alkyl) ,-OH ,-O (C
1-C
4Alkyl) ,-CH
2OH ,-CH
2O (C
1-C
4Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement.
23. compound according to claim 1, wherein R
5Optional by R
7Occur to replace for y time, wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ", wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
24. compound according to claim 23, wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4OR ".
25. compound according to claim 23, wherein y is 1,2 or 3 and R
7Each appearance independently be F, Cl, Br, CN, OH, NH
2,-CH
2OH, C
1-C
6Alkyl ,-O (C
1-C
6Alkyl) ,-CH
2O (C
1-C
6Alkyl) ,-CO (C
1-C
6Alkyl) ,-COO (C
1-C
6Alkyl) ,-NHSO
2(C
1-C
6Alkyl) ,-SO
2NH
2,-CONH
2-,-CON (C
1-C
6Alkyl) ,-SO
2(C
1-C
6Alkyl) ,-SO
2Phenyl, phenyl, benzyl ,-N (C
1-C
6Alkyl)
2,-S (C
1-C
6Alkyl), wherein aforementioned phenyl, benzyl and C
1-C
6Independent separately and optional being substituted of alkyl, and aforementioned C
1-C
6Alkyl each straight chain, side chain or cyclic naturally.
26. compound according to claim 1, wherein x is 1,2 or 3; R
5at least once occur be-N (R ')
2,-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ', NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-OR ' ,-NR ' COR ' ,-NR ' COCH
2R ' or-NR ' CO (CH
2)
2R ', and R ' is C
1-C
6Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R
7Occur to replace for y time.
27. compound according to claim 26, wherein R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
6Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R
7Occur to replace for 1-3 time.
28. compound according to claim 26, wherein R ' is a hydrogen, optional by R
7The C that occur to replace for 1-3 time
1-C
4Alkyl, or ring are selected from:
Wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ", wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain two methylene units are optional and independent by NR at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
29. compound according to claim 1, wherein R
5Be-N (R ')
2And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from:
Wherein y is 0-5 and R
7Be=O ,=NR " ,=S, halogen ,-CN ,-NO
2, or W-R ", wherein W is valence link or the optional C that replaces
1-C
6Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO
2-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO
2-,-SO
2NR " ,-NR " SO
2-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO
2NR " ,-SO-,-SO
2-,-PO-,-PO
2-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
30. be selected from the compound of table 1.
32. according to claim 1,14 or 31 any one described compound, wherein R
2And R
4Independently be selected from separately H, Cl, Br, F ,-CN ,-COOH ,-COOR ' ,-NH
2,-N (CH
3)
2,-N (Et)
2,-N (iPr)
2,-NHR ' ,-OR ' ,-SR ' ,-O (CH
2)
2OCH
3,-CONH
2,-CONHR ', CON (R ')
2,-OH ,-CH
2OH, CH
2NH
2,-CH
2NHR ' ,-CH
2N (R ')
2,-C (R ')
2N (R ')
2,-NHCOCH
3,-N (R ') COR ' ,-SO
2NH
2,-SO
2N (Me)
2, or the optional group that replaces, be selected from C
1-C
6Aliphatic group, C
1-C
6Alkoxyl group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.
33. compound according to claim 32, wherein R
2And R
4Each is hydrogen naturally.
34. compound according to claim 31, wherein R
1Be selected from hydrogen, C
1-C
4Alkyl ,-COR ' ,-SO
2R ' or-Si (R ')
3
35. compound according to claim 34, wherein R
1Be hydrogen.
36. compound according to claim 31, wherein R
3Be selected from H, Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH
2,-N (R ')
2,-NO
2,-OR ' ,-CON (R ')
2,-COOR ' ,-OH ,-SR ' ,-C (R ')
2OR ' ,-N (R ') COR ' ,-N (R ') C (O) OR ' ,-SO
2NH
2,-SO
2N (R ')
2Or the optional group that replaces, be selected from C
1-C
4Aliphatic group, C
1-C
4Alkoxyl group or-C ≡ C-C
1-C
4Aliphatic group.
37. compound according to claim 36, wherein R
3Be selected from H, Cl ,-Br ,-CN ,-COOH ,-COOMe ,-CONHR ' ,-CON (Me)
2,-CH
2OH ,-NO
2,-NH
2Or the optional C that replaces
1-C
4Aliphatic group.
38. according to the described compound of claim 37, wherein R
3Be selected from Cl ,-Br ,-CN or the optional C that replaces
1-C
4Aliphatic group.
39. according to the described compound of claim 37, wherein R
3Be Cl.
40. according to claim 1,14 or 31 any one described compound, wherein R
1, R
2And R
4Be hydrogen and R
3Be selected from Cl ,-Br ,-CN or the optional C that replaces
1-C
4Aliphatic group.
41. according to the described compound of claim 37, wherein R
3Be H, OR ', NR ' C (O) R ', NR ' C (O) OR ', CON (R ')
2Or COOMe.
42. according to the described compound of claim 37, wherein R
3Be OR ', NR ' C (O) R ' or NR ' C (O) OR '.
43. according to claim 1,14 or 31 any one described compound, wherein R
1, R
2And R
4Be hydrogen and R
3Be selected from H, OR ', NR ' C (O) R ', NR ' C (O) OR ', CON (R ')
2Or COOMe.
44. compound according to claim 31, wherein x is 1,2 or 3; R wherein
5Each appearance independently be selected from R ' ,-CH
2R ', halogen, CN, NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COR
8R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' R
8N (R ')
2,-OR
8OR ' ,-OR
8N (R ')
2,-NR ' CH (R
9) R ' ,-NR ' CH (R
9) C (O) OR ' ,-N (R ') R
8R ' ,-N (R ') R
8R ' ,-N (R ') R
8N (R ')
2,-N (R ') R
8OR ' ,-NR ' CH (R
9) R ' ,-NR ' CH
2C (O) N (R ')
2, or-NR ' CH (R
9) C (O) N (R ')
2, R wherein
8Be the optional C that replaces
1-C
4Alkyl and R
9Be the optional C that replaces
1-C
6Aliphatic group.
45. according to the described compound of claim 44, wherein R
5Each appearance independently be selected from R ' ,-CH
2R ', halogen ,-CN ,-NO
2,-N (R ')
2,-CH
2N (R ')
2,-OR ' ,-CH
2OR ' ,-SR ' ,-CH
2SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH
2R ' ,-NR ' CO (CH
2)
2R ' ,-NR ' COOR ' ,-CON (R ')
2,-SO
2N (R ')
2,-CONR ' (CH
2)
2N (R ')
2,-CONR (CH
2)
3N (R ')
2,-CONR ' (CH
2)
4N (R ')
2,-O (CH
2)
2OR ', O (CH
2)
3OR ', O (CH
2)
4OR ' ,-O (CH
2)
2N (R ')
2,-O (CH
2)
3N (R ')
2,-O (CH
2)
4N (R ')
2,-NR ' CH (CH
2OR
9) R ' ,-NR ' CH (CH
2CH
2OR
9) R ' ,-NR ' CH (CH
3) R ', NR ' CH (CF
3) R ' ,-NR ' CH (CH
3) C (O) OR ' ,-NR ' CH (CF
3) C (O) OR ' ,-NR ' (CH
2) R ' ,-NR ' (CH
2)
2R ' ,-NR ' (CH
2)
3R ' ,-NR ' (CH
2)
4R ' ,-NR ' (CH
2) N (R ')
2,-NR ' (CH
2)
2N (R ')
2,-NR ' (CH
2)
3N (R ')
2,-NR ' (CH
2)
4N (R ')
2,-NR ' (CH
2) OR ' ,-NR ' (CH
2)
2OR ' ,-NR ' (CH
2)
3OR ' ,-NR ' (CH
2)
4OR ' ,-NR ' CH (CH
2CH
3) R ' ,-NR ' CH
2C (O) N (R ')
2,-NR ' CH (CH
3) C (O) N (R ')
2, NR ' CH (CF
3) C (O) N (R ')
2,-NR ' CH (CH
2CH
3) C (O) N (R ')
2,-NR ' CH (CH (CH
3)
2) C (O) N (R ')
2,-NR ' CH (C (CH
3)
3) C (O) N (R ')
2,-NR ' CH (CH
2CH (CH
3)
2) C (O) N (R ')
2,-NR ' CH (CH
2OR
9) C (O) N (R ')
2, or-NR ' CH (CH
2CH
2N (Me)
2) C (O) N (R ')
2
46. according to the compound of claim 44, wherein R
5at least once occur independently be selected from-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2OMe) R ' ,-NR ' CH (CH
2OEt) R ' ,-NR ' CH (CH
2OCF
3) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' CH (CH
2CH
2OMe) R ' ,-NR ' CH (CH
2CH
2OEt) R ' ,-NR ' CH (CH
2CH
2OCF
3) R ' ,-NR ' CH (CH
3) C (O) OR ' ,-NR ' CH (CF
3) C (O) OR ' ,-NR ' CH (CH
3) C (O) N (R ')
2,-NR ' CH (CF
3) C (O) N (R ')
2,-NR ' CH (CH
2CH
3) C (O) N (R ')
2,-NR ' CH (CH
2OH) C (O) N (R ')
2,-NR ' CH (CH
2OMe) C (O) N (R ')
2,-NR ' CH (CH
2OEt) C (O) N (R ')
2Or-NR ' CH (CH
2OCF
3) C (O) N (R ')
2, wherein R ' is the optional C that replaces
1-C
4Aliphatic group.
47. according to the described compound of claim 44, wherein said R
5NHCH at least once appears being selected from
2C (O) NHR ' ,-NHCH (CH
3) C (O) NHR ' ,-NHCH (CH
2CH
3) C (O) NHR ' ,-NHCH (CH (CH
3)
2) C (O) NHR ' ,-NHCH (C (CH
3)
3) C (O) NHR ' ,-NHCH (CH
2CH (CH
3)
2) C (O) NHR ' ,-NHCH (CH
2OH) C (O) NHR ' ,-NHCH (CH
2OMe) C (O) NHR ' or-NHCH (CH
2CH
2N (Me)
2) C (O) NHR ', wherein R ' is the optional C that replaces
1-C
4Aliphatic group.
48. according to the described compound of claim 44, wherein R
5at least once occur independently be selected from-NHR ' ,-NH (CH
2) R ' ,-NH (CH
2)
2R ' ,-NHCH (CH
3) R ' ,-NHCH
2C (O) NHR ' ,-NHCH (CH
3) C (O) NHR ' ,-NHCH (CH
2CH
3) C (O) NHR ' ,-NHCH (CH (CH
3)
2) C (O) NHR ' ,-NHCH (C (CH
3)
3) C (O) NHR ', NHCH (CH
2CH (CH
3)
2) C (O) NHR ' ,-NHCH (CH
2OH) C (O) NHR ' ,-NHCH (CH
2OMe) C (O) NHR ' or-NHCH (CH
2CH
2N (Me)
2) C (O) NHR ', wherein R ' is the optional phenyl that replaces.
49. according to the described compound of claim 44, wherein said R
5at least once occur be-NHCH (CH
3) R ', wherein R ' is the optional phenyl that replaces.
50. according to the described compound of claim 44, wherein R
5At least once to occur be H, halogen, CH
3, CF
3, COOH, COOMe or OR ', wherein R ' is C
1-C
4Aliphatic group.
51. according to the described compound of claim 44, wherein x is 2 or 3 and R
5At least once to occur be F.
52. according to the described compound of claim 44, wherein R
1, R
2And R
4Be hydrogen and R
5Be selected from-NHR ' ,-NH (CH
2) R ' ,-NH (CH
2)
2R ' ,-NHCH (CH
3) R ' ,-NHCH
2C (O) NHR ' ,-NHCH (CH
3) C (O) NHR ' ,-NHCH (CH
2CH
3) C (O) NHR ' ,-NHCH (CH (CH
3)
2) C (O) NHR ' ,-NHCH (C (CH
3)
3) C (O) NHR ' ,-NHCH (CH
2CH (CH
3)
2) C (O) NHR ' ,-NHCH (CH
2OH) C (O) NHR ' ,-NHCH (CH
2OMe) C (O) NHR ' or-NHCH (CH
2CH
2N (Me)
2) C (O) NHR ', wherein R ' is the optional phenyl that replaces.
53. according to the described compound of claim 44, wherein R
1, R
2And R
4Be hydrogen and R
5Be selected from-NR ' CH (CH
2OH) R ' ,-NR ' CH (CH
2OMe) R ' ,-NR ' CH (CH
2OEt) R ' ,-NR ' CH (CH
2OCF
3) R ' ,-NR ' CH (CH
2CH
2OH) R ' ,-NR ' CH (CH
2CH
2OMe) R ' ,-NR ' CH (CH
2CH
2OEt) R ' ,-NR ' CH (CH
2CH
2OCF
3) R ' ,-NR ' CH (CH
3) C (O) OR ' ,-NR ' CH (CF
3) C (O) OR ' ,-NR ' CH (CH
3) C (O) N (R ')
2,-NR ' CH (CF
3) C (O) N (R ')
2,-NR ' CH (CH
2CH
3) C (O) N (R ')
2,-NR ' CH (CH
2OH) C (O) N (R ')
2,-NR ' CH (CH
2OMe) C (O) N (R ')
2,-NR ' CH (CH
2OEt) C (O) N (R ')
2Or-NR ' CH (CH
2OCF
3) C (O) N (R ')
2, wherein R ' is the optional C that replaces
1-C
4Aliphatic group.
54. compound according to claim 31, wherein R ' is selected from hydrogen, optional by R
7The C that occur to replace for y time
1-C
6Aliphatic group, or R ' be the ring, be selected from:
Or twice appearance of R ' with and their bonded nitrogen-atoms are common forms optional 3-10 unit's monocycle or the bicyclic heterocycle that replaces, be selected from:
Wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4The each appearance of OR ", and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
55. compound according to claim 31, wherein x be 2,3 or 4 and the adjacent ring member at least two R
5Be R ', and wherein said two R
5With common form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated with their bonded atoms, fractional saturation or complete undersaturated monocycle or dicyclo.
56. according to the described compound of claim 55, wherein said compound has formula I-B-vii embedding or I-B-viii:
Wherein y is 0,1,2 or 3, and R
7Each appearance independently be hydrogen, R " ,-CH
2R ", halogen, CN, NO
2,-N (R ")
2,-CH
2N (R ")
2,-OR " ,-CH
2OR " ,-SR " ,-CH
2SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ")
2,-SO
2N (R ")
2,-CONR " (CH
2)
2N (R ")
2,-CONR (CH
2)
3N (R ")
2,-CONR " (CH
2)
4N (R ")
2,-O (CH
2)
2OR ", O (CH
2)
3OR ", O (CH
2)
4OR " ,-O (CH
2)
2N (R ")
2,-O (CH
2)
3N (R ")
2,-O (CH
2)
4N (R ")
2,-NR " CH (CH
2OH) R " ,-NR " CH (CH
2CH
2OH) R " ,-NR " (CH
2) R " ,-NR " (CH
2)
2R " ,-NR " (CH
2)
3R " ,-NR " (CH
2)
4R " ,-NR " (CH
2) N (R ")
2,-NR " (CH
2)
2N (R ")
2,-NR " (CH
2)
3N (R ")
2,-NR " (CH
2)
4N (R ")
2,-NR " (CH
2) OR " ,-NR " (CH
2)
2OR " ,-NR " (CH
2)
3OR " or-NR " (CH
2)
4The each appearance of OR ", and R " independently is the C of hydrogen or optional replacement
1-C
6Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and common formation of their bonded atoms have 0-4 the heteroatomic 3-12 unit that independently is selected from nitrogen, oxygen or sulphur be saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.
57. be selected from the compound of table 2.
58. pharmaceutical composition that comprises claim 1,30,31 or 57 any one described compound and pharmaceutically acceptable carrier, auxiliary agent or vehicle.
59. according to the described composition of claim 58, further comprise the additional treatment agent, be selected from chemotherapy or antiproliferative, the therapeutical agent of Alzheimer's, parkinsonian therapeutical agent, the medicament that is used for the treatment of multiple sclerosis (MS), the treatment of asthma agent, be used for the treatment of schizoid medicament, anti-inflammatory agent, immunomodulatory or immunosuppressor, neurotrophic factor, the medicament that is used for the treatment of cardiovascular diseases, the medicament that is used for the treatment of destructive osteopathy, the medicament that is used for the treatment of hepatopathy, be used for the treatment of hemopathic medicament, or be used for the treatment of the medicament of immunodeficiency disease.
60. a method that suppresses JAK-3, ROCK among biological sample or the patient or Aurora kinase activity, comprise make described biological sample or described patient with:
A) the described composition of claim 58; Or
B) step of the described compound contact of claim 1 or claim 31.
61. the method for the treatment of or alleviating following disease or illness is selected from immune response such as allergy or type i allergic reaction or asthma; Autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis or multiple sclerosis; Neurodegenerative disorders; Or entity and hematologic malignancies, when described method is included in needs of patients, give described composition of its claim 58 or claim 1 or the described compound of claim 31.
62., comprise the step that gives the agent of described patient's additional treatment according to the described method of claim 61.
63. according to the described method of claim 61, wherein this disease is autoimmune disease and transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis or multiple sclerosis.
64. according to the described method of claim 61, wherein this disease is hypertension, stenocardia, cerebrovascular atrophy, asthma, peripheral circulation illness, premature labor, cancer, erectile dysfunction, arteriosclerosis, spasm (cerebral vasospasm and coronary artery spasm), retinopathy (for example, glaucoma), inflammatory conditions, autoimmune disorder, AIDS, osteoporosis, myocardial hypertrophy, local asphyxia/pour into inductive again to damage or endothelial dysfunction.
65. treatment, prevention or alleviate following disease or disease serious degree methods, be selected from heart trouble, diabetes, Alzheimer's, the immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive osteopathy, osteoporosis, proliferative disorders, catch, immune-mediated disease, virus disease, hyperplasia, perfusion/local asphyxia again in the apoplexy, heart attack, the platelet aggregation of organ anoxic thrombin induction, chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer, the liver local asphyxia, myocardial infarction, congestive heart failure, the pathologic immune disorders that relates to the T cell activation, and neurodegenerative disorders, when described method is included in needs of patients, give described composition of its claim 58 or claim 1 or the described compound of claim 31.
66. according to the described method of claim 65, wherein said cancer is selected from melanoma, lymphoma, neuroblastoma, leukemia or is selected from colon, mammary gland, lung, kidney, ovary, uterine endometrium, pancreas, kidney, central nervous system, uterine cervix, prostatic cancer or cancer of the stomach, CML, AML, APL, acute lymphoblastic leukemia (ALL), mastocytosis or gastrointestinal stromal tumors (GIST).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55750304P | 2004-03-30 | 2004-03-30 | |
US60/557,503 | 2004-03-30 | ||
US60/625,599 | 2004-11-05 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310486314.2A Division CN103554104A (en) | 2004-03-30 | 2005-03-30 | Azaindoles useful as inhibitors of jak and other protein kinases |
CN200910206575A Division CN101676285A (en) | 2004-03-30 | 2005-03-30 | Azaindoles useful as inhibitors of JAK and other protein kinases |
CN2009102065762A Division CN101676286B (en) | 2004-03-30 | 2005-03-30 | Azaindoles useful as inhibitors of JAK and other protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1938303A true CN1938303A (en) | 2007-03-28 |
CN100569772C CN100569772C (en) | 2009-12-16 |
Family
ID=37955154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005800103488A Expired - Fee Related CN100569772C (en) | 2004-03-30 | 2005-03-30 | Azaindole as JAK and other kinases inhibitor |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN100569772C (en) |
SI (1) | SI2332940T1 (en) |
UA (1) | UA87494C2 (en) |
ZA (1) | ZA200607981B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102458581A (en) * | 2009-05-22 | 2012-05-16 | 因塞特公司 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CN102858769A (en) * | 2010-01-27 | 2013-01-02 | 沃泰克斯药物股份有限公司 | Pyrazolopyridine kinase inhibitors |
CN103180322A (en) * | 2010-04-30 | 2013-06-26 | 塞尔佐姆有限公司 | Pyrazole compounds as jak inhibitors |
CN103492382A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
CN103492381A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
CN103502247A (en) * | 2011-02-01 | 2014-01-08 | 默克专利股份公司 | 7-azaindole derivatives |
CN103562205A (en) * | 2010-12-16 | 2014-02-05 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
CN103702998A (en) * | 2011-07-05 | 2014-04-02 | 沃泰克斯药物股份有限公司 | Processes and intermediates for producing azaindoles |
CN103748076A (en) * | 2011-02-11 | 2014-04-23 | 默沙东公司 | Rorgammat inhibitors |
CN108299426A (en) * | 2018-03-20 | 2018-07-20 | 宝鸡文理学院 | One kind [1,2,4]-triazol [4,3-a] pyridine compounds and their and its synthetic method |
CN109641868A (en) * | 2016-08-30 | 2019-04-16 | 广东东阳光药业有限公司 | Inhibitors of influenza viruses replication and its application method and purposes |
CN110128421A (en) * | 2018-02-09 | 2019-08-16 | 新发药业有限公司 | A kind of simple and convenient process for preparing of the halogenated -7- azaindole of 5- |
-
2005
- 2005-03-30 SI SI200531659T patent/SI2332940T1/en unknown
- 2005-03-30 CN CNB2005800103488A patent/CN100569772C/en not_active Expired - Fee Related
- 2005-03-30 UA UAA200611365A patent/UA87494C2/en unknown
- 2005-03-30 ZA ZA200607981A patent/ZA200607981B/en unknown
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102458581B (en) * | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | As pyrazoles-4-base-pyrrolo-[2,3-d] pyrimidine of JANUS kinase inhibitor and N-(mixing) the aryl-pyrrolidine derivative of pyrroles-3-base-pyrrolo-[2,3-d] pyrimidine |
CN102458581A (en) * | 2009-05-22 | 2012-05-16 | 因塞特公司 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CN102858769A (en) * | 2010-01-27 | 2013-01-02 | 沃泰克斯药物股份有限公司 | Pyrazolopyridine kinase inhibitors |
CN103180322A (en) * | 2010-04-30 | 2013-06-26 | 塞尔佐姆有限公司 | Pyrazole compounds as jak inhibitors |
CN103492382A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
CN103492381A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
CN103562205A (en) * | 2010-12-16 | 2014-02-05 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
CN103502247B (en) * | 2011-02-01 | 2016-02-24 | 默克专利股份公司 | 7-7-azaindole derivatives |
CN103502247A (en) * | 2011-02-01 | 2014-01-08 | 默克专利股份公司 | 7-azaindole derivatives |
CN103748076A (en) * | 2011-02-11 | 2014-04-23 | 默沙东公司 | Rorgammat inhibitors |
CN103702998A (en) * | 2011-07-05 | 2014-04-02 | 沃泰克斯药物股份有限公司 | Processes and intermediates for producing azaindoles |
CN106432311A (en) * | 2011-07-05 | 2017-02-22 | 沃泰克斯药物股份有限公司 | Processes and intermediates for producing azaindoles |
CN109641868A (en) * | 2016-08-30 | 2019-04-16 | 广东东阳光药业有限公司 | Inhibitors of influenza viruses replication and its application method and purposes |
CN109641868B (en) * | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | Inhibitors of influenza virus replication and methods of use and uses thereof |
CN110128421A (en) * | 2018-02-09 | 2019-08-16 | 新发药业有限公司 | A kind of simple and convenient process for preparing of the halogenated -7- azaindole of 5- |
CN110128421B (en) * | 2018-02-09 | 2020-08-11 | 新发药业有限公司 | Simple preparation method of 5-halogenated-7-azaindole |
CN108299426A (en) * | 2018-03-20 | 2018-07-20 | 宝鸡文理学院 | One kind [1,2,4]-triazol [4,3-a] pyridine compounds and their and its synthetic method |
Also Published As
Publication number | Publication date |
---|---|
SI2332940T1 (en) | 2013-03-29 |
CN100569772C (en) | 2009-12-16 |
ZA200607981B (en) | 2008-06-25 |
UA87494C2 (en) | 2009-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101676286B (en) | Azaindoles useful as inhibitors of JAK and other protein kinases | |
CN100569772C (en) | Azaindole as JAK and other kinases inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1098471 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1098471 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091216 |